DK2376480T3 - Sulfonamidderivater som bcl-2-selektive apoptoseinducerende midler til behandling af cancer og immunsygdomme - Google Patents
Sulfonamidderivater som bcl-2-selektive apoptoseinducerende midler til behandling af cancer og immunsygdomme Download PDFInfo
- Publication number
- DK2376480T3 DK2376480T3 DK09795606.4T DK09795606T DK2376480T3 DK 2376480 T3 DK2376480 T3 DK 2376480T3 DK 09795606 T DK09795606 T DK 09795606T DK 2376480 T3 DK2376480 T3 DK 2376480T3
- Authority
- DK
- Denmark
- Prior art keywords
- methyl
- sulfonyl
- piperazin
- yloxy
- indol
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims description 15
- 201000011510 cancer Diseases 0.000 title claims description 8
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 title description 5
- 230000006907 apoptotic process Effects 0.000 title description 5
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 title description 4
- 208000026278 immune system disease Diseases 0.000 title description 2
- 230000001939 inductive effect Effects 0.000 title 1
- 229940124530 sulfonamide Drugs 0.000 title 1
- 150000003456 sulfonamides Chemical class 0.000 title 1
- -1 S (0) R 37 Chemical compound 0.000 claims description 992
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 486
- 150000001924 cycloalkanes Chemical class 0.000 claims description 283
- 150000001925 cycloalkenes Chemical class 0.000 claims description 260
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 221
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 206
- 229910052717 sulfur Inorganic materials 0.000 claims description 197
- 125000000217 alkyl group Chemical group 0.000 claims description 166
- 229910052801 chlorine Inorganic materials 0.000 claims description 150
- 229910052731 fluorine Inorganic materials 0.000 claims description 150
- 229910052794 bromium Inorganic materials 0.000 claims description 134
- 125000001072 heteroaryl group Chemical group 0.000 claims description 129
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 128
- 229910052740 iodine Inorganic materials 0.000 claims description 123
- 150000001875 compounds Chemical class 0.000 claims description 118
- 229910052799 carbon Inorganic materials 0.000 claims description 115
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 104
- 125000000304 alkynyl group Chemical group 0.000 claims description 98
- OTXBWGUYZNKPMG-UHFFFAOYSA-N isofulminic acid Chemical compound O[N+]#[C-] OTXBWGUYZNKPMG-UHFFFAOYSA-N 0.000 claims description 98
- 125000001424 substituent group Chemical group 0.000 claims description 93
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 90
- 125000003342 alkenyl group Chemical group 0.000 claims description 87
- 229910052760 oxygen Inorganic materials 0.000 claims description 87
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 claims description 71
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 68
- 101150009274 nhr-1 gene Proteins 0.000 claims description 65
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 49
- 229910052739 hydrogen Inorganic materials 0.000 claims description 43
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 43
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 39
- 150000003839 salts Chemical class 0.000 claims description 37
- 101100516568 Caenorhabditis elegans nhr-7 gene Proteins 0.000 claims description 34
- 101100294120 Caenorhabditis elegans nhr-55 gene Proteins 0.000 claims description 33
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims description 33
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 32
- 239000000203 mixture Substances 0.000 claims description 32
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 30
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 claims description 30
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 28
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 27
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 22
- 101100240518 Caenorhabditis elegans nhr-12 gene Proteins 0.000 claims description 20
- 101100240527 Caenorhabditis elegans nhr-22 gene Proteins 0.000 claims description 20
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims description 20
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims description 20
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 19
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims description 18
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 18
- 229910052757 nitrogen Inorganic materials 0.000 claims description 17
- 102220598631 5-hydroxytryptamine receptor 1E_R49A_mutation Human genes 0.000 claims description 15
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 14
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 14
- SOIIHESTBYNJRH-PMPSAXMXSA-N (3r,6r,8as)-6-(benzylsulfonylamino)-n-[3-(diaminomethylideneamino)propyl]-5-oxo-2,3,6,7,8,8a-hexahydro-[1,3]thiazolo[3,2-a]pyridine-3-carboxamide Chemical compound N([C@@H]1CC[C@@H]2SC[C@H](N2C1=O)C(=O)NCCCN=C(N)N)S(=O)(=O)CC1=CC=CC=C1 SOIIHESTBYNJRH-PMPSAXMXSA-N 0.000 claims description 13
- 102220605470 Coilin_R15A_mutation Human genes 0.000 claims description 13
- 102220605399 Coilin_R40A_mutation Human genes 0.000 claims description 12
- 102220595473 Major vault protein_R18A_mutation Human genes 0.000 claims description 12
- 102220608648 Methyl-CpG-binding domain protein 1_R30A_mutation Human genes 0.000 claims description 12
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 12
- 125000003118 aryl group Chemical group 0.000 claims description 12
- 101100294108 Caenorhabditis elegans nhr-41 gene Proteins 0.000 claims description 11
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 10
- 101100096664 Drosophila melanogaster B52 gene Proteins 0.000 claims description 10
- 102220555063 Holliday junction recognition protein_R25A_mutation Human genes 0.000 claims description 10
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 10
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 10
- 229910006074 SO2NH2 Inorganic materials 0.000 claims description 10
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 10
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 10
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims description 10
- 125000004484 1-methylpiperidin-4-yl group Chemical group CN1CCC(CC1)* 0.000 claims description 9
- 206010005003 Bladder cancer Diseases 0.000 claims description 8
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 8
- 206010006187 Breast cancer Diseases 0.000 claims description 8
- 208000026310 Breast neoplasm Diseases 0.000 claims description 8
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 8
- 206010009944 Colon cancer Diseases 0.000 claims description 8
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 8
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 8
- 208000003445 Mouth Neoplasms Diseases 0.000 claims description 8
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 8
- 206010033128 Ovarian cancer Diseases 0.000 claims description 8
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 8
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 8
- 206010060862 Prostate cancer Diseases 0.000 claims description 8
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 8
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 8
- 208000000277 Splenic Neoplasms Diseases 0.000 claims description 8
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 8
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 8
- 201000006491 bone marrow cancer Diseases 0.000 claims description 8
- 201000010881 cervical cancer Diseases 0.000 claims description 8
- 201000004101 esophageal cancer Diseases 0.000 claims description 8
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 8
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims description 8
- 208000014018 liver neoplasm Diseases 0.000 claims description 8
- 208000003747 lymphoid leukemia Diseases 0.000 claims description 8
- 230000036210 malignancy Effects 0.000 claims description 8
- 201000001441 melanoma Diseases 0.000 claims description 8
- 208000025113 myeloid leukemia Diseases 0.000 claims description 8
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 8
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 8
- 201000002471 spleen cancer Diseases 0.000 claims description 8
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 8
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 8
- 102220507254 Rab11 family-interacting protein 1_R38K_mutation Human genes 0.000 claims description 7
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 7
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 7
- 201000003444 follicular lymphoma Diseases 0.000 claims description 7
- 102220595577 Major vault protein_R24A_mutation Human genes 0.000 claims description 6
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 125000004312 morpholin-2-yl group Chemical group [H]N1C([H])([H])C([H])([H])OC([H])(*)C1([H])[H] 0.000 claims description 3
- OZWOMJMXMXRNPG-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-(4-morpholin-4-ylsulfonylphenyl)sulfonylbenzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1)=CC=C1S(=O)(=O)N1CCOCC1 OZWOMJMXMXRNPG-UHFFFAOYSA-N 0.000 claims description 2
- WHIXIPPWXNHPEA-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-[2-(1,3-dioxolan-2-yl)ethyl]-3-nitrophenyl]sulfonyl-2-(1h-indol-5-yloxy)benzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1CCC1OCCO1 WHIXIPPWXNHPEA-UHFFFAOYSA-N 0.000 claims description 2
- VMOKNHRSPQAOPS-XPROACGBSA-N n-[4-[[(3s,4r)-1-benzyl-3-hydroxypiperidin-4-yl]amino]-3-nitrophenyl]sulfonyl-4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)benzamide Chemical compound C([C@H]([C@H](C1)O)NC2=CC=C(C=C2[N+]([O-])=O)S(=O)(=O)NC(=O)C2=CC=C(C=C2OC=2C=C3C=CNC3=CC=2)N2CCN(CC2)CC=2CCC(CC=2C=2C=CC(Cl)=CC=2)(C)C)CN1CC1=CC=CC=C1 VMOKNHRSPQAOPS-XPROACGBSA-N 0.000 claims description 2
- XCUAIINAJCDIPM-XVFCMESISA-N N(4)-hydroxycytidine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=NO)C=C1 XCUAIINAJCDIPM-XVFCMESISA-N 0.000 claims 49
- 102220544041 60S ribosomal protein L27_R10A_mutation Human genes 0.000 claims 8
- 102220542308 60S ribosomal protein L27_R20A_mutation Human genes 0.000 claims 8
- 102220608644 Methyl-CpG-binding domain protein 1_R44K_mutation Human genes 0.000 claims 8
- 102220492955 Nuclear RNA export factor 1_R34A_mutation Human genes 0.000 claims 8
- 102220639610 Paraneoplastic antigen-like protein 6A_R48A_mutation Human genes 0.000 claims 8
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 8
- 102220507253 Rab11 family-interacting protein 1_R42A_mutation Human genes 0.000 claims 6
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 5
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 5
- 125000006763 (C3-C9) cycloalkyl group Chemical group 0.000 claims 4
- 102220542311 60S ribosomal protein L27_R19A_mutation Human genes 0.000 claims 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 4
- 102220608655 Methyl-CpG-binding domain protein 1_R47A_mutation Human genes 0.000 claims 3
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims 3
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 102220605451 Coilin_R36A_mutation Human genes 0.000 claims 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims 2
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- WILFKSVSWSOFBW-UHFFFAOYSA-N 1-(2-methoxyethyl)piperidine Chemical compound COCCN1CCCCC1 WILFKSVSWSOFBW-UHFFFAOYSA-N 0.000 claims 1
- JUBXTBVKELTJEX-UHFFFAOYSA-N 1-cyclopropylpiperidine Chemical compound C1CC1N1CCCCC1 JUBXTBVKELTJEX-UHFFFAOYSA-N 0.000 claims 1
- MCTWTZJPVLRJOU-UHFFFAOYSA-N 1-methyl-1H-imidazole Chemical compound CN1C=CN=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 claims 1
- CHXUFRRQOZZSNV-UHFFFAOYSA-N 1-methylpiperidine Chemical compound [CH2]N1CCCCC1 CHXUFRRQOZZSNV-UHFFFAOYSA-N 0.000 claims 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims 1
- PPDVKOJDTOQWBU-UHFFFAOYSA-N 4-cyclopropylmorpholine Chemical compound C1CC1N1CCOCC1 PPDVKOJDTOQWBU-UHFFFAOYSA-N 0.000 claims 1
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 claims 1
- YZTYCKGPJGDHTC-UHFFFAOYSA-N C(C1=CC=CC=C1)(=O)NOC=1C=C2C=CNC2=CC=1 Chemical compound C(C1=CC=CC=C1)(=O)NOC=1C=C2C=CNC2=CC=1 YZTYCKGPJGDHTC-UHFFFAOYSA-N 0.000 claims 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims 1
- PAMIQIKDUOTOBW-UHFFFAOYSA-N N-methylcyclohexylamine Natural products CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 claims 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- BHLHFLZCAWDBKS-UHFFFAOYSA-N n-[4-(3-morpholin-4-ylpropylamino)-3-nitrophenyl]sulfonylbenzamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C=CC=CC=2)=CC=C1NCCCN1CCOCC1 BHLHFLZCAWDBKS-UHFFFAOYSA-N 0.000 claims 1
- MQAYFGXOFCEZRW-UHFFFAOYSA-N oxane-2-carboxylic acid Chemical compound OC(=O)C1CCCCO1 MQAYFGXOFCEZRW-UHFFFAOYSA-N 0.000 claims 1
- DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 claims 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 1
- 150000002390 heteroarenes Chemical class 0.000 description 185
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 165
- 229910003204 NH2 Inorganic materials 0.000 description 111
- 239000000460 chlorine Substances 0.000 description 108
- 239000003112 inhibitor Substances 0.000 description 31
- 125000004432 carbon atom Chemical group C* 0.000 description 27
- VOPWNXZWBYDODV-UHFFFAOYSA-N Chlorodifluoromethane Chemical compound FC(F)Cl VOPWNXZWBYDODV-UHFFFAOYSA-N 0.000 description 24
- 230000027455 binding Effects 0.000 description 21
- CPRRHERYRRXBRZ-SRVKXCTJSA-N methyl n-[(2s)-1-[[(2s)-1-hydroxy-3-[(3s)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]carbamate Chemical compound COC(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CO)C[C@@H]1CCNC1=O CPRRHERYRRXBRZ-SRVKXCTJSA-N 0.000 description 21
- 230000002424 anti-apoptotic effect Effects 0.000 description 20
- 239000003814 drug Substances 0.000 description 20
- 125000000565 sulfonamide group Chemical group 0.000 description 19
- 102000013535 Proto-Oncogene Proteins c-bcl-2 Human genes 0.000 description 18
- 108010090931 Proto-Oncogene Proteins c-bcl-2 Proteins 0.000 description 18
- 125000004429 atom Chemical group 0.000 description 16
- 238000000034 method Methods 0.000 description 16
- 125000002757 morpholinyl group Chemical group 0.000 description 16
- 125000004193 piperazinyl group Chemical group 0.000 description 16
- 125000003386 piperidinyl group Chemical group 0.000 description 16
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 16
- 102000004169 proteins and genes Human genes 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 15
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 15
- 125000000335 thiazolyl group Chemical group 0.000 description 15
- 125000002950 monocyclic group Chemical group 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 125000001183 hydrocarbyl group Chemical group 0.000 description 12
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 12
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 12
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 12
- 125000005879 dioxolanyl group Chemical group 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 125000002632 imidazolidinyl group Chemical group 0.000 description 11
- 125000003566 oxetanyl group Chemical group 0.000 description 11
- 125000004076 pyridyl group Chemical group 0.000 description 11
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 10
- 102000014914 Carrier Proteins Human genes 0.000 description 10
- 108091008324 binding proteins Proteins 0.000 description 10
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 10
- 125000004122 cyclic group Chemical group 0.000 description 10
- 125000000532 dioxanyl group Chemical group 0.000 description 10
- FEIACFYXEWBKHU-UHFFFAOYSA-N (2-aminopyridin-3-yl)methanol Chemical compound NC1=NC=CC=C1CO FEIACFYXEWBKHU-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 102220507255 Rab11 family-interacting protein 1_R39K_mutation Human genes 0.000 description 9
- 102220642468 Gap junction alpha-8 protein_R19A_mutation Human genes 0.000 description 8
- 239000000427 antigen Substances 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 229940124597 therapeutic agent Drugs 0.000 description 8
- 102220506785 Vitelline membrane outer layer protein 1 homolog_R44A_mutation Human genes 0.000 description 7
- GCVFCUPRTZORNH-UHFFFAOYSA-N n,n-dimethyl-3-[4-(1,10-phenanthrolin-4-yl)butoxy]aniline;2-pyridin-2-ylpyridine;ruthenium Chemical compound [Ru].N1=CC=CC=C1C1=CC=CC=N1.N1=CC=CC=C1C1=CC=CC=N1.CN(C)C1=CC=CC(OCCCCC=2C3=C(C4=NC=CC=C4C=C3)N=CC=2)=C1 GCVFCUPRTZORNH-UHFFFAOYSA-N 0.000 description 7
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 7
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 6
- JAZMZJDLZUDIDG-NSCUHMNNSA-N (4-bromophenyl)[4-({(2e)-4-[cyclopropyl(methyl)amino]but-2-enyl}oxy)phenyl]methanone Chemical compound C1CC1N(C)C\C=C\COC(C=C1)=CC=C1C(=O)C1=CC=C(Br)C=C1 JAZMZJDLZUDIDG-NSCUHMNNSA-N 0.000 description 6
- 102220598664 5-hydroxytryptamine receptor 1E_R36A_mutation Human genes 0.000 description 6
- 102220598618 5-hydroxytryptamine receptor 1E_R43A_mutation Human genes 0.000 description 6
- DGGKXQQCVPAUEA-UHFFFAOYSA-N 8-azabicyclo[3.2.1]octane Chemical compound C1CCC2CCC1N2 DGGKXQQCVPAUEA-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 102220614548 Calmodulin-3_R23A_mutation Human genes 0.000 description 6
- 102220473072 Chemerin-like receptor 2_R14Q_mutation Human genes 0.000 description 6
- 102220642541 Gap junction alpha-8 protein_R47A_mutation Human genes 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 102220519218 Trypsin-2_R31A_mutation Human genes 0.000 description 6
- 102220519117 Trypsin-2_R48A_mutation Human genes 0.000 description 6
- 102220479644 Voltage-dependent L-type calcium channel subunit beta-2_R42A_mutation Human genes 0.000 description 6
- 125000002947 alkylene group Chemical group 0.000 description 6
- 150000001721 carbon Chemical group 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 102220500097 eIF5-mimic protein 2_R34A_mutation Human genes 0.000 description 6
- 125000002541 furyl group Chemical group 0.000 description 6
- 125000005842 heteroatom Chemical group 0.000 description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 125000002883 imidazolyl group Chemical group 0.000 description 6
- 125000001786 isothiazolyl group Chemical group 0.000 description 6
- 125000000842 isoxazolyl group Chemical group 0.000 description 6
- 229940043355 kinase inhibitor Drugs 0.000 description 6
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 6
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 6
- 125000003373 pyrazinyl group Chemical group 0.000 description 6
- 125000003226 pyrazolyl group Chemical group 0.000 description 6
- 125000002098 pyridazinyl group Chemical group 0.000 description 6
- 125000000714 pyrimidinyl group Chemical group 0.000 description 6
- 125000000168 pyrrolyl group Chemical group 0.000 description 6
- 229930195734 saturated hydrocarbon Natural products 0.000 description 6
- 125000003831 tetrazolyl group Chemical group 0.000 description 6
- 125000001544 thienyl group Chemical group 0.000 description 6
- 125000004306 triazinyl group Chemical group 0.000 description 6
- 125000001425 triazolyl group Chemical group 0.000 description 6
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 5
- 102220503968 Endogenous retrovirus group K member 6 Rec protein_R20A_mutation Human genes 0.000 description 5
- 235000019483 Peanut oil Nutrition 0.000 description 5
- 229940124639 Selective inhibitor Drugs 0.000 description 5
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 5
- 125000002393 azetidinyl group Chemical group 0.000 description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 5
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 5
- 125000002971 oxazolyl group Chemical group 0.000 description 5
- 239000000312 peanut oil Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 229940002612 prodrug Drugs 0.000 description 5
- 239000000651 prodrug Substances 0.000 description 5
- 102000001301 EGF receptor Human genes 0.000 description 4
- 108060006698 EGF receptor Proteins 0.000 description 4
- 102220503974 Endogenous retrovirus group K member 6 Rec protein_R13A_mutation Human genes 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 102220506783 Vitelline membrane outer layer protein 1 homolog_R10A_mutation Human genes 0.000 description 4
- 102220469750 Voltage-dependent L-type calcium channel subunit beta-2_R50A_mutation Human genes 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 108700000711 bcl-X Proteins 0.000 description 4
- 102000055104 bcl-X Human genes 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- MNJVRJDLRVPLFE-UHFFFAOYSA-N etoricoxib Chemical compound C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- AYUNIORJHRXIBJ-TXHRRWQRSA-N tanespimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCC=C)C(=O)C=C1C2=O AYUNIORJHRXIBJ-TXHRRWQRSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 229910001868 water Inorganic materials 0.000 description 4
- PVCULFYROUOVGJ-UHFFFAOYSA-N 1-[2-chloroethyl(methylsulfonyl)amino]-3-methyl-1-methylsulfonylurea Chemical compound CNC(=O)N(S(C)(=O)=O)N(S(C)(=O)=O)CCCl PVCULFYROUOVGJ-UHFFFAOYSA-N 0.000 description 3
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 3
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 description 3
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 3
- 102000009058 Death Domain Receptors Human genes 0.000 description 3
- 108010049207 Death Domain Receptors Proteins 0.000 description 3
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 3
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 3
- 108091008606 PDGF receptors Proteins 0.000 description 3
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 3
- 102220507264 Rab11 family-interacting protein 1_R29A_mutation Human genes 0.000 description 3
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 229940049595 antibody-drug conjugate Drugs 0.000 description 3
- 239000003719 aurora kinase inhibitor Substances 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 235000019437 butane-1,3-diol Nutrition 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 235000005687 corn oil Nutrition 0.000 description 3
- 239000002285 corn oil Substances 0.000 description 3
- 235000012343 cottonseed oil Nutrition 0.000 description 3
- 239000002385 cottonseed oil Substances 0.000 description 3
- 229910052805 deuterium Inorganic materials 0.000 description 3
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 3
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 3
- 229960004945 etoricoxib Drugs 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 3
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 3
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 229960000435 oblimersen Drugs 0.000 description 3
- MIMNFCVQODTQDP-NDLVEFNKSA-N oblimersen Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(S)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)CO)[C@@H](O)C1 MIMNFCVQODTQDP-NDLVEFNKSA-N 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- 230000000704 physical effect Effects 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 229940121649 protein inhibitor Drugs 0.000 description 3
- 239000012268 protein inhibitor Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000002336 ribonucleotide Substances 0.000 description 3
- 102220264184 rs1554736515 Human genes 0.000 description 3
- BTIHMVBBUGXLCJ-OAHLLOKOSA-N seliciclib Chemical compound C=12N=CN(C(C)C)C2=NC(N[C@@H](CO)CC)=NC=1NCC1=CC=CC=C1 BTIHMVBBUGXLCJ-OAHLLOKOSA-N 0.000 description 3
- 239000008159 sesame oil Substances 0.000 description 3
- 235000011803 sesame oil Nutrition 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 125000006033 1,1-dimethyl-2-propenyl group Chemical group 0.000 description 2
- 229940058015 1,3-butylene glycol Drugs 0.000 description 2
- SWQQELWGJDXCFT-PNHWDRBUSA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-ethynylimidazole-4-carboxamide Chemical compound C#CC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 SWQQELWGJDXCFT-PNHWDRBUSA-N 0.000 description 2
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- UTQNKKSJPHTPBS-UHFFFAOYSA-N 2,2,2-trichloroethanone Chemical group ClC(Cl)(Cl)[C]=O UTQNKKSJPHTPBS-UHFFFAOYSA-N 0.000 description 2
- 125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 description 2
- 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 2
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 2
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 2
- 125000006032 3-methyl-3-butenyl group Chemical group 0.000 description 2
- AEKIACAQLIWCTL-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-[4-[(4-morpholin-4-ylcyclohexyl)amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NC(CC1)CCC1N1CCOCC1 AEKIACAQLIWCTL-UHFFFAOYSA-N 0.000 description 2
- PRDHHOYRFMTLDT-UHFFFAOYSA-N 4-[5-[[2-[4-(3-carboxypropanoyloxymethyl)piperidin-1-yl]phenyl]methylsulfamoyl]-2,4-dimethoxyanilino]-4-oxobutanoic acid Chemical compound C1=C(NC(=O)CCC(O)=O)C(OC)=CC(OC)=C1S(=O)(=O)NCC1=CC=CC=C1N1CCC(COC(=O)CCC(O)=O)CC1 PRDHHOYRFMTLDT-UHFFFAOYSA-N 0.000 description 2
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 2
- HPLNQCPCUACXLM-PGUFJCEWSA-N ABT-737 Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 HPLNQCPCUACXLM-PGUFJCEWSA-N 0.000 description 2
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- 101100516553 Caenorhabditis elegans nhr-59 gene Proteins 0.000 description 2
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 2
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 2
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 2
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102000001398 Granzyme Human genes 0.000 description 2
- 108060005986 Granzyme Proteins 0.000 description 2
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 2
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 2
- 108090000353 Histone deacetylase Proteins 0.000 description 2
- 102000003964 Histone deacetylase Human genes 0.000 description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 229940121730 Janus kinase 2 inhibitor Drugs 0.000 description 2
- 102000010638 Kinesin Human genes 0.000 description 2
- 108010063296 Kinesin Proteins 0.000 description 2
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 2
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 2
- 102000000424 Matrix Metalloproteinase 2 Human genes 0.000 description 2
- 108010016165 Matrix Metalloproteinase 2 Proteins 0.000 description 2
- 102000001776 Matrix metalloproteinase-9 Human genes 0.000 description 2
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 2
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 2
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 2
- 108091007960 PI3Ks Proteins 0.000 description 2
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 2
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 2
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 2
- 108091028664 Ribonucleotide Proteins 0.000 description 2
- 235000019485 Safflower oil Nutrition 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 2
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 2
- 102220470249 Voltage-dependent L-type calcium channel subunit beta-2_R28A_mutation Human genes 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 229950009084 adecatumumab Drugs 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 125000004450 alkenylene group Chemical group 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000004037 angiogenesis inhibitor Substances 0.000 description 2
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 2
- 230000000340 anti-metabolite Effects 0.000 description 2
- 239000000611 antibody drug conjugate Substances 0.000 description 2
- 229940100197 antimetabolite Drugs 0.000 description 2
- 239000002256 antimetabolite Substances 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 229940121357 antivirals Drugs 0.000 description 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 2
- 125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 description 2
- 125000004266 aziridin-1-yl group Chemical group [H]C1([H])N(*)C1([H])[H] 0.000 description 2
- 229960002707 bendamustine Drugs 0.000 description 2
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 229960003008 blinatumomab Drugs 0.000 description 2
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical group C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 2
- 125000002668 chloroacetyl group Chemical group ClCC(=O)* 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 2
- 125000005724 cycloalkenylene group Chemical group 0.000 description 2
- 125000002993 cycloalkylene group Chemical group 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 229960002448 dasatinib Drugs 0.000 description 2
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 2
- WAZQAZKAZLXFMK-UHFFFAOYSA-N deracoxib Chemical compound C1=C(F)C(OC)=CC=C1C1=CC(C(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 WAZQAZKAZLXFMK-UHFFFAOYSA-N 0.000 description 2
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 229960001433 erlotinib Drugs 0.000 description 2
- NNYBQONXHNTVIJ-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=C1C(C=CC=C1CC)=C1N2 NNYBQONXHNTVIJ-UHFFFAOYSA-N 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 2
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 2
- 229960004891 lapatinib Drugs 0.000 description 2
- 229950002884 lexatumumab Drugs 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- KHPKQFYUPIUARC-UHFFFAOYSA-N lumiracoxib Chemical compound OC(=O)CC1=CC(C)=CC=C1NC1=C(F)C=CC=C1Cl KHPKQFYUPIUARC-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 2
- 229960001924 melphalan Drugs 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 2
- 125000004092 methylthiomethyl group Chemical group [H]C([H])([H])SC([H])([H])* 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 229960002009 naproxen Drugs 0.000 description 2
- 229950004847 navitoclax Drugs 0.000 description 2
- JLYAXFNOILIKPP-KXQOOQHDSA-N navitoclax Chemical compound C([C@@H](NC1=CC=C(C=C1S(=O)(=O)C(F)(F)F)S(=O)(=O)NC(=O)C1=CC=C(C=C1)N1CCN(CC1)CC1=C(CCC(C1)(C)C)C=1C=CC(Cl)=CC=1)CSC=1C=CC=CC=1)CN1CCOCC1 JLYAXFNOILIKPP-KXQOOQHDSA-N 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- WBXPDJSOTKVWSJ-ZDUSSCGKSA-N pemetrexed Chemical compound C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 WBXPDJSOTKVWSJ-ZDUSSCGKSA-N 0.000 description 2
- 229930192851 perforin Natural products 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 2
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 2
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 229940069328 povidone Drugs 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 125000002652 ribonucleotide group Chemical group 0.000 description 2
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 2
- 239000003813 safflower oil Substances 0.000 description 2
- 235000005713 safflower oil Nutrition 0.000 description 2
- WVYADZUPLLSGPU-UHFFFAOYSA-N salsalate Chemical compound OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O WVYADZUPLLSGPU-UHFFFAOYSA-N 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 229960000894 sulindac Drugs 0.000 description 2
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 2
- 229960000235 temsirolimus Drugs 0.000 description 2
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000000037 tert-butyldiphenylsilyl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1[Si]([H])([*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 2
- 229940126585 therapeutic drug Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 229960000575 trastuzumab Drugs 0.000 description 2
- 150000003852 triazoles Chemical class 0.000 description 2
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 2
- 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 2
- 125000005455 trithianyl group Chemical group 0.000 description 2
- 229940094060 tykerb Drugs 0.000 description 2
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- WZRFLSDVFPIXOV-LRQRDZAKSA-N (2s)-1-[(2s)-2-cyclohexyl-2-[[(2s)-2-(methylamino)propanoyl]amino]acetyl]-n-(4-phenylthiadiazol-5-yl)pyrrolidine-2-carboxamide Chemical compound C1([C@H](NC(=O)[C@H](C)NC)C(=O)N2[C@@H](CCC2)C(=O)NC2=C(N=NS2)C=2C=CC=CC=2)CCCCC1 WZRFLSDVFPIXOV-LRQRDZAKSA-N 0.000 description 1
- BXTJCSYMGFJEID-XMTADJHZSA-N (2s)-2-[[(2r,3r)-3-[(2s)-1-[(3r,4s,5s)-4-[[(2s)-2-[[(2s)-2-[6-[3-[(2r)-2-amino-2-carboxyethyl]sulfanyl-2,5-dioxopyrrolidin-1-yl]hexanoyl-methylamino]-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methoxy-5-methylheptanoyl]pyrrolidin-2-yl]-3-met Chemical compound C([C@H](NC(=O)[C@H](C)[C@@H](OC)[C@@H]1CCCN1C(=O)C[C@H]([C@H]([C@@H](C)CC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)CCCCCN1C(C(SC[C@H](N)C(O)=O)CC1=O)=O)C(C)C)OC)C(O)=O)C1=CC=CC=C1 BXTJCSYMGFJEID-XMTADJHZSA-N 0.000 description 1
- QXOPTIPQEVJERB-JQWIXIFHSA-N (2s)-2-[[5-[2-[(6s)-2-amino-4-oxo-5,6,7,8-tetrahydro-1h-pyrido[2,3-d]pyrimidin-6-yl]ethyl]-4-methylthiophene-2-carbonyl]amino]pentanedioic acid Chemical compound C1=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)SC(CC[C@H]2CC=3C(=O)N=C(N)NC=3NC2)=C1C QXOPTIPQEVJERB-JQWIXIFHSA-N 0.000 description 1
- MHFUWOIXNMZFIW-WNQIDUERSA-N (2s)-2-hydroxypropanoic acid;n-[4-[4-(4-methylpiperazin-1-yl)-6-[(5-methyl-1h-pyrazol-3-yl)amino]pyrimidin-2-yl]sulfanylphenyl]cyclopropanecarboxamide Chemical compound C[C@H](O)C(O)=O.C1CN(C)CCN1C1=CC(NC2=NNC(C)=C2)=NC(SC=2C=CC(NC(=O)C3CC3)=CC=2)=N1 MHFUWOIXNMZFIW-WNQIDUERSA-N 0.000 description 1
- ZFKBWSREWJOSSJ-VIFPVBQESA-N (2s)-6,8-dichloro-2-(trifluoromethyl)-2h-chromene-3-carboxylic acid Chemical compound ClC1=CC(Cl)=C2O[C@H](C(F)(F)F)C(C(=O)O)=CC2=C1 ZFKBWSREWJOSSJ-VIFPVBQESA-N 0.000 description 1
- UFPFGVNKHCLJJO-SSKFGXFMSA-N (2s)-n-[(1s)-1-cyclohexyl-2-[(2s)-2-[4-(4-fluorobenzoyl)-1,3-thiazol-2-yl]pyrrolidin-1-yl]-2-oxoethyl]-2-(methylamino)propanamide Chemical compound C1([C@H](NC(=O)[C@H](C)NC)C(=O)N2[C@@H](CCC2)C=2SC=C(N=2)C(=O)C=2C=CC(F)=CC=2)CCCCC1 UFPFGVNKHCLJJO-SSKFGXFMSA-N 0.000 description 1
- HCSMRSHIIKPNAK-LSAVBLLPSA-N (2s)-n-[(1s)-2-[(3ar,7as)-6-(2-phenylethyl)-3,3a,4,5,7,7a-hexahydro-2h-pyrrolo[2,3-c]pyridin-1-yl]-1-cyclohexyl-2-oxoethyl]-2-(methylamino)propanamide Chemical compound C1([C@H](NC(=O)[C@H](C)NC)C(=O)N2[C@@H]3CN(CCC=4C=CC=CC=4)CC[C@@H]3CC2)CCCCC1 HCSMRSHIIKPNAK-LSAVBLLPSA-N 0.000 description 1
- PSVUJBVBCOISSP-SPFKKGSWSA-N (2s,3r,4s,5s,6r)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound OC[C@H]1O[C@@H](OP(=O)(NCCCl)NCCCl)[C@H](O)[C@@H](O)[C@@H]1O PSVUJBVBCOISSP-SPFKKGSWSA-N 0.000 description 1
- CVCLJVVBHYOXDC-IAZSKANUSA-N (2z)-2-[(5z)-5-[(3,5-dimethyl-1h-pyrrol-2-yl)methylidene]-4-methoxypyrrol-2-ylidene]indole Chemical compound COC1=C\C(=C/2N=C3C=CC=CC3=C\2)N\C1=C/C=1NC(C)=CC=1C CVCLJVVBHYOXDC-IAZSKANUSA-N 0.000 description 1
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- BWDQBBCUWLSASG-MDZDMXLPSA-N (e)-n-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1h-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide Chemical compound C=1NC2=CC=CC=C2C=1CCN(CCO)CC1=CC=C(\C=C\C(=O)NO)C=C1 BWDQBBCUWLSASG-MDZDMXLPSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 125000005940 1,4-dioxanyl group Chemical group 0.000 description 1
- YJEVAUSLDPCMNO-UHFFFAOYSA-N 1,6-dihydropentalene Chemical compound C1C=CC2=C1CC=C2 YJEVAUSLDPCMNO-UHFFFAOYSA-N 0.000 description 1
- WPHKIQPVPYJNAX-UHFFFAOYSA-N 1-[4-[4-amino-7-[1-(2-hydroxyethyl)pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl]phenyl]-3-(3-fluorophenyl)urea Chemical compound C1=2SC=C(C=3C=CC(NC(=O)NC=4C=C(F)C=CC=4)=CC=3)C=2C(N)=NC=C1C=1C=NN(CCO)C=1 WPHKIQPVPYJNAX-UHFFFAOYSA-N 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- CZDWSKBKCZWXFI-UHFFFAOYSA-N 1-morpholin-4-yl-3-[4-oxo-3-[4-[2-oxo-2-(4-propan-2-ylpiperazin-1-yl)ethoxy]phenyl]-1h-indeno[1,2-c]pyrazol-5-yl]urea Chemical compound C1CN(C(C)C)CCN1C(=O)COC1=CC=C(C=2C=3C(=O)C4=C(NC(=O)NN5CCOCC5)C=CC=C4C=3NN=2)C=C1 CZDWSKBKCZWXFI-UHFFFAOYSA-N 0.000 description 1
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- KUFRQPKVAWMTJO-QSTRRNJOSA-N 17-dmag Chemical compound N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(NCCN(C)C)C(=O)C=C1C2=O KUFRQPKVAWMTJO-QSTRRNJOSA-N 0.000 description 1
- 125000003562 2,2-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- 125000003660 2,3-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- LXFQSRIDYRFTJW-UHFFFAOYSA-M 2,4,6-trimethylbenzenesulfonate Chemical compound CC1=CC(C)=C(S([O-])(=O)=O)C(C)=C1 LXFQSRIDYRFTJW-UHFFFAOYSA-M 0.000 description 1
- AHCNJNSTHZDOPE-UHFFFAOYSA-N 2-(1h-benzimidazol-4-yloxy)-4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonylbenzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=3N=CNC=3C=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 AHCNJNSTHZDOPE-UHFFFAOYSA-N 0.000 description 1
- OJDQNDOVWCXMMU-UHFFFAOYSA-N 2-(1h-benzimidazol-4-yloxy)-4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[3-nitro-4-(oxolan-3-ylmethylamino)phenyl]sulfonylbenzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=3N=CNC=3C=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOC1 OJDQNDOVWCXMMU-UHFFFAOYSA-N 0.000 description 1
- NJUUYEWPFTWRRI-UHFFFAOYSA-N 2-(1h-benzimidazol-4-yloxy)-4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[3-nitro-4-[[1-(oxan-4-yl)piperidin-4-yl]amino]phenyl]sulfonylbenzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=3N=CNC=3C=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NC(CC1)CCN1C1CCOCC1 NJUUYEWPFTWRRI-UHFFFAOYSA-N 0.000 description 1
- BNSDGMSTNVNXSD-UHFFFAOYSA-N 2-(1h-benzimidazol-4-yloxy)-4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[3-nitro-4-[[4-(oxetan-3-yl)morpholin-2-yl]methylamino]phenyl]sulfonylbenzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=3N=CNC=3C=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC(OCC1)CN1C1COC1 BNSDGMSTNVNXSD-UHFFFAOYSA-N 0.000 description 1
- UZVXJUUTDBPGFF-UHFFFAOYSA-N 2-(1h-benzimidazol-4-yloxy)-4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-(1,4-dioxan-2-ylmethylamino)-3-nitrophenyl]sulfonylbenzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=3N=CNC=3C=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1COCCO1 UZVXJUUTDBPGFF-UHFFFAOYSA-N 0.000 description 1
- GSUQXGOHVLEXDA-UHFFFAOYSA-N 2-(1h-benzimidazol-4-yloxy)-4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-[(1-cyclopropylpiperidin-4-yl)amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=3N=CNC=3C=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NC(CC1)CCN1C1CC1 GSUQXGOHVLEXDA-UHFFFAOYSA-N 0.000 description 1
- CZKGCFBPARXHCX-UHFFFAOYSA-N 2-(1h-benzimidazol-4-yloxy)-4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-[(1-methylpiperidin-4-yl)amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C1CN(C)CCC1NC1=CC=C(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3CCC(C)(C)CC=3C=3C=CC(Cl)=CC=3)CC2)OC=2C=3N=CNC=3C=CC=2)C=C1[N+]([O-])=O CZKGCFBPARXHCX-UHFFFAOYSA-N 0.000 description 1
- ZUMPWFPPUYDMOU-UHFFFAOYSA-N 2-(1h-benzimidazol-4-yloxy)-4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-[(1-methylpiperidin-4-yl)methylamino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C1CN(C)CCC1CNC1=CC=C(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3CCC(C)(C)CC=3C=3C=CC(Cl)=CC=3)CC2)OC=2C=3N=CNC=3C=CC=2)C=C1[N+]([O-])=O ZUMPWFPPUYDMOU-UHFFFAOYSA-N 0.000 description 1
- QUXVRLXQBAEVJI-UHFFFAOYSA-N 2-(1h-benzimidazol-4-yloxy)-4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-[(4,4-difluorocyclohexyl)methylamino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=3N=CNC=3C=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCC(F)(F)CC1 QUXVRLXQBAEVJI-UHFFFAOYSA-N 0.000 description 1
- WIUHVGICAIKYBB-UHFFFAOYSA-N 2-(1h-benzimidazol-4-yloxy)-4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-[(4-cyclopropylmorpholin-2-yl)methylamino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=3N=CNC=3C=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC(OCC1)CN1C1CC1 WIUHVGICAIKYBB-UHFFFAOYSA-N 0.000 description 1
- PBDHGHZMYNBYFZ-UHFFFAOYSA-N 2-(1h-benzimidazol-4-yloxy)-4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-[(4-fluorooxan-4-yl)methylamino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=3N=CNC=3C=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1(F)CCOCC1 PBDHGHZMYNBYFZ-UHFFFAOYSA-N 0.000 description 1
- JLJXTTBIPXLTSF-UHFFFAOYSA-N 2-(1h-benzimidazol-4-yloxy)-4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-[(4-methylpiperazin-1-yl)amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C1CN(C)CCN1NC1=CC=C(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3CCC(C)(C)CC=3C=3C=CC(Cl)=CC=3)CC2)OC=2C=3N=CNC=3C=CC=2)C=C1[N+]([O-])=O JLJXTTBIPXLTSF-UHFFFAOYSA-N 0.000 description 1
- JZAWPVMEFGREHJ-UHFFFAOYSA-N 2-(1h-benzimidazol-4-yloxy)-4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-[(4-methylsulfonylmorpholin-2-yl)methylamino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=3N=CNC=3C=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CN(S(C)(=O)=O)CCO1 JZAWPVMEFGREHJ-UHFFFAOYSA-N 0.000 description 1
- FOTGOGLEQJRYAN-JGCGQSQUSA-N 2-(1h-benzimidazol-4-yloxy)-4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-[[(3r)-1-(2,2-difluoroethyl)pyrrolidin-3-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=3N=CNC=3C=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1N[C@@H]1CCN(CC(F)F)C1 FOTGOGLEQJRYAN-JGCGQSQUSA-N 0.000 description 1
- LSYDVFJIKOIVLC-MGBGTMOVSA-N 2-(1h-benzimidazol-4-yloxy)-4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-[[(3r)-1-(cyanomethyl)pyrrolidin-3-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=3N=CNC=3C=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1N[C@@H]1CCN(CC#N)C1 LSYDVFJIKOIVLC-MGBGTMOVSA-N 0.000 description 1
- IWGXFILGZJSXOB-UUWRZZSWSA-N 2-(1h-benzimidazol-4-yloxy)-4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-[[(3r)-1-[2-(dimethylamino)acetyl]pyrrolidin-3-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C1N(C(=O)CN(C)C)CC[C@H]1NC1=CC=C(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3CCC(C)(C)CC=3C=3C=CC(Cl)=CC=3)CC2)OC=2C=3N=CNC=3C=CC=2)C=C1[N+]([O-])=O IWGXFILGZJSXOB-UUWRZZSWSA-N 0.000 description 1
- AZUKQLALTVVZID-UHFFFAOYSA-N 2-(1h-benzimidazol-4-yloxy)-4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-[[4-(2,2-difluoroethyl)morpholin-2-yl]methylamino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=3N=CNC=3C=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CN(CC(F)F)CCO1 AZUKQLALTVVZID-UHFFFAOYSA-N 0.000 description 1
- ORWXNNZFIKXSNV-UHFFFAOYSA-N 2-(1h-benzimidazol-4-yloxy)-4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[5-fluoro-6-[(4-fluorooxan-4-yl)methoxy]pyridin-3-yl]sulfonylbenzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=3N=CNC=3C=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1F)=CN=C1OCC1(F)CCOCC1 ORWXNNZFIKXSNV-UHFFFAOYSA-N 0.000 description 1
- XNTLXAUHLBBEKP-UHFFFAOYSA-N 2-(3,4-difluorophenyl)-4-(3-hydroxy-3-methylbutoxy)-5-(4-methylsulfonylphenyl)pyridazin-3-one Chemical compound O=C1C(OCCC(C)(O)C)=C(C=2C=CC(=CC=2)S(C)(=O)=O)C=NN1C1=CC=C(F)C(F)=C1 XNTLXAUHLBBEKP-UHFFFAOYSA-N 0.000 description 1
- PBUUPFTVAPUWDE-UGZDLDLSSA-N 2-[[(2S,4S)-2-[bis(2-chloroethyl)amino]-2-oxo-1,3,2lambda5-oxazaphosphinan-4-yl]sulfanyl]ethanesulfonic acid Chemical compound OS(=O)(=O)CCS[C@H]1CCO[P@](=O)(N(CCCl)CCCl)N1 PBUUPFTVAPUWDE-UGZDLDLSSA-N 0.000 description 1
- PZGDGDLBNWDMGL-UHFFFAOYSA-N 2-benzyl-4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-(3-morpholin-4-ylpropylamino)-3-nitrophenyl]sulfonylbenzamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)CC=2C=CC=CC=2)=CC=C1NCCCN1CCOCC1 PZGDGDLBNWDMGL-UHFFFAOYSA-N 0.000 description 1
- IXVAISUDODBKOU-UHFFFAOYSA-N 2-benzyl-4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-(oxan-4-ylmethylamino)phenyl]sulfonylbenzamide Chemical compound C1=CC(Cl)=CC=C1C1=CC=CC=C1CN1CCN(C=2C=C(CC=3C=CC=CC=3)C(C(=O)NS(=O)(=O)C=3C=CC(NCC4CCOCC4)=CC=3)=CC=2)CC1 IXVAISUDODBKOU-UHFFFAOYSA-N 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical class C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 1
- 125000006022 2-methyl-2-propenyl group Chemical group 0.000 description 1
- CJCOBMTYEDBBSY-UHFFFAOYSA-N 2-phenoxybenzamide Chemical compound NC(=O)C1=CC=CC=C1OC1=CC=CC=C1 CJCOBMTYEDBBSY-UHFFFAOYSA-N 0.000 description 1
- GTKIGDZXPDCIKR-UHFFFAOYSA-N 2-phenylbenzamide Chemical compound NC(=O)C1=CC=CC=C1C1=CC=CC=C1 GTKIGDZXPDCIKR-UHFFFAOYSA-N 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- 125000002774 3,4-dimethoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
- RQUCIYUYJHVVIL-UHFFFAOYSA-N 3-[[5-(4-chlorobenzoyl)-1,4-dimethylpyrrol-2-yl]methyl]-1h-pyridazin-6-one Chemical compound CN1C(C(=O)C=2C=CC(Cl)=CC=2)=C(C)C=C1CC=1C=CC(=O)NN=1 RQUCIYUYJHVVIL-UHFFFAOYSA-N 0.000 description 1
- LICHZOBEUWVYSY-UHFFFAOYSA-N 3-azabicyclo[3.2.2]nonane Chemical compound C1CC2CCC1CNC2 LICHZOBEUWVYSY-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- 125000004080 3-carboxypropanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C(O[H])=O 0.000 description 1
- 125000003469 3-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- JRBAQAMOIBHJRP-UHFFFAOYSA-N 4,5,6,7-tetrahydro-3ah-indene Chemical compound C1CCCC2=CC=CC21 JRBAQAMOIBHJRP-UHFFFAOYSA-N 0.000 description 1
- WJRRGYBTGDJBFX-UHFFFAOYSA-N 4-(2-methyl-3-propan-2-yl-4-imidazolyl)-N-(4-methylsulfonylphenyl)-2-pyrimidinamine Chemical compound CC(C)N1C(C)=NC=C1C1=CC=NC(NC=2C=CC(=CC=2)S(C)(=O)=O)=N1 WJRRGYBTGDJBFX-UHFFFAOYSA-N 0.000 description 1
- SRLPXQPMWLUFFB-UHFFFAOYSA-N 4-[4-[1-[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]ethyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonylbenzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1C(C)N(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 SRLPXQPMWLUFFB-UHFFFAOYSA-N 0.000 description 1
- LOAYDUWNYSUJBB-UHFFFAOYSA-N 4-[4-[1-[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]ethyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-[3-nitro-4-[[1-(oxan-4-yl)piperidin-4-yl]amino]phenyl]sulfonylbenzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1C(C)N(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NC(CC1)CCN1C1CCOCC1 LOAYDUWNYSUJBB-UHFFFAOYSA-N 0.000 description 1
- BUZLZTNLOGFYNY-UHFFFAOYSA-N 4-[4-[1-[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]ethyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-[4-(3-morpholin-4-ylpropylamino)-3-nitrophenyl]sulfonylbenzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1C(C)N(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCCCN1CCOCC1 BUZLZTNLOGFYNY-UHFFFAOYSA-N 0.000 description 1
- KYKSQHVYRDJDDF-UHFFFAOYSA-N 4-[4-[1-[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]ethyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-[4-[(4-methylpiperazin-1-yl)amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1C(C)N(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NN1CCN(C)CC1 KYKSQHVYRDJDDF-UHFFFAOYSA-N 0.000 description 1
- JMWXUESQMMAVFU-UHFFFAOYSA-N 4-[4-[1-[2-(4-chlorophenyl)phenyl]ethyl]piperazin-1-yl]-2-(1h-indol-4-yloxy)-n-[4-(3-morpholin-4-ylpropylamino)-3-nitrophenyl]sulfonylbenzamide Chemical compound C=1C=CC=C(C=2C=CC(Cl)=CC=2)C=1C(C)N(CC1)CCN1C(C=C1OC=2C=3C=CNC=3C=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCCCN1CCOCC1 JMWXUESQMMAVFU-UHFFFAOYSA-N 0.000 description 1
- DPTBOBFTJGDLPT-UHFFFAOYSA-N 4-[4-[1-[2-(4-chlorophenyl)phenyl]ethyl]piperazin-1-yl]-2-(1h-indol-4-yloxy)-n-[4-[(1-methylpiperidin-4-yl)amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C=1C=CC=C(C=2C=CC(Cl)=CC=2)C=1C(C)N(CC1)CCN1C(C=C1OC=2C=3C=CNC=3C=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NC1CCN(C)CC1 DPTBOBFTJGDLPT-UHFFFAOYSA-N 0.000 description 1
- GBYVRBFRWLRCDQ-UHFFFAOYSA-N 4-[4-[1-[2-(4-chlorophenyl)phenyl]ethyl]piperazin-1-yl]-2-(1h-indol-4-yloxy)-n-[4-[(4-methylpiperazin-1-yl)amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C=1C=CC=C(C=2C=CC(Cl)=CC=2)C=1C(C)N(CC1)CCN1C(C=C1OC=2C=3C=CNC=3C=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NN1CCN(C)CC1 GBYVRBFRWLRCDQ-UHFFFAOYSA-N 0.000 description 1
- DOIRGIGOPKQZNI-UHFFFAOYSA-N 4-[4-[1-[2-(4-chlorophenyl)phenyl]ethyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonylbenzamide Chemical compound C=1C=CC=C(C=2C=CC(Cl)=CC=2)C=1C(C)N(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 DOIRGIGOPKQZNI-UHFFFAOYSA-N 0.000 description 1
- MBGREGDWTYAYPX-UHFFFAOYSA-N 4-[4-[[2-(3-azabicyclo[3.2.2]nonan-3-yl)phenyl]methyl]piperazin-1-yl]-n-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonyl-2-phenoxybenzamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)N3CC4CCC(CC4)C3)CC2)OC=2C=CC=CC=2)=CC=C1NCC1CCOCC1 MBGREGDWTYAYPX-UHFFFAOYSA-N 0.000 description 1
- RCFZDDLKUGEZEB-UHFFFAOYSA-N 4-[4-[[2-(3-azabicyclo[3.2.2]nonan-3-yl)phenyl]methyl]piperazin-1-yl]-n-[4-(oxan-4-ylmethylamino)-3-(trifluoromethylsulfonyl)phenyl]sulfonyl-2-phenoxybenzamide Chemical compound FC(F)(F)S(=O)(=O)C1=CC(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)N3CC4CCC(CC4)C3)CC2)OC=2C=CC=CC=2)=CC=C1NCC1CCOCC1 RCFZDDLKUGEZEB-UHFFFAOYSA-N 0.000 description 1
- IIOZHUNRXKEBED-UHFFFAOYSA-N 4-[4-[[2-(3-azabicyclo[3.2.2]nonan-3-yl)phenyl]methyl]piperazin-1-yl]-n-[4-(oxan-4-ylmethylamino)phenyl]sulfonyl-2-phenoxybenzamide Chemical compound C=1C=C(N2CCN(CC=3C(=CC=CC=3)N3CC4CCC(CC4)C3)CC2)C=C(OC=2C=CC=CC=2)C=1C(=O)NS(=O)(=O)C(C=C1)=CC=C1NCC1CCOCC1 IIOZHUNRXKEBED-UHFFFAOYSA-N 0.000 description 1
- JWXNIPIHRFDSPV-UHFFFAOYSA-N 4-[4-[[2-(3-fluorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-4-yloxy)-n-[3-nitro-4-(3-pyrrolidin-1-ylpropylamino)phenyl]sulfonylbenzamide Chemical compound C=1C=CC(F)=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=3C=CNC=3C=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCCCN1CCCC1 JWXNIPIHRFDSPV-UHFFFAOYSA-N 0.000 description 1
- GYYXORHPOYPHPN-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]-3-(hydroxymethyl)piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-[4-[(1-methylpiperidin-4-yl)amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C1CN(C)CCC1NC1=CC=C(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CC(CO)N(CC=3CCC(C)(C)CC=3C=3C=CC(Cl)=CC=3)CC2)OC=2C=C3C=CNC3=CC=2)C=C1[N+]([O-])=O GYYXORHPOYPHPN-UHFFFAOYSA-N 0.000 description 1
- IIKYWYNMTFUCFU-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-4-yloxy)-n-[3-nitro-4-(3-pyrrolidin-1-ylpropylamino)phenyl]sulfonylbenzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=3C=CNC=3C=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCCCN1CCCC1 IIKYWYNMTFUCFU-UHFFFAOYSA-N 0.000 description 1
- ORKPNCUVXKYCRR-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-4-yloxy)-n-[3-nitro-4-(oxan-4-ylmethoxy)phenyl]sulfonylbenzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=3C=CNC=3C=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1OCC1CCOCC1 ORKPNCUVXKYCRR-UHFFFAOYSA-N 0.000 description 1
- ANGYQYQCNXYHET-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-4-yloxy)-n-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonylbenzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=3C=CNC=3C=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 ANGYQYQCNXYHET-UHFFFAOYSA-N 0.000 description 1
- UEHUWXJYTIDVSQ-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-4-yloxy)-n-[3-nitro-4-[2-(3-oxopiperazin-1-yl)ethylamino]phenyl]sulfonylbenzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=3C=CNC=3C=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCCN1CCNC(=O)C1 UEHUWXJYTIDVSQ-UHFFFAOYSA-N 0.000 description 1
- KOWTVLSRGCDXBR-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-4-yloxy)-n-[3-nitro-4-[2-(trifluoromethoxy)ethylamino]phenyl]sulfonylbenzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=3C=CNC=3C=CC=2)=CC=C1C(=O)NS(=O)(=O)C1=CC=C(NCCOC(F)(F)F)C([N+]([O-])=O)=C1 KOWTVLSRGCDXBR-UHFFFAOYSA-N 0.000 description 1
- LXMJHVXHVBKNEE-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-4-yloxy)-n-[3-nitro-4-[3-(3-oxopiperazin-1-yl)propylamino]phenyl]sulfonylbenzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=3C=CNC=3C=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCCCN1CCNC(=O)C1 LXMJHVXHVBKNEE-UHFFFAOYSA-N 0.000 description 1
- DKXBXPNDIWPVSD-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-4-yloxy)-n-[3-nitro-4-[[1-(2,2,2-trifluoroethyl)piperidin-4-yl]amino]phenyl]sulfonylbenzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=3C=CNC=3C=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NC1CCN(CC(F)(F)F)CC1 DKXBXPNDIWPVSD-UHFFFAOYSA-N 0.000 description 1
- YTWHFNWPMBBDGQ-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-4-yloxy)-n-[3-nitro-4-[[1-(4,4,4-trifluorobutyl)piperidin-4-yl]amino]phenyl]sulfonylbenzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=3C=CNC=3C=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NC1CCN(CCCC(F)(F)F)CC1 YTWHFNWPMBBDGQ-UHFFFAOYSA-N 0.000 description 1
- AMSTUFUVRHXYIH-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-4-yloxy)-n-[4-(2-methoxyethylamino)-3-nitrophenyl]sulfonylbenzamide Chemical compound C1=C([N+]([O-])=O)C(NCCOC)=CC=C1S(=O)(=O)NC(=O)C1=CC=C(N2CCN(CC=3CCC(C)(C)CC=3C=3C=CC(Cl)=CC=3)CC2)C=C1OC1=CC=CC2=C1C=CN2 AMSTUFUVRHXYIH-UHFFFAOYSA-N 0.000 description 1
- YUGFYQJCMWTPQD-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-4-yloxy)-n-[4-(3-methoxypropylamino)-3-nitrophenyl]sulfonylbenzamide Chemical compound C1=C([N+]([O-])=O)C(NCCCOC)=CC=C1S(=O)(=O)NC(=O)C1=CC=C(N2CCN(CC=3CCC(C)(C)CC=3C=3C=CC(Cl)=CC=3)CC2)C=C1OC1=CC=CC2=C1C=CN2 YUGFYQJCMWTPQD-UHFFFAOYSA-N 0.000 description 1
- LFVCWNFYAYKXPY-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-4-yloxy)-n-[4-(3-methylsulfonylpropoxy)-3-nitrophenyl]sulfonylbenzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=3C=CNC=3C=CC=2)=CC=C1C(=O)NS(=O)(=O)C1=CC=C(OCCCS(C)(=O)=O)C([N+]([O-])=O)=C1 LFVCWNFYAYKXPY-UHFFFAOYSA-N 0.000 description 1
- ORVZVQHRPILFPL-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-4-yloxy)-n-[4-(3-morpholin-4-ylpropylamino)-3-(trifluoromethylsulfonyl)phenyl]sulfonylbenzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=3C=CNC=3C=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1S(=O)(=O)C(F)(F)F)=CC=C1NCCCN1CCOCC1 ORVZVQHRPILFPL-UHFFFAOYSA-N 0.000 description 1
- HINHREFNLCARQO-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-4-yloxy)-n-[4-(3-morpholin-4-ylpropylamino)-3-nitrophenyl]sulfonylbenzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=3C=CNC=3C=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCCCN1CCOCC1 HINHREFNLCARQO-UHFFFAOYSA-N 0.000 description 1
- GULFHRJQQXLORG-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-4-yloxy)-n-[4-(methylamino)-3-nitrophenyl]sulfonylbenzamide Chemical compound C1=C([N+]([O-])=O)C(NC)=CC=C1S(=O)(=O)NC(=O)C1=CC=C(N2CCN(CC=3CCC(C)(C)CC=3C=3C=CC(Cl)=CC=3)CC2)C=C1OC1=CC=CC2=C1C=CN2 GULFHRJQQXLORG-UHFFFAOYSA-N 0.000 description 1
- LSKQIKORFDACDH-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-4-yloxy)-n-[4-(morpholin-4-ylamino)-3-nitrophenyl]sulfonylbenzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=3C=CNC=3C=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NN1CCOCC1 LSKQIKORFDACDH-UHFFFAOYSA-N 0.000 description 1
- QJPHHGOMJZFEDC-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-4-yloxy)-n-[4-[(1-methylpiperidin-4-yl)amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C1CN(C)CCC1NC1=CC=C(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3CCC(C)(C)CC=3C=3C=CC(Cl)=CC=3)CC2)OC=2C=3C=CNC=3C=CC=2)C=C1[N+]([O-])=O QJPHHGOMJZFEDC-UHFFFAOYSA-N 0.000 description 1
- SIHXPTZCFZKXNO-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-4-yloxy)-n-[4-[(1-methylpiperidin-4-yl)methylamino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C1CN(C)CCC1CNC1=CC=C(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3CCC(C)(C)CC=3C=3C=CC(Cl)=CC=3)CC2)OC=2C=3C=CNC=3C=CC=2)C=C1[N+]([O-])=O SIHXPTZCFZKXNO-UHFFFAOYSA-N 0.000 description 1
- WRLFTPLREDDPRW-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-4-yloxy)-n-[4-[(4-methylpiperazin-1-yl)amino]-3-(trifluoromethylsulfonyl)phenyl]sulfonylbenzamide Chemical compound C1CN(C)CCN1NC1=CC=C(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3CCC(C)(C)CC=3C=3C=CC(Cl)=CC=3)CC2)OC=2C=3C=CNC=3C=CC=2)C=C1S(=O)(=O)C(F)(F)F WRLFTPLREDDPRW-UHFFFAOYSA-N 0.000 description 1
- QEAGDBYWUQBOMU-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-4-yloxy)-n-[4-[(4-morpholin-4-ylcyclohexyl)amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=3C=CNC=3C=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NC(CC1)CCC1N1CCOCC1 QEAGDBYWUQBOMU-UHFFFAOYSA-N 0.000 description 1
- KHLVRXUJMWWUOO-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-4-yloxy)-n-[4-[2-(2-methoxyethoxy)ethylamino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C1=C([N+]([O-])=O)C(NCCOCCOC)=CC=C1S(=O)(=O)NC(=O)C1=CC=C(N2CCN(CC=3CCC(C)(C)CC=3C=3C=CC(Cl)=CC=3)CC2)C=C1OC1=CC=CC2=C1C=CN2 KHLVRXUJMWWUOO-UHFFFAOYSA-N 0.000 description 1
- HFTDAXLMCHSNAI-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-4-yloxy)-n-[4-[2-(4-methylpiperazin-1-yl)ethylamino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C1CN(C)CCN1CCNC1=CC=C(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3CCC(C)(C)CC=3C=3C=CC(Cl)=CC=3)CC2)OC=2C=3C=CNC=3C=CC=2)C=C1[N+]([O-])=O HFTDAXLMCHSNAI-UHFFFAOYSA-N 0.000 description 1
- SRLJYFFBVXDOTI-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-4-yloxy)-n-[4-[3-(4-methylpiperazin-1-yl)propylamino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C1CN(C)CCN1CCCNC1=CC=C(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3CCC(C)(C)CC=3C=3C=CC(Cl)=CC=3)CC2)OC=2C=3C=CNC=3C=CC=2)C=C1[N+]([O-])=O SRLJYFFBVXDOTI-UHFFFAOYSA-N 0.000 description 1
- SLNWXLQLGAPAHN-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-4-yloxy)-n-[6-(oxan-4-ylmethylamino)-5-(1,3-thiazol-2-yl)pyridin-3-yl]sulfonylbenzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=3C=CNC=3C=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1C=2SC=CN=2)=CN=C1NCC1CCOCC1 SLNWXLQLGAPAHN-UHFFFAOYSA-N 0.000 description 1
- SKKYPZPXYWYIQZ-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-(4-morpholin-4-yl-3-nitrophenyl)sulfonylbenzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1N1CCOCC1 SKKYPZPXYWYIQZ-UHFFFAOYSA-N 0.000 description 1
- HFDOAPBMMXPZDJ-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-[3-(oxan-4-ylmethylcarbamoyl)phenyl]sulfonylbenzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=1)=CC=CC=1C(=O)NCC1CCOCC1 HFDOAPBMMXPZDJ-UHFFFAOYSA-N 0.000 description 1
- UYRCGZKXPUFIQX-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-[3-nitro-4-(1,3-thiazol-5-ylmethylamino)phenyl]sulfonylbenzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1=CN=CS1 UYRCGZKXPUFIQX-UHFFFAOYSA-N 0.000 description 1
- GSCOZNGMHBLYSQ-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-[3-nitro-4-(2-pyridin-4-ylethylamino)phenyl]sulfonylbenzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCCC1=CC=NC=C1 GSCOZNGMHBLYSQ-UHFFFAOYSA-N 0.000 description 1
- WQMOMLXCXGUTED-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-[3-nitro-4-(oxan-3-ylmethylamino)phenyl]sulfonylbenzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCCOC1 WQMOMLXCXGUTED-UHFFFAOYSA-N 0.000 description 1
- SBMXYHCYNLVMNA-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-[3-nitro-4-(oxan-4-ylamino)phenyl]sulfonylbenzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NC1CCOCC1 SBMXYHCYNLVMNA-UHFFFAOYSA-N 0.000 description 1
- ALOBUWIMEZJCIY-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-[3-nitro-4-(oxan-4-ylmethoxy)phenyl]sulfonylbenzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1OCC1CCOCC1 ALOBUWIMEZJCIY-UHFFFAOYSA-N 0.000 description 1
- QJRIMYPQWHCYNY-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonylbenzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 QJRIMYPQWHCYNY-UHFFFAOYSA-N 0.000 description 1
- ZTRJCUPPQQJUQR-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-[3-nitro-4-(piperidin-1-ylamino)phenyl]sulfonylbenzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NN1CCCCC1 ZTRJCUPPQQJUQR-UHFFFAOYSA-N 0.000 description 1
- YGFFRJONYMXROX-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-[3-nitro-4-[(1-oxothian-4-yl)methylamino]phenyl]sulfonylbenzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCS(=O)CC1 YGFFRJONYMXROX-UHFFFAOYSA-N 0.000 description 1
- PSBQZFDJDWUJLN-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-[3-nitro-4-[2-(2-oxoimidazolidin-1-yl)ethylamino]phenyl]sulfonylbenzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCCN1CCNC1=O PSBQZFDJDWUJLN-UHFFFAOYSA-N 0.000 description 1
- GCGZNELJYIUAJB-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-[3-nitro-4-[2-(2-oxopiperidin-1-yl)ethylamino]phenyl]sulfonylbenzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCCN1CCCCC1=O GCGZNELJYIUAJB-UHFFFAOYSA-N 0.000 description 1
- TYIOZYNTSJXXAN-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-[3-nitro-4-[2-(2-oxopyrrolidin-1-yl)ethylamino]phenyl]sulfonylbenzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCCN1CCCC1=O TYIOZYNTSJXXAN-UHFFFAOYSA-N 0.000 description 1
- BSLXDTVQIVVDEM-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-[3-nitro-4-[2-(3-oxopiperazin-1-yl)ethylamino]phenyl]sulfonylbenzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCCN1CCNC(=O)C1 BSLXDTVQIVVDEM-UHFFFAOYSA-N 0.000 description 1
- COHDECXSJJUJRQ-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-[3-nitro-4-[2-(4-sulfamoylphenyl)ethylamino]phenyl]sulfonylbenzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCCC1=CC=C(S(N)(=O)=O)C=C1 COHDECXSJJUJRQ-UHFFFAOYSA-N 0.000 description 1
- CTEAWTHONHQCLP-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-[3-nitro-4-[2-(oxan-4-yl)ethyl]phenyl]sulfonylbenzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1CCC1CCOCC1 CTEAWTHONHQCLP-UHFFFAOYSA-N 0.000 description 1
- HIVCWZIUBQOPBV-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-[3-nitro-4-[2-(oxan-4-yl)ethylamino]phenyl]sulfonylbenzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCCC1CCOCC1 HIVCWZIUBQOPBV-UHFFFAOYSA-N 0.000 description 1
- JQPVIAGZLNAOLF-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-[3-nitro-4-[2-(trifluoromethoxy)ethylamino]phenyl]sulfonylbenzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C1=CC=C(NCCOC(F)(F)F)C([N+]([O-])=O)=C1 JQPVIAGZLNAOLF-UHFFFAOYSA-N 0.000 description 1
- LQMFNMJCPWGIRJ-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-[3-nitro-4-[3-(2-oxopyrrolidin-1-yl)propylamino]phenyl]sulfonylbenzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCCCN1CCCC1=O LQMFNMJCPWGIRJ-UHFFFAOYSA-N 0.000 description 1
- LQIAJVNXAMEVPX-PSXMRANNSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-[3-nitro-4-[[(2r)-oxolan-2-yl]methylamino]phenyl]sulfonylbenzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NC[C@H]1CCCO1 LQIAJVNXAMEVPX-PSXMRANNSA-N 0.000 description 1
- WQMOMLXCXGUTED-WJOKGBTCSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-[3-nitro-4-[[(3r)-oxan-3-yl]methylamino]phenyl]sulfonylbenzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NC[C@H]1CCCOC1 WQMOMLXCXGUTED-WJOKGBTCSA-N 0.000 description 1
- WQMOMLXCXGUTED-HKBQPEDESA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-[3-nitro-4-[[(3s)-oxan-3-yl]methylamino]phenyl]sulfonylbenzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NC[C@@H]1CCCOC1 WQMOMLXCXGUTED-HKBQPEDESA-N 0.000 description 1
- SDVMJOLLRWIDPQ-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-[3-nitro-4-[[1-(2-pyrazol-1-ylethyl)piperidin-4-yl]amino]phenyl]sulfonylbenzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NC(CC1)CCN1CCN1C=CC=N1 SDVMJOLLRWIDPQ-UHFFFAOYSA-N 0.000 description 1
- TVUJMLXTEWOSIU-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-[4-(1-methylpiperidin-4-yl)oxy-3-nitrophenyl]sulfonylbenzamide Chemical compound C1CN(C)CCC1OC1=CC=C(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3CCC(C)(C)CC=3C=3C=CC(Cl)=CC=3)CC2)OC=2C=C3C=CNC3=CC=2)C=C1[N+]([O-])=O TVUJMLXTEWOSIU-UHFFFAOYSA-N 0.000 description 1
- KHCRXKZHBLEMMC-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-[4-(2-methoxyethylamino)-3-nitrophenyl]sulfonylbenzamide Chemical compound C1=C([N+]([O-])=O)C(NCCOC)=CC=C1S(=O)(=O)NC(=O)C1=CC=C(N2CCN(CC=3CCC(C)(C)CC=3C=3C=CC(Cl)=CC=3)CC2)C=C1OC1=CC=C(NC=C2)C2=C1 KHCRXKZHBLEMMC-UHFFFAOYSA-N 0.000 description 1
- CKMGRPWZAGVLGD-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-[4-(2-morpholin-4-ylethylamino)-3-(trifluoromethylsulfonyl)phenyl]sulfonylbenzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1S(=O)(=O)C(F)(F)F)=CC=C1NCCN1CCOCC1 CKMGRPWZAGVLGD-UHFFFAOYSA-N 0.000 description 1
- HUGMARAUDAMVGP-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-[4-(4-methoxyanilino)-3-nitrophenyl]sulfonylbenzamide Chemical compound C1=CC(OC)=CC=C1NC1=CC=C(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3CCC(C)(C)CC=3C=3C=CC(Cl)=CC=3)CC2)OC=2C=C3C=CNC3=CC=2)C=C1[N+]([O-])=O HUGMARAUDAMVGP-UHFFFAOYSA-N 0.000 description 1
- CDVCPMHQQKVGNQ-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-[4-(4-methoxypiperidin-1-yl)-3-nitrophenyl]sulfonylbenzamide Chemical compound C1CC(OC)CCN1C1=CC=C(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3CCC(C)(C)CC=3C=3C=CC(Cl)=CC=3)CC2)OC=2C=C3C=CNC3=CC=2)C=C1[N+]([O-])=O CDVCPMHQQKVGNQ-UHFFFAOYSA-N 0.000 description 1
- VGMFFOOYSDOAHN-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-[4-(4-methylpiperazin-1-yl)-3-nitrophenyl]sulfonylbenzamide Chemical compound C1CN(C)CCN1C1=CC=C(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3CCC(C)(C)CC=3C=3C=CC(Cl)=CC=3)CC2)OC=2C=C3C=CNC3=CC=2)C=C1[N+]([O-])=O VGMFFOOYSDOAHN-UHFFFAOYSA-N 0.000 description 1
- MGKOIPDAMJNJHX-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-[4-(methylamino)-3-nitrophenyl]sulfonylbenzamide Chemical compound C1=C([N+]([O-])=O)C(NC)=CC=C1S(=O)(=O)NC(=O)C1=CC=C(N2CCN(CC=3CCC(C)(C)CC=3C=3C=CC(Cl)=CC=3)CC2)C=C1OC1=CC=C(NC=C2)C2=C1 MGKOIPDAMJNJHX-UHFFFAOYSA-N 0.000 description 1
- FSYWFZOKXHYDOQ-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-[4-(morpholin-4-ylamino)-3-nitrophenyl]sulfonylbenzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NN1CCOCC1 FSYWFZOKXHYDOQ-UHFFFAOYSA-N 0.000 description 1
- SLTHTBRSQHDRJM-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-[4-(oxan-4-ylmethylamino)-3-(trifluoromethyl)phenyl]sulfonylbenzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1C(F)(F)F)=CC=C1NCC1CCOCC1 SLTHTBRSQHDRJM-UHFFFAOYSA-N 0.000 description 1
- LIUGYXVBDBKFBW-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-[4-[(1-methyl-5-oxopyrrolidin-3-yl)amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C1C(=O)N(C)CC1NC1=CC=C(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3CCC(C)(C)CC=3C=3C=CC(Cl)=CC=3)CC2)OC=2C=C3C=CNC3=CC=2)C=C1[N+]([O-])=O LIUGYXVBDBKFBW-UHFFFAOYSA-N 0.000 description 1
- DZYYZTIUTLEBDO-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-[4-[(1-methyl-6-oxopiperidin-3-yl)amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C1CC(=O)N(C)CC1NC1=CC=C(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3CCC(C)(C)CC=3C=3C=CC(Cl)=CC=3)CC2)OC=2C=C3C=CNC3=CC=2)C=C1[N+]([O-])=O DZYYZTIUTLEBDO-UHFFFAOYSA-N 0.000 description 1
- RRVGGZQEEIZHGA-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-[4-[(1-methylpiperidin-4-yl)amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C1CN(C)CCC1NC1=CC=C(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3CCC(C)(C)CC=3C=3C=CC(Cl)=CC=3)CC2)OC=2C=C3C=CNC3=CC=2)C=C1[N+]([O-])=O RRVGGZQEEIZHGA-UHFFFAOYSA-N 0.000 description 1
- QTRWQAGIHZWZSY-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-[4-[(1-methylpiperidin-4-yl)methoxy]-3-nitrophenyl]sulfonylbenzamide Chemical compound C1CN(C)CCC1COC1=CC=C(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3CCC(C)(C)CC=3C=3C=CC(Cl)=CC=3)CC2)OC=2C=C3C=CNC3=CC=2)C=C1[N+]([O-])=O QTRWQAGIHZWZSY-UHFFFAOYSA-N 0.000 description 1
- GGDFMDSVRULIKN-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-[4-[(1-methylpiperidin-4-yl)methylamino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C1CN(C)CCC1CNC1=CC=C(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3CCC(C)(C)CC=3C=3C=CC(Cl)=CC=3)CC2)OC=2C=C3C=CNC3=CC=2)C=C1[N+]([O-])=O GGDFMDSVRULIKN-UHFFFAOYSA-N 0.000 description 1
- BHRRDEZKQXUBAF-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-[4-[(3-methyloxetan-3-yl)methoxy]-3-nitrophenyl]sulfonylbenzamide Chemical compound C=1C=C(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3CCC(C)(C)CC=3C=3C=CC(Cl)=CC=3)CC2)OC=2C=C3C=CNC3=CC=2)C=C([N+]([O-])=O)C=1OCC1(C)COC1 BHRRDEZKQXUBAF-UHFFFAOYSA-N 0.000 description 1
- CITZLDVAYKLPTM-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-[4-[(3-methyloxetan-3-yl)methylamino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C=1C=C(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3CCC(C)(C)CC=3C=3C=CC(Cl)=CC=3)CC2)OC=2C=C3C=CNC3=CC=2)C=C([N+]([O-])=O)C=1NCC1(C)COC1 CITZLDVAYKLPTM-UHFFFAOYSA-N 0.000 description 1
- NICFSNPGJLPMPH-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-[4-[(4-methoxycyclohexyl)amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C1CC(OC)CCC1NC1=CC=C(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3CCC(C)(C)CC=3C=3C=CC(Cl)=CC=3)CC2)OC=2C=C3C=CNC3=CC=2)C=C1[N+]([O-])=O NICFSNPGJLPMPH-UHFFFAOYSA-N 0.000 description 1
- NXDLWPJOJJLWER-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-[4-[(4-methylpiperazin-1-yl)amino]-3-(trifluoromethylsulfonyl)phenyl]sulfonylbenzamide Chemical compound C1CN(C)CCN1NC1=CC=C(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3CCC(C)(C)CC=3C=3C=CC(Cl)=CC=3)CC2)OC=2C=C3C=CNC3=CC=2)C=C1S(=O)(=O)C(F)(F)F NXDLWPJOJJLWER-UHFFFAOYSA-N 0.000 description 1
- YKDBHBPCBRJIJM-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-[4-[2-(2-methoxyethoxy)ethylamino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C1=C([N+]([O-])=O)C(NCCOCCOC)=CC=C1S(=O)(=O)NC(=O)C1=CC=C(N2CCN(CC=3CCC(C)(C)CC=3C=3C=CC(Cl)=CC=3)CC2)C=C1OC1=CC=C(NC=C2)C2=C1 YKDBHBPCBRJIJM-UHFFFAOYSA-N 0.000 description 1
- OZZNCUWTNDYZJX-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-[4-[2-(4-methylpiperazin-1-yl)ethylamino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C1CN(C)CCN1CCNC1=CC=C(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3CCC(C)(C)CC=3C=3C=CC(Cl)=CC=3)CC2)OC=2C=C3C=CNC3=CC=2)C=C1[N+]([O-])=O OZZNCUWTNDYZJX-UHFFFAOYSA-N 0.000 description 1
- FIMFVSJLHCOYLX-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-[4-[3-(4-methylpiperazin-1-yl)propylamino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C1CN(C)CCN1CCCNC1=CC=C(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3CCC(C)(C)CC=3C=3C=CC(Cl)=CC=3)CC2)OC=2C=C3C=CNC3=CC=2)C=C1[N+]([O-])=O FIMFVSJLHCOYLX-UHFFFAOYSA-N 0.000 description 1
- NFCFIIICOCRIAE-SCGMLGLWSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-[4-[[(1s,5r)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@]1(CC[C@@](C2)(N1C)[H])[H])C2NC(C(=C1)[N+]([O-])=O)=CC=C1S(=O)(=O)NC(=O)C(C(=C1)OC=2C=C3C=CNC3=CC=2)=CC=C1N(CC1)CCN1CC(CCC(C)(C)C1)=C1C1=CC=C(Cl)C=C1 NFCFIIICOCRIAE-SCGMLGLWSA-N 0.000 description 1
- YENNOLACGCZVRA-UMSFTDKQSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-[4-[[(3s)-1-methylpyrrolidin-3-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C1N(C)CC[C@@H]1NC1=CC=C(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3CCC(C)(C)CC=3C=3C=CC(Cl)=CC=3)CC2)OC=2C=C3C=CNC3=CC=2)C=C1[N+]([O-])=O YENNOLACGCZVRA-UMSFTDKQSA-N 0.000 description 1
- BZOMSQXXULNGHO-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-[4-[[1-(2-methoxyethyl)piperidin-4-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C1CN(CCOC)CCC1NC1=CC=C(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3CCC(C)(C)CC=3C=3C=CC(Cl)=CC=3)CC2)OC=2C=C3C=CNC3=CC=2)C=C1[N+]([O-])=O BZOMSQXXULNGHO-UHFFFAOYSA-N 0.000 description 1
- PDMCJVGZQRFXJM-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-3-fluoro-2-(1h-indol-5-yloxy)-n-[3-nitro-4-[[1-(oxan-4-yl)piperidin-4-yl]amino]phenyl]sulfonylbenzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C(=C1OC=2C=C3C=CNC3=CC=2)F)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NC(CC1)CCN1C1CCOCC1 PDMCJVGZQRFXJM-UHFFFAOYSA-N 0.000 description 1
- YEXYEOSSVVOMEK-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-3-fluoro-2-(1h-indol-5-yloxy)-n-[4-[(1-methylpiperidin-4-yl)amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C1CN(C)CCC1NC1=CC=C(S(=O)(=O)NC(=O)C=2C(=C(F)C(N3CCN(CC=4CCC(C)(C)CC=4C=4C=CC(Cl)=CC=4)CC3)=CC=2)OC=2C=C3C=CNC3=CC=2)C=C1[N+]([O-])=O YEXYEOSSVVOMEK-UHFFFAOYSA-N 0.000 description 1
- QNRMTVLRUDENQS-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[3-cyano-4-(oxan-4-ylmethylamino)phenyl]sulfonyl-2-(1h-indol-4-yloxy)benzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=3C=CNC=3C=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1C#N)=CC=C1NCC1CCOCC1 QNRMTVLRUDENQS-UHFFFAOYSA-N 0.000 description 1
- QFTZVZDGRJGEDP-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[3-cyano-4-(oxan-4-ylmethylamino)phenyl]sulfonyl-2-(1h-indol-5-yloxy)benzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1C#N)=CC=C1NCC1CCOCC1 QFTZVZDGRJGEDP-UHFFFAOYSA-N 0.000 description 1
- OBPNYRIJRAROOC-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[3-cyano-4-[3-(dimethylamino)propylamino]phenyl]sulfonyl-2-(1h-indol-5-yloxy)benzamide Chemical compound C1=C(C#N)C(NCCCN(C)C)=CC=C1S(=O)(=O)NC(=O)C1=CC=C(N2CCN(CC=3CCC(C)(C)CC=3C=3C=CC(Cl)=CC=3)CC2)C=C1OC1=CC=C(NC=C2)C2=C1 OBPNYRIJRAROOC-UHFFFAOYSA-N 0.000 description 1
- FDRWZCDJGQBDLH-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonyl-2-phenoxybenzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=CC=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 FDRWZCDJGQBDLH-UHFFFAOYSA-N 0.000 description 1
- MZHPZOAVIRBKCI-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-(1,4-dioxan-2-ylmethoxy)-3-nitrophenyl]sulfonyl-2-(1h-indazol-4-yloxy)benzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=3C=NNC=3C=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1OCC1COCCO1 MZHPZOAVIRBKCI-UHFFFAOYSA-N 0.000 description 1
- YPPIANDSXPRKGO-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-(1,4-dioxan-2-ylmethoxy)-3-nitrophenyl]sulfonyl-2-(1h-indol-5-yloxy)benzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1OCC1COCCO1 YPPIANDSXPRKGO-UHFFFAOYSA-N 0.000 description 1
- LZWJRWXIYRXJAL-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-(2,2-difluoroethylamino)-3-nitrophenyl]sulfonyl-2-(1h-indol-5-yloxy)benzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C1=CC=C(NCC(F)F)C([N+]([O-])=O)=C1 LZWJRWXIYRXJAL-UHFFFAOYSA-N 0.000 description 1
- JEROGKFKVZACNB-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-(2-cyanoethylamino)-3-nitrophenyl]sulfonyl-2-(1h-indol-4-yloxy)benzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=3C=CNC=3C=CC=2)=CC=C1C(=O)NS(=O)(=O)C1=CC=C(NCCC#N)C([N+]([O-])=O)=C1 JEROGKFKVZACNB-UHFFFAOYSA-N 0.000 description 1
- CBZWLYHEOWVRAI-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-(2-cyanoethylamino)-3-nitrophenyl]sulfonyl-2-(1h-indol-5-yloxy)benzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C1=CC=C(NCCC#N)C([N+]([O-])=O)=C1 CBZWLYHEOWVRAI-UHFFFAOYSA-N 0.000 description 1
- CYJWZETZXDLHFP-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-(3,3-dimethylbutylamino)-3-nitrophenyl]sulfonyl-2-(1h-indol-5-yloxy)benzamide Chemical compound C1=C([N+]([O-])=O)C(NCCC(C)(C)C)=CC=C1S(=O)(=O)NC(=O)C1=CC=C(N2CCN(CC=3CCC(C)(C)CC=3C=3C=CC(Cl)=CC=3)CC2)C=C1OC1=CC=C(NC=C2)C2=C1 CYJWZETZXDLHFP-UHFFFAOYSA-N 0.000 description 1
- YSOUKHHJEJOOJG-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-(3-morpholin-4-ylpropylamino)-3-nitrophenyl]sulfonyl-2-(1,2,3,4-tetrahydroquinolin-6-yloxy)benzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3CCCNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCCCN1CCOCC1 YSOUKHHJEJOOJG-UHFFFAOYSA-N 0.000 description 1
- YETDCHFGFWSUDU-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-(3-morpholin-4-ylpropylamino)-3-nitrophenyl]sulfonyl-2-phenoxybenzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=CC=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCCCN1CCOCC1 YETDCHFGFWSUDU-UHFFFAOYSA-N 0.000 description 1
- OXYTZRQXJLBCSB-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-(4-hydroxyanilino)-3-nitrophenyl]sulfonyl-2-(1h-indol-5-yloxy)benzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NC1=CC=C(O)C=C1 OXYTZRQXJLBCSB-UHFFFAOYSA-N 0.000 description 1
- NCFSRPFKVPOFAI-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-(cyclohexylmethylamino)-3-nitrophenyl]sulfonyl-2-(1h-indol-5-yloxy)benzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCCCC1 NCFSRPFKVPOFAI-UHFFFAOYSA-N 0.000 description 1
- JQBZVVAPPUYUEK-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-[(1,1-dioxo-1,4-thiazinan-4-yl)amino]-3-nitrophenyl]sulfonyl-2-(1h-indol-5-yloxy)benzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NN1CCS(=O)(=O)CC1 JQBZVVAPPUYUEK-UHFFFAOYSA-N 0.000 description 1
- QYPAOWWQMSMEBL-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-[(1,1-dioxothiolan-3-yl)amino]-3-nitrophenyl]sulfonyl-2-(1h-indol-4-yloxy)benzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=3C=CNC=3C=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NC1CCS(=O)(=O)C1 QYPAOWWQMSMEBL-UHFFFAOYSA-N 0.000 description 1
- ZVTXGPAQDJJJCV-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-[(1,1-dioxothiolan-3-yl)amino]-3-nitrophenyl]sulfonyl-2-(1h-indol-5-yloxy)benzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NC1CCS(=O)(=O)C1 ZVTXGPAQDJJJCV-UHFFFAOYSA-N 0.000 description 1
- QWJDWCNJMNMOQJ-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-[(1,1-dioxothiolan-3-yl)methylamino]-3-nitrophenyl]sulfonyl-2-(1h-indol-5-yloxy)benzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCS(=O)(=O)C1 QWJDWCNJMNMOQJ-UHFFFAOYSA-N 0.000 description 1
- QBTBJUWDRCDALR-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-[(1-cyclopentylpiperidin-4-yl)amino]-3-nitrophenyl]sulfonyl-2-(1h-indol-5-yloxy)benzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NC(CC1)CCN1C1CCCC1 QBTBJUWDRCDALR-UHFFFAOYSA-N 0.000 description 1
- TWXHYGGXLOBCBH-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-[(1-cyclopropylpiperidin-4-yl)amino]-3-nitrophenyl]sulfonyl-2-(1h-indazol-4-yloxy)benzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=3C=NNC=3C=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NC(CC1)CCN1C1CC1 TWXHYGGXLOBCBH-UHFFFAOYSA-N 0.000 description 1
- RRQWIMLOWGGGRH-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-[(1-hydroxycyclohexyl)methylamino]-3-nitrophenyl]sulfonyl-2-(1h-indol-5-yloxy)benzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1(O)CCCCC1 RRQWIMLOWGGGRH-UHFFFAOYSA-N 0.000 description 1
- DVGRSDKQPTZTPI-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-[(1-methylpiperidin-4-yl)amino]-3-nitrophenyl]sulfonyl-2-(1,2,3,4-tetrahydroquinolin-6-yloxy)benzamide Chemical compound C1CN(C)CCC1NC1=CC=C(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3CCC(C)(C)CC=3C=3C=CC(Cl)=CC=3)CC2)OC=2C=C3CCCNC3=CC=2)C=C1[N+]([O-])=O DVGRSDKQPTZTPI-UHFFFAOYSA-N 0.000 description 1
- GUAYTSRMACXMRF-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-[(1-methylpiperidin-4-yl)amino]-3-nitrophenyl]sulfonyl-2-phenoxybenzamide Chemical compound C1CN(C)CCC1NC1=CC=C(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3CCC(C)(C)CC=3C=3C=CC(Cl)=CC=3)CC2)OC=2C=CC=CC=2)C=C1[N+]([O-])=O GUAYTSRMACXMRF-UHFFFAOYSA-N 0.000 description 1
- ZMDJXQFOWXODAG-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-[(4,4-difluorocyclohexyl)amino]-3-nitrophenyl]sulfonyl-2-(1h-indol-5-yloxy)benzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NC1CCC(F)(F)CC1 ZMDJXQFOWXODAG-UHFFFAOYSA-N 0.000 description 1
- BWFOGRAJGRCWJV-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-[(4-cyclopropylmorpholin-2-yl)methylamino]-3-nitrophenyl]sulfonyl-2-(1h-indazol-4-yloxy)benzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=3C=NNC=3C=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC(OCC1)CN1C1CC1 BWFOGRAJGRCWJV-UHFFFAOYSA-N 0.000 description 1
- XSZJGRAXGXYIAI-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-[(4-fluorooxan-4-yl)methylamino]-3-nitrophenyl]sulfonyl-2-(1h-indazol-4-yloxy)benzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=3C=NNC=3C=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1(F)CCOCC1 XSZJGRAXGXYIAI-UHFFFAOYSA-N 0.000 description 1
- GBRQSEQIORQXID-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-[(4-hydroxy-1-methylpiperidin-4-yl)methylamino]-3-nitrophenyl]sulfonyl-2-(1h-indol-4-yloxy)benzamide Chemical compound C1CN(C)CCC1(O)CNC1=CC=C(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3CCC(C)(C)CC=3C=3C=CC(Cl)=CC=3)CC2)OC=2C=3C=CNC=3C=CC=2)C=C1[N+]([O-])=O GBRQSEQIORQXID-UHFFFAOYSA-N 0.000 description 1
- GTELRJOBWSBNEK-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-[2-(4-hydroxy-1-methylpiperidin-4-yl)ethylamino]-3-nitrophenyl]sulfonyl-2-(1h-indol-5-yloxy)benzamide Chemical compound C1CN(C)CCC1(O)CCNC1=CC=C(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3CCC(C)(C)CC=3C=3C=CC(Cl)=CC=3)CC2)OC=2C=C3C=CNC3=CC=2)C=C1[N+]([O-])=O GTELRJOBWSBNEK-UHFFFAOYSA-N 0.000 description 1
- DRPKRUPYCSPJKV-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-[3-(1,1-dioxo-1,4-thiazinan-4-yl)propylamino]-3-nitrophenyl]sulfonyl-2-(1h-indol-4-yloxy)benzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=3C=CNC=3C=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCCCN1CCS(=O)(=O)CC1 DRPKRUPYCSPJKV-UHFFFAOYSA-N 0.000 description 1
- VCUZHBJUBQHJGU-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-[3-(1,1-dioxo-1,4-thiazinan-4-yl)propylamino]-3-nitrophenyl]sulfonyl-2-(1h-indol-5-yloxy)benzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCCCN1CCS(=O)(=O)CC1 VCUZHBJUBQHJGU-UHFFFAOYSA-N 0.000 description 1
- GJUKOIGIHZSHEL-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-[3-(dimethylamino)propoxy]-3-nitrophenyl]sulfonyl-2-(1h-indol-4-yloxy)benzamide Chemical compound C1=C([N+]([O-])=O)C(OCCCN(C)C)=CC=C1S(=O)(=O)NC(=O)C1=CC=C(N2CCN(CC=3CCC(C)(C)CC=3C=3C=CC(Cl)=CC=3)CC2)C=C1OC1=CC=CC2=C1C=CN2 GJUKOIGIHZSHEL-UHFFFAOYSA-N 0.000 description 1
- OUCMBZRPWWNIAL-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-[3-(dimethylamino)propoxy]-3-nitrophenyl]sulfonyl-2-(1h-indol-5-yloxy)benzamide Chemical compound C1=C([N+]([O-])=O)C(OCCCN(C)C)=CC=C1S(=O)(=O)NC(=O)C1=CC=C(N2CCN(CC=3CCC(C)(C)CC=3C=3C=CC(Cl)=CC=3)CC2)C=C1OC1=CC=C(NC=C2)C2=C1 OUCMBZRPWWNIAL-UHFFFAOYSA-N 0.000 description 1
- LVMREPBBIXMPHP-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-[3-(dimethylamino)propylamino]-3-(trifluoromethyl)phenyl]sulfonyl-2-(1h-indol-5-yloxy)benzamide Chemical compound C1=C(C(F)(F)F)C(NCCCN(C)C)=CC=C1S(=O)(=O)NC(=O)C1=CC=C(N2CCN(CC=3CCC(C)(C)CC=3C=3C=CC(Cl)=CC=3)CC2)C=C1OC1=CC=C(NC=C2)C2=C1 LVMREPBBIXMPHP-UHFFFAOYSA-N 0.000 description 1
- UOUKYUVJFCOKSR-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-[3-(dimethylamino)propylamino]-3-(trifluoromethylsulfonyl)phenyl]sulfonyl-2-(1h-indol-5-yloxy)benzamide Chemical compound C1=C(S(=O)(=O)C(F)(F)F)C(NCCCN(C)C)=CC=C1S(=O)(=O)NC(=O)C1=CC=C(N2CCN(CC=3CCC(C)(C)CC=3C=3C=CC(Cl)=CC=3)CC2)C=C1OC1=CC=C(NC=C2)C2=C1 UOUKYUVJFCOKSR-UHFFFAOYSA-N 0.000 description 1
- VATOIXQWCVURLV-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-[3-(dimethylamino)propylamino]-3-nitrophenyl]sulfonyl-2-(1h-indol-4-yloxy)benzamide Chemical compound C1=C([N+]([O-])=O)C(NCCCN(C)C)=CC=C1S(=O)(=O)NC(=O)C1=CC=C(N2CCN(CC=3CCC(C)(C)CC=3C=3C=CC(Cl)=CC=3)CC2)C=C1OC1=CC=CC2=C1C=CN2 VATOIXQWCVURLV-UHFFFAOYSA-N 0.000 description 1
- FBQLXSWAELMCJR-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-[3-(dimethylamino)propylamino]-3-nitrophenyl]sulfonyl-2-(1h-indol-5-yloxy)benzamide Chemical compound C1=C([N+]([O-])=O)C(NCCCN(C)C)=CC=C1S(=O)(=O)NC(=O)C1=CC=C(N2CCN(CC=3CCC(C)(C)CC=3C=3C=CC(Cl)=CC=3)CC2)C=C1OC1=CC=C(NC=C2)C2=C1 FBQLXSWAELMCJR-UHFFFAOYSA-N 0.000 description 1
- YPPIANDSXPRKGO-PSXMRANNSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-[[(2r)-1,4-dioxan-2-yl]methoxy]-3-nitrophenyl]sulfonyl-2-(1h-indol-5-yloxy)benzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1OC[C@H]1COCCO1 YPPIANDSXPRKGO-PSXMRANNSA-N 0.000 description 1
- YPPIANDSXPRKGO-BHVANESWSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-[[(2s)-1,4-dioxan-2-yl]methoxy]-3-nitrophenyl]sulfonyl-2-(1h-indol-5-yloxy)benzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1OC[C@@H]1COCCO1 YPPIANDSXPRKGO-BHVANESWSA-N 0.000 description 1
- HRZVEGBRQVBQDU-DHUJRADRSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-[[(2s)-1-hydroxy-4-methylpentan-2-yl]amino]-3-nitrophenyl]sulfonyl-2-(1h-indol-5-yloxy)benzamide Chemical compound C1=C([N+]([O-])=O)C(N[C@H](CO)CC(C)C)=CC=C1S(=O)(=O)NC(=O)C1=CC=C(N2CCN(CC=3CCC(C)(C)CC=3C=3C=CC(Cl)=CC=3)CC2)C=C1OC1=CC=C(NC=C2)C2=C1 HRZVEGBRQVBQDU-DHUJRADRSA-N 0.000 description 1
- VWCNNHIZKCUMLI-GNQASRIASA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-[[(3r)-4-hydroxy-1-adamantyl]methylamino]-3-nitrophenyl]sulfonyl-2-(1h-indol-5-yloxy)benzamide Chemical compound C([C@](C1)(C2O)[H])C(C3)CC2CC13CNC(C(=C1)[N+]([O-])=O)=CC=C1S(=O)(=O)NC(=O)C(C(=C1)OC=2C=C3C=CNC3=CC=2)=CC=C1N(CC1)CCN1CC(CCC(C)(C)C1)=C1C1=CC=C(Cl)C=C1 VWCNNHIZKCUMLI-GNQASRIASA-N 0.000 description 1
- PNPZFAWTJGMGPY-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-[[1-(2,3-dihydro-1h-inden-2-yl)piperidin-4-yl]amino]-3-nitrophenyl]sulfonyl-2-(1h-indol-4-yloxy)benzamide Chemical compound C1C(C)(C)CCC(CN2CCN(CC2)C=2C=C(OC=3C=4C=CNC=4C=CC=3)C(C(=O)NS(=O)(=O)C=3C=C(C(NC4CCN(CC4)C4CC5=CC=CC=C5C4)=CC=3)[N+]([O-])=O)=CC=2)=C1C1=CC=C(Cl)C=C1 PNPZFAWTJGMGPY-UHFFFAOYSA-N 0.000 description 1
- FZZWTDPBTWZIJW-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-[[1-(2,3-dihydro-1h-inden-2-yl)piperidin-4-yl]amino]-3-nitrophenyl]sulfonyl-2-(1h-indol-5-yloxy)benzamide Chemical compound C1C(C)(C)CCC(CN2CCN(CC2)C=2C=C(OC=3C=C4C=CNC4=CC=3)C(C(=O)NS(=O)(=O)C=3C=C(C(NC4CCN(CC4)C4CC5=CC=CC=C5C4)=CC=3)[N+]([O-])=O)=CC=2)=C1C1=CC=C(Cl)C=C1 FZZWTDPBTWZIJW-UHFFFAOYSA-N 0.000 description 1
- JJIQROGTCDBMIE-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-[[1-(3-fluoropropyl)piperidin-4-yl]amino]-3-nitrophenyl]sulfonyl-2-(1h-indol-5-yloxy)benzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NC1CCN(CCCF)CC1 JJIQROGTCDBMIE-UHFFFAOYSA-N 0.000 description 1
- VEMYLWICDPYFKM-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-[[1-(cyclopropylmethyl)piperidin-4-yl]amino]-3-nitrophenyl]sulfonyl-2-(1h-indol-5-yloxy)benzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NC(CC1)CCN1CC1CC1 VEMYLWICDPYFKM-UHFFFAOYSA-N 0.000 description 1
- AQPZFSZYDOPNPD-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-[[4-(diethylamino)cyclohexyl]amino]-3-nitrophenyl]sulfonyl-2-(1h-indol-4-yloxy)benzamide Chemical compound C1CC(N(CC)CC)CCC1NC1=CC=C(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3CCC(C)(C)CC=3C=3C=CC(Cl)=CC=3)CC2)OC=2C=3C=CNC=3C=CC=2)C=C1[N+]([O-])=O AQPZFSZYDOPNPD-UHFFFAOYSA-N 0.000 description 1
- BFOILMVMTMHDRA-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-[[4-(diethylamino)cyclohexyl]amino]-3-nitrophenyl]sulfonyl-2-(1h-indol-5-yloxy)benzamide Chemical compound C1CC(N(CC)CC)CCC1NC1=CC=C(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3CCC(C)(C)CC=3C=3C=CC(Cl)=CC=3)CC2)OC=2C=C3C=CNC3=CC=2)C=C1[N+]([O-])=O BFOILMVMTMHDRA-UHFFFAOYSA-N 0.000 description 1
- QOYPUCHVCCZABM-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-[[4-(dimethylamino)-1-methylpiperidin-4-yl]methylamino]-3-nitrophenyl]sulfonyl-2-(1h-indol-5-yloxy)benzamide Chemical compound C=1C=C(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3CCC(C)(C)CC=3C=3C=CC(Cl)=CC=3)CC2)OC=2C=C3C=CNC3=CC=2)C=C([N+]([O-])=O)C=1NCC1(N(C)C)CCN(C)CC1 QOYPUCHVCCZABM-UHFFFAOYSA-N 0.000 description 1
- QUADVIAKTTXSFQ-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-[[4-(dimethylamino)cyclohexyl]amino]-3-nitrophenyl]sulfonyl-2-(1h-indol-4-yloxy)benzamide Chemical compound C1CC(N(C)C)CCC1NC1=CC=C(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3CCC(C)(C)CC=3C=3C=CC(Cl)=CC=3)CC2)OC=2C=3C=CNC=3C=CC=2)C=C1[N+]([O-])=O QUADVIAKTTXSFQ-UHFFFAOYSA-N 0.000 description 1
- HTRNACNYLVPERU-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-[[4-(dimethylamino)oxan-4-yl]methylamino]-3-nitrophenyl]sulfonyl-2-(1h-indol-5-yloxy)benzamide Chemical compound C=1C=C(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3CCC(C)(C)CC=3C=3C=CC(Cl)=CC=3)CC2)OC=2C=C3C=CNC3=CC=2)C=C([N+]([O-])=O)C=1NCC1(N(C)C)CCOCC1 HTRNACNYLVPERU-UHFFFAOYSA-N 0.000 description 1
- FIYOJKVYMGFIQD-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-[[4-(hydroxymethyl)oxan-4-yl]amino]-3-nitrophenyl]sulfonyl-2-(1h-indol-4-yloxy)benzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=3C=CNC=3C=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NC1(CO)CCOCC1 FIYOJKVYMGFIQD-UHFFFAOYSA-N 0.000 description 1
- RSXSBNZHOZGKLL-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-[[4-(hydroxymethyl)oxan-4-yl]amino]-3-nitrophenyl]sulfonyl-2-(1h-indol-5-yloxy)benzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NC1(CO)CCOCC1 RSXSBNZHOZGKLL-UHFFFAOYSA-N 0.000 description 1
- GTRWZUWLUGKYEA-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-[[4-(hydroxymethyl)oxan-4-yl]methylamino]-3-nitrophenyl]sulfonyl-2-(1h-indol-5-yloxy)benzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1(CO)CCOCC1 GTRWZUWLUGKYEA-UHFFFAOYSA-N 0.000 description 1
- PWMOHHPBAHCNPM-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[5-cyano-6-(oxan-4-ylmethylamino)pyridin-3-yl]sulfonyl-2-(1h-indol-5-yloxy)benzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1C#N)=CN=C1NCC1CCOCC1 PWMOHHPBAHCNPM-UHFFFAOYSA-N 0.000 description 1
- XWZRRBMVCZMROV-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclopenten-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-4-yloxy)-n-[4-[(1-methylpiperidin-4-yl)amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C1CN(C)CCC1NC1=CC=C(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3CC(C)(C)CC=3C=3C=CC(Cl)=CC=3)CC2)OC=2C=3C=CNC=3C=CC=2)C=C1[N+]([O-])=O XWZRRBMVCZMROV-UHFFFAOYSA-N 0.000 description 1
- HFHVLYKKOFCZEG-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4-(trifluoromethyl)phenyl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-[3-nitro-4-(oxan-4-ylmethoxy)phenyl]sulfonylbenzamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3C(=CC(=CC=3)C(F)(F)F)C=3C=CC(Cl)=CC=3)CC2)OC=2C=C3C=CNC3=CC=2)=CC=C1OCC1CCOCC1 HFHVLYKKOFCZEG-UHFFFAOYSA-N 0.000 description 1
- MYDCOOVIBADJSB-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4-(trifluoromethyl)phenyl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonylbenzamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3C(=CC(=CC=3)C(F)(F)F)C=3C=CC(Cl)=CC=3)CC2)OC=2C=C3C=CNC3=CC=2)=CC=C1NCC1CCOCC1 MYDCOOVIBADJSB-UHFFFAOYSA-N 0.000 description 1
- RIDKQCZGPUZSOL-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-5,5-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-4-yloxy)-n-[4-(3-morpholin-4-ylpropylamino)-3-nitrophenyl]sulfonylbenzamide Chemical compound C1C(C)(C)CCC(C=2C=CC(Cl)=CC=2)=C1CN(CC1)CCN1C(C=C1OC=2C=3C=CNC=3C=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCCCN1CCOCC1 RIDKQCZGPUZSOL-UHFFFAOYSA-N 0.000 description 1
- PIJHEECHFCTUJK-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-5,5-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonylbenzamide Chemical compound C1C(C)(C)CCC(C=2C=CC(Cl)=CC=2)=C1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 PIJHEECHFCTUJK-UHFFFAOYSA-N 0.000 description 1
- IRPABQKHYSMIKO-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-5,5-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-[4-(3-morpholin-4-ylpropylamino)-3-nitrophenyl]sulfonylbenzamide Chemical compound C1C(C)(C)CCC(C=2C=CC(Cl)=CC=2)=C1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCCCN1CCOCC1 IRPABQKHYSMIKO-UHFFFAOYSA-N 0.000 description 1
- PYAGFDJPIVTYLD-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-5,5-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-(3-morpholin-4-ylpropylamino)-3-nitrophenyl]sulfonyl-2-phenoxybenzamide Chemical compound C1C(C)(C)CCC(C=2C=CC(Cl)=CC=2)=C1CN(CC1)CCN1C(C=C1OC=2C=CC=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCCCN1CCOCC1 PYAGFDJPIVTYLD-UHFFFAOYSA-N 0.000 description 1
- IQZKXZMPZAILBN-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-5,5-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-[3-(dimethylamino)propylamino]-3-nitrophenyl]sulfonyl-2-(1h-indol-4-yloxy)benzamide Chemical compound C1=C([N+]([O-])=O)C(NCCCN(C)C)=CC=C1S(=O)(=O)NC(=O)C1=CC=C(N2CCN(CC=3CC(C)(C)CCC=3C=3C=CC(Cl)=CC=3)CC2)C=C1OC1=CC=CC2=C1C=CN2 IQZKXZMPZAILBN-UHFFFAOYSA-N 0.000 description 1
- YPYOAKXSAAPHDC-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-5,5-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-n-[4-[3-(dimethylamino)propylamino]-3-nitrophenyl]sulfonyl-2-(1h-indol-5-yloxy)benzamide Chemical compound C1=C([N+]([O-])=O)C(NCCCN(C)C)=CC=C1S(=O)(=O)NC(=O)C1=CC=C(N2CCN(CC=3CC(C)(C)CCC=3C=3C=CC(Cl)=CC=3)CC2)C=C1OC1=CC=C(NC=C2)C2=C1 YPYOAKXSAAPHDC-UHFFFAOYSA-N 0.000 description 1
- YTQWUBDANDLLOG-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-5-(2-morpholin-4-ylethoxy)phenyl]methyl]piperazin-1-yl]-2-(1h-indol-4-yloxy)-n-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonylbenzamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3C(=CC=C(OCCN4CCOCC4)C=3)C=3C=CC(Cl)=CC=3)CC2)OC=2C=3C=CNC=3C=CC=2)=CC=C1NCC1CCOCC1 YTQWUBDANDLLOG-UHFFFAOYSA-N 0.000 description 1
- UDBXCLFGQRGCBQ-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-5-(2-morpholin-4-ylethoxy)phenyl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-[3-nitro-4-(3-pyrrolidin-1-ylpropylamino)phenyl]sulfonylbenzamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3C(=CC=C(OCCN4CCOCC4)C=3)C=3C=CC(Cl)=CC=3)CC2)OC=2C=C3C=CNC3=CC=2)=CC=C1NCCCN1CCCC1 UDBXCLFGQRGCBQ-UHFFFAOYSA-N 0.000 description 1
- LTLXALAQZBAMCL-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-5-(2-morpholin-4-ylethoxy)phenyl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonylbenzamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3C(=CC=C(OCCN4CCOCC4)C=3)C=3C=CC(Cl)=CC=3)CC2)OC=2C=C3C=CNC3=CC=2)=CC=C1NCC1CCOCC1 LTLXALAQZBAMCL-UHFFFAOYSA-N 0.000 description 1
- NSBSBXIPIVARAG-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-5-(2-morpholin-4-ylethoxy)phenyl]methyl]piperazin-1-yl]-n-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonyl-2-phenoxybenzamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3C(=CC=C(OCCN4CCOCC4)C=3)C=3C=CC(Cl)=CC=3)CC2)OC=2C=CC=CC=2)=CC=C1NCC1CCOCC1 NSBSBXIPIVARAG-UHFFFAOYSA-N 0.000 description 1
- HDGPJIUZFPCHNV-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-5-(2-morpholin-4-ylethoxy)phenyl]methyl]piperazin-1-yl]-n-[4-(oxan-4-ylmethylamino)-3-(trifluoromethylsulfonyl)phenyl]sulfonyl-2-phenoxybenzamide Chemical compound FC(F)(F)S(=O)(=O)C1=CC(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3C(=CC=C(OCCN4CCOCC4)C=3)C=3C=CC(Cl)=CC=3)CC2)OC=2C=CC=CC=2)=CC=C1NCC1CCOCC1 HDGPJIUZFPCHNV-UHFFFAOYSA-N 0.000 description 1
- IFYSCBSTYRSEKN-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-5-(2-pyrrolidin-1-ylethoxy)phenyl]methyl]piperazin-1-yl]-n-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonyl-2-phenoxybenzamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3C(=CC=C(OCCN4CCCC4)C=3)C=3C=CC(Cl)=CC=3)CC2)OC=2C=CC=CC=2)=CC=C1NCC1CCOCC1 IFYSCBSTYRSEKN-UHFFFAOYSA-N 0.000 description 1
- PHQATMGDENFREI-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-5-(2-pyrrolidin-1-ylethyl)phenyl]methyl]piperazin-1-yl]-2-(1h-indol-4-yloxy)-n-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonylbenzamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3C(=CC=C(CCN4CCCC4)C=3)C=3C=CC(Cl)=CC=3)CC2)OC=2C=3C=CNC=3C=CC=2)=CC=C1NCC1CCOCC1 PHQATMGDENFREI-UHFFFAOYSA-N 0.000 description 1
- YINFYGDRRATERP-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-5-(3-piperidin-1-ylpropoxy)phenyl]methyl]piperazin-1-yl]-n-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonyl-2-phenoxybenzamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3C(=CC=C(OCCCN4CCCCC4)C=3)C=3C=CC(Cl)=CC=3)CC2)OC=2C=CC=CC=2)=CC=C1NCC1CCOCC1 YINFYGDRRATERP-UHFFFAOYSA-N 0.000 description 1
- XAVDLZNLUHHFQE-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-5-(pyrrolidin-1-ylmethyl)phenyl]methyl]piperazin-1-yl]-2-(1h-indol-4-yloxy)-n-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonylbenzamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3C(=CC=C(CN4CCCC4)C=3)C=3C=CC(Cl)=CC=3)CC2)OC=2C=3C=CNC=3C=CC=2)=CC=C1NCC1CCOCC1 XAVDLZNLUHHFQE-UHFFFAOYSA-N 0.000 description 1
- HIKUZKXVWZPBDT-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-5-[2-(dimethylamino)ethoxy]phenyl]methyl]piperazin-1-yl]-2-(1h-indol-4-yloxy)-n-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonylbenzamide Chemical compound C=1C(OCCN(C)C)=CC=C(C=2C=CC(Cl)=CC=2)C=1CN(CC1)CCN1C(C=C1OC=2C=3C=CNC=3C=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 HIKUZKXVWZPBDT-UHFFFAOYSA-N 0.000 description 1
- VAEHFQPIZHKQLW-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-5-[2-(dimethylamino)ethoxy]phenyl]methyl]piperazin-1-yl]-2-(1h-indol-4-yloxy)-n-[4-[(4-methylpiperazin-1-yl)amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C=1C(OCCN(C)C)=CC=C(C=2C=CC(Cl)=CC=2)C=1CN(CC1)CCN1C(C=C1OC=2C=3C=CNC=3C=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NN1CCN(C)CC1 VAEHFQPIZHKQLW-UHFFFAOYSA-N 0.000 description 1
- GNVIXAXXISLWSM-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-5-[2-(dimethylamino)ethoxy]phenyl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-[3-nitro-4-(3-pyrrolidin-1-ylpropylamino)phenyl]sulfonylbenzamide Chemical compound C=1C(OCCN(C)C)=CC=C(C=2C=CC(Cl)=CC=2)C=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCCCN1CCCC1 GNVIXAXXISLWSM-UHFFFAOYSA-N 0.000 description 1
- AGAKEEXNVYBQGL-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-5-[2-(dimethylamino)ethoxy]phenyl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonylbenzamide Chemical compound C=1C(OCCN(C)C)=CC=C(C=2C=CC(Cl)=CC=2)C=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 AGAKEEXNVYBQGL-UHFFFAOYSA-N 0.000 description 1
- VDDZOSJVISLSSO-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-5-[2-(dimethylamino)ethoxy]phenyl]methyl]piperazin-1-yl]-n-[3-nitro-4-(3-pyrrolidin-1-ylpropylamino)phenyl]sulfonyl-2-phenoxybenzamide Chemical compound C=1C(OCCN(C)C)=CC=C(C=2C=CC(Cl)=CC=2)C=1CN(CC1)CCN1C(C=C1OC=2C=CC=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCCCN1CCCC1 VDDZOSJVISLSSO-UHFFFAOYSA-N 0.000 description 1
- CSWDRUYPMNENSI-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-5-[2-(dimethylamino)ethoxy]phenyl]methyl]piperazin-1-yl]-n-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonyl-2-phenoxybenzamide Chemical compound C=1C(OCCN(C)C)=CC=C(C=2C=CC(Cl)=CC=2)C=1CN(CC1)CCN1C(C=C1OC=2C=CC=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 CSWDRUYPMNENSI-UHFFFAOYSA-N 0.000 description 1
- JCJVZDOUFFOXNU-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-5-[2-(dimethylamino)ethoxy]phenyl]methyl]piperazin-1-yl]-n-[3-nitro-4-[[1-(2,2,2-trifluoroethyl)piperidin-4-yl]amino]phenyl]sulfonyl-2-phenoxybenzamide Chemical compound C=1C(OCCN(C)C)=CC=C(C=2C=CC(Cl)=CC=2)C=1CN(CC1)CCN1C(C=C1OC=2C=CC=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NC1CCN(CC(F)(F)F)CC1 JCJVZDOUFFOXNU-UHFFFAOYSA-N 0.000 description 1
- YIUOFRPUNBWDJE-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-5-[2-(dimethylamino)ethoxy]phenyl]methyl]piperazin-1-yl]-n-[4-(oxan-4-ylmethylamino)-3-(trifluoromethylsulfonyl)phenyl]sulfonyl-2-phenoxybenzamide Chemical compound C=1C(OCCN(C)C)=CC=C(C=2C=CC(Cl)=CC=2)C=1CN(CC1)CCN1C(C=C1OC=2C=CC=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1S(=O)(=O)C(F)(F)F)=CC=C1NCC1CCOCC1 YIUOFRPUNBWDJE-UHFFFAOYSA-N 0.000 description 1
- YEJWXWHFGIFBQS-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-5-[2-[di(propan-2-yl)amino]ethoxy]phenyl]methyl]piperazin-1-yl]-n-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonyl-2-phenoxybenzamide Chemical compound C=1C(OCCN(C(C)C)C(C)C)=CC=C(C=2C=CC(Cl)=CC=2)C=1CN(CC1)CCN1C(C=C1OC=2C=CC=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 YEJWXWHFGIFBQS-UHFFFAOYSA-N 0.000 description 1
- XDAIUCOVXYEUKH-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-5-[3-(dimethylamino)prop-1-ynyl]phenyl]methyl]piperazin-1-yl]-2-(1h-indol-4-yloxy)-n-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonylbenzamide Chemical compound C=1C(C#CCN(C)C)=CC=C(C=2C=CC(Cl)=CC=2)C=1CN(CC1)CCN1C(C=C1OC=2C=3C=CNC=3C=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 XDAIUCOVXYEUKH-UHFFFAOYSA-N 0.000 description 1
- WLTGMSVWPSTTDM-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-5-[3-(dimethylamino)propoxy]phenyl]methyl]piperazin-1-yl]-n-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonyl-2-phenoxybenzamide Chemical compound C=1C(OCCCN(C)C)=CC=C(C=2C=CC(Cl)=CC=2)C=1CN(CC1)CCN1C(C=C1OC=2C=CC=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 WLTGMSVWPSTTDM-UHFFFAOYSA-N 0.000 description 1
- QMWVXOVFIWJKFO-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-5-hydroxycyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonylbenzamide Chemical compound C1C(O)CCC(C=2C=CC(Cl)=CC=2)=C1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 QMWVXOVFIWJKFO-UHFFFAOYSA-N 0.000 description 1
- JTKJTOUFKQYQGN-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-5-hydroxycyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-[3-nitro-4-[[1-(oxan-4-yl)piperidin-4-yl]amino]phenyl]sulfonylbenzamide Chemical compound C1C(O)CCC(C=2C=CC(Cl)=CC=2)=C1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NC(CC1)CCN1C1CCOCC1 JTKJTOUFKQYQGN-UHFFFAOYSA-N 0.000 description 1
- DHNKZBFSIIOYQJ-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-5-hydroxycyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-[4-[(1-methylpiperidin-4-yl)amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C1CN(C)CCC1NC1=CC=C(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3CC(O)CCC=3C=3C=CC(Cl)=CC=3)CC2)OC=2C=C3C=CNC3=CC=2)C=C1[N+]([O-])=O DHNKZBFSIIOYQJ-UHFFFAOYSA-N 0.000 description 1
- ZEVLNCJKGMKJNS-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-5-hydroxycyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-[4-[(4-methylpiperazin-1-yl)amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C1CN(C)CCN1NC1=CC=C(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3CC(O)CCC=3C=3C=CC(Cl)=CC=3)CC2)OC=2C=C3C=CNC3=CC=2)C=C1[N+]([O-])=O ZEVLNCJKGMKJNS-UHFFFAOYSA-N 0.000 description 1
- KQYJGMPTUNIRII-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-5-morpholin-4-ylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonylbenzamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3CC(CCC=3C=3C=CC(Cl)=CC=3)N3CCOCC3)CC2)OC=2C=C3C=CNC3=CC=2)=CC=C1NCC1CCOCC1 KQYJGMPTUNIRII-UHFFFAOYSA-N 0.000 description 1
- WPCFQNFZHUYXAC-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-5-morpholin-4-ylphenyl]methyl]piperazin-1-yl]-2-(1h-indol-4-yloxy)-n-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonylbenzamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3C(=CC=C(C=3)N3CCOCC3)C=3C=CC(Cl)=CC=3)CC2)OC=2C=3C=CNC=3C=CC=2)=CC=C1NCC1CCOCC1 WPCFQNFZHUYXAC-UHFFFAOYSA-N 0.000 description 1
- LFHLHGLJRBZRPT-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-6-(2-morpholin-4-ylethoxy)phenyl]methyl]piperazin-1-yl]-2-(1h-indol-4-yloxy)-n-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonylbenzamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3OCCN3CCOCC3)C=3C=CC(Cl)=CC=3)CC2)OC=2C=3C=CNC=3C=CC=2)=CC=C1NCC1CCOCC1 LFHLHGLJRBZRPT-UHFFFAOYSA-N 0.000 description 1
- XBYYMUSZLWFIST-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-6-(2-morpholin-4-ylethoxy)phenyl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonylbenzamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3OCCN3CCOCC3)C=3C=CC(Cl)=CC=3)CC2)OC=2C=C3C=CNC3=CC=2)=CC=C1NCC1CCOCC1 XBYYMUSZLWFIST-UHFFFAOYSA-N 0.000 description 1
- SZWHFKVOTWZREA-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-6-[2-(dimethylamino)ethoxy]phenyl]methyl]piperazin-1-yl]-2-(1h-indol-4-yloxy)-n-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonylbenzamide Chemical compound CN(C)CCOC1=CC=CC(C=2C=CC(Cl)=CC=2)=C1CN(CC1)CCN1C(C=C1OC=2C=3C=CNC=3C=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 SZWHFKVOTWZREA-UHFFFAOYSA-N 0.000 description 1
- MFQKRPNAEIVIFU-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-6-[2-(dimethylamino)ethoxy]phenyl]methyl]piperazin-1-yl]-2-(1h-indol-4-yloxy)-n-[3-nitro-4-[[1-(oxan-4-yl)piperidin-4-yl]amino]phenyl]sulfonylbenzamide Chemical compound CN(C)CCOC1=CC=CC(C=2C=CC(Cl)=CC=2)=C1CN(CC1)CCN1C(C=C1OC=2C=3C=CNC=3C=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NC(CC1)CCN1C1CCOCC1 MFQKRPNAEIVIFU-UHFFFAOYSA-N 0.000 description 1
- NORVWWGAABSVQM-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-6-[2-(dimethylamino)ethoxy]phenyl]methyl]piperazin-1-yl]-2-(1h-indol-4-yloxy)-n-[4-[(1-methylpiperidin-4-yl)amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound CN(C)CCOC1=CC=CC(C=2C=CC(Cl)=CC=2)=C1CN(CC1)CCN1C(C=C1OC=2C=3C=CNC=3C=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NC1CCN(C)CC1 NORVWWGAABSVQM-UHFFFAOYSA-N 0.000 description 1
- VFNRSKYFZOWCAW-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-6-[2-(dimethylamino)ethoxy]phenyl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-[3-nitro-4-(3-pyrrolidin-1-ylpropylamino)phenyl]sulfonylbenzamide Chemical compound CN(C)CCOC1=CC=CC(C=2C=CC(Cl)=CC=2)=C1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCCCN1CCCC1 VFNRSKYFZOWCAW-UHFFFAOYSA-N 0.000 description 1
- OEPSXIVYHBPSCA-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-6-[2-(dimethylamino)ethoxy]phenyl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonylbenzamide Chemical compound CN(C)CCOC1=CC=CC(C=2C=CC(Cl)=CC=2)=C1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 OEPSXIVYHBPSCA-UHFFFAOYSA-N 0.000 description 1
- UOTAFOWSRWWFFQ-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-6-[2-(dimethylamino)ethoxy]phenyl]methyl]piperazin-1-yl]-n-[3-nitro-4-(3-pyrrolidin-1-ylpropylamino)phenyl]sulfonyl-2-phenoxybenzamide Chemical compound CN(C)CCOC1=CC=CC(C=2C=CC(Cl)=CC=2)=C1CN(CC1)CCN1C(C=C1OC=2C=CC=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCCCN1CCCC1 UOTAFOWSRWWFFQ-UHFFFAOYSA-N 0.000 description 1
- UPDLREHRDBSYQN-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-6-[2-(dimethylamino)ethoxy]phenyl]methyl]piperazin-1-yl]-n-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonyl-2-phenoxybenzamide Chemical compound CN(C)CCOC1=CC=CC(C=2C=CC(Cl)=CC=2)=C1CN(CC1)CCN1C(C=C1OC=2C=CC=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 UPDLREHRDBSYQN-UHFFFAOYSA-N 0.000 description 1
- ZVJALCCBVRKQDX-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-6-[2-(dimethylamino)ethoxy]phenyl]methyl]piperazin-1-yl]-n-[4-(oxan-4-ylmethylamino)-3-(trifluoromethylsulfonyl)phenyl]sulfonyl-2-phenoxybenzamide Chemical compound CN(C)CCOC1=CC=CC(C=2C=CC(Cl)=CC=2)=C1CN(CC1)CCN1C(C=C1OC=2C=CC=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1S(=O)(=O)C(F)(F)F)=CC=C1NCC1CCOCC1 ZVJALCCBVRKQDX-UHFFFAOYSA-N 0.000 description 1
- YKRZFFJISSHQLK-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-6-[3-(dimethylamino)propyl]phenyl]methyl]piperazin-1-yl]-2-(1h-indol-4-yloxy)-n-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonylbenzamide Chemical compound CN(C)CCCC1=CC=CC(C=2C=CC(Cl)=CC=2)=C1CN(CC1)CCN1C(C=C1OC=2C=3C=CNC=3C=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 YKRZFFJISSHQLK-UHFFFAOYSA-N 0.000 description 1
- DUQDHDNHANMXPP-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)cyclohepten-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-4-yloxy)-n-[3-nitro-4-(3-pyrrolidin-1-ylpropylamino)phenyl]sulfonylbenzamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3CCCCCC=3C=3C=CC(Cl)=CC=3)CC2)OC=2C=3C=CNC=3C=CC=2)=CC=C1NCCCN1CCCC1 DUQDHDNHANMXPP-UHFFFAOYSA-N 0.000 description 1
- FCDNSKDIJSTJLA-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)cyclohepten-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-4-yloxy)-n-[4-[(1-methylpiperidin-4-yl)amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C1CN(C)CCC1NC1=CC=C(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3CCCCCC=3C=3C=CC(Cl)=CC=3)CC2)OC=2C=3C=CNC=3C=CC=2)C=C1[N+]([O-])=O FCDNSKDIJSTJLA-UHFFFAOYSA-N 0.000 description 1
- HYGNGAXAQFQVKR-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)cyclohepten-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-[4-[(1-methylpiperidin-4-yl)amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C1CN(C)CCC1NC1=CC=C(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3CCCCCC=3C=3C=CC(Cl)=CC=3)CC2)OC=2C=C3C=CNC3=CC=2)C=C1[N+]([O-])=O HYGNGAXAQFQVKR-UHFFFAOYSA-N 0.000 description 1
- FWBSYNQAEXSXIS-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)cyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-4-yloxy)-n-[4-[(1-methylpiperidin-4-yl)amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C1CN(C)CCC1NC1=CC=C(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3CCCCC=3C=3C=CC(Cl)=CC=3)CC2)OC=2C=3C=CNC=3C=CC=2)C=C1[N+]([O-])=O FWBSYNQAEXSXIS-UHFFFAOYSA-N 0.000 description 1
- NAISINVAVLLMCV-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)cyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-[4-[(1-methylpiperidin-4-yl)amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C1CN(C)CCC1NC1=CC=C(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3CCCCC=3C=3C=CC(Cl)=CC=3)CC2)OC=2C=C3C=CNC3=CC=2)C=C1[N+]([O-])=O NAISINVAVLLMCV-UHFFFAOYSA-N 0.000 description 1
- QFZKNRYPOVGUIP-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)cycloocten-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-4-yloxy)-n-[3-nitro-4-(3-pyrrolidin-1-ylpropylamino)phenyl]sulfonylbenzamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3CCCCCCC=3C=3C=CC(Cl)=CC=3)CC2)OC=2C=3C=CNC=3C=CC=2)=CC=C1NCCCN1CCCC1 QFZKNRYPOVGUIP-UHFFFAOYSA-N 0.000 description 1
- QTIWKELYIHAPRB-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)cycloocten-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-4-yloxy)-n-[4-[(1-methylpiperidin-4-yl)amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C1CN(C)CCC1NC1=CC=C(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3CCCCCCC=3C=3C=CC(Cl)=CC=3)CC2)OC=2C=3C=CNC=3C=CC=2)C=C1[N+]([O-])=O QTIWKELYIHAPRB-UHFFFAOYSA-N 0.000 description 1
- YGOUOHIEISNVPU-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)cyclopenten-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-4-yloxy)-n-[3-nitro-4-(3-pyrrolidin-1-ylpropylamino)phenyl]sulfonylbenzamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3CCCC=3C=3C=CC(Cl)=CC=3)CC2)OC=2C=3C=CNC=3C=CC=2)=CC=C1NCCCN1CCCC1 YGOUOHIEISNVPU-UHFFFAOYSA-N 0.000 description 1
- WXJAPUWTZHRPLV-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)cyclopenten-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-4-yloxy)-n-[4-[(1-methylpiperidin-4-yl)amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C1CN(C)CCC1NC1=CC=C(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3CCCC=3C=3C=CC(Cl)=CC=3)CC2)OC=2C=3C=CNC=3C=CC=2)C=C1[N+]([O-])=O WXJAPUWTZHRPLV-UHFFFAOYSA-N 0.000 description 1
- DDTOEVMJPPVWBI-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]-3-(2-methylpropyl)piperazin-1-yl]-n-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonyl-2-phenoxybenzamide Chemical compound CC(C)CC1CN(C=2C=C(OC=3C=CC=CC=3)C(C(=O)NS(=O)(=O)C=3C=C(C(NCC4CCOCC4)=CC=3)[N+]([O-])=O)=CC=2)CCN1CC1=CC=CC=C1C1=CC=C(Cl)C=C1 DDTOEVMJPPVWBI-UHFFFAOYSA-N 0.000 description 1
- HRKBXRVHIIMZLP-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-2-(1h-indol-4-yloxy)-n-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonylbenzamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)OC=2C=3C=CNC=3C=CC=2)=CC=C1NCC1CCOCC1 HRKBXRVHIIMZLP-UHFFFAOYSA-N 0.000 description 1
- BXQUXUDGWFIKPO-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-2-(1h-indol-4-yloxy)-n-[4-(3-morpholin-4-ylpropylamino)-3-(trifluoromethylsulfonyl)phenyl]sulfonylbenzamide Chemical compound FC(F)(F)S(=O)(=O)C1=CC(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)OC=2C=3C=CNC=3C=CC=2)=CC=C1NCCCN1CCOCC1 BXQUXUDGWFIKPO-UHFFFAOYSA-N 0.000 description 1
- BTAWRMDNUWZRCF-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-2-(1h-indol-4-yloxy)-n-[4-(3-morpholin-4-ylpropylamino)-3-nitrophenyl]sulfonylbenzamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)OC=2C=3C=CNC=3C=CC=2)=CC=C1NCCCN1CCOCC1 BTAWRMDNUWZRCF-UHFFFAOYSA-N 0.000 description 1
- MPMJQJNNPDTWBC-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-2-(1h-indol-4-yloxy)-n-[4-(oxan-4-ylmethylamino)-3-(trifluoromethylsulfonyl)phenyl]sulfonylbenzamide Chemical compound FC(F)(F)S(=O)(=O)C1=CC(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)OC=2C=3C=CNC=3C=CC=2)=CC=C1NCC1CCOCC1 MPMJQJNNPDTWBC-UHFFFAOYSA-N 0.000 description 1
- WRIGKXLSTCWKGV-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonylbenzamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)OC=2C=C3C=CNC3=CC=2)=CC=C1NCC1CCOCC1 WRIGKXLSTCWKGV-UHFFFAOYSA-N 0.000 description 1
- YBDDZSSVFSAFRD-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-[4-(3-morpholin-4-ylpropylamino)-3-nitrophenyl]sulfonylbenzamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)OC=2C=C3C=CNC3=CC=2)=CC=C1NCCCN1CCOCC1 YBDDZSSVFSAFRD-UHFFFAOYSA-N 0.000 description 1
- XKYQLOOIAHGBPE-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-[4-(oxan-4-ylmethylamino)-3-(trifluoromethylsulfonyl)phenyl]sulfonylbenzamide Chemical compound FC(F)(F)S(=O)(=O)C1=CC(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)OC=2C=C3C=CNC3=CC=2)=CC=C1NCC1CCOCC1 XKYQLOOIAHGBPE-UHFFFAOYSA-N 0.000 description 1
- PLFKTZMTPJWFLH-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-2-(2,3-dihydro-1,4-benzodioxin-5-yloxy)-n-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonylbenzamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)OC=2C=3OCCOC=3C=CC=2)=CC=C1NCC1CCOCC1 PLFKTZMTPJWFLH-UHFFFAOYSA-N 0.000 description 1
- MUEYTPGQGSALDR-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-2-(2,3-dihydro-1h-indol-5-yloxy)-n-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonylbenzamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)OC=2C=C3CCNC3=CC=2)=CC=C1NCC1CCOCC1 MUEYTPGQGSALDR-UHFFFAOYSA-N 0.000 description 1
- DFRYRTBUCOEAPJ-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-2-isoquinolin-5-yloxy-n-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonylbenzamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)OC=2C3=CC=NC=C3C=CC=2)=CC=C1NCC1CCOCC1 DFRYRTBUCOEAPJ-UHFFFAOYSA-N 0.000 description 1
- QVPKQQXPIWKQNE-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-2-isoquinolin-7-yloxy-n-[4-(3-morpholin-4-ylpropylamino)-3-nitrophenyl]sulfonylbenzamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)OC=2C=C3C=NC=CC3=CC=2)=CC=C1NCCCN1CCOCC1 QVPKQQXPIWKQNE-UHFFFAOYSA-N 0.000 description 1
- VNQWYETYEGAROZ-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-2-naphthalen-2-yloxy-n-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonylbenzamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)OC=2C=C3C=CC=CC3=CC=2)=CC=C1NCC1CCOCC1 VNQWYETYEGAROZ-UHFFFAOYSA-N 0.000 description 1
- IGSBFCVQONNDTJ-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-2-naphthalen-2-yloxy-n-[4-(oxan-4-ylmethylamino)-3-(trifluoromethylsulfonyl)phenyl]sulfonylbenzamide Chemical compound FC(F)(F)S(=O)(=O)C1=CC(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)OC=2C=C3C=CC=CC3=CC=2)=CC=C1NCC1CCOCC1 IGSBFCVQONNDTJ-UHFFFAOYSA-N 0.000 description 1
- KHAFRZYEHFHBAI-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-2-phenoxy-n-[2-(2-piperidin-1-ylethoxy)phenyl]sulfonylbenzamide Chemical compound C1=CC(Cl)=CC=C1C1=CC=CC=C1CN1CCN(C=2C=C(OC=3C=CC=CC=3)C(C(=O)NS(=O)(=O)C=3C(=CC=CC=3)OCCN3CCCCC3)=CC=2)CC1 KHAFRZYEHFHBAI-UHFFFAOYSA-N 0.000 description 1
- NHOOMCROSFSDFP-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-(4-methoxyphenyl)sulfonyl-2-phenoxybenzamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)NC(=O)C1=CC=C(N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)C=C1OC1=CC=CC=C1 NHOOMCROSFSDFP-UHFFFAOYSA-N 0.000 description 1
- WDEAQOCUFQUDLI-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-(4-methylphenyl)sulfonyl-2-phenoxybenzamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)C1=CC=C(N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)C=C1OC1=CC=CC=C1 WDEAQOCUFQUDLI-UHFFFAOYSA-N 0.000 description 1
- IYCDEVPZWOIJQV-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[3-[(1-ethylpyrrolidin-2-yl)methylcarbamoyl]-4-methoxyphenyl]sulfonyl-2-phenoxybenzamide Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)OC=2C=CC=CC=2)=CC=C1OC IYCDEVPZWOIJQV-UHFFFAOYSA-N 0.000 description 1
- HTYMZBPCAZNWAL-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[3-cyano-4-[3-(dimethylamino)propylamino]phenyl]sulfonyl-2-phenoxybenzamide Chemical compound C1=C(C#N)C(NCCCN(C)C)=CC=C1S(=O)(=O)NC(=O)C1=CC=C(N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)C=C1OC1=CC=CC=C1 HTYMZBPCAZNWAL-UHFFFAOYSA-N 0.000 description 1
- UCRZGSMIIVFPKF-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[3-nitro-4-(2-pyridin-4-ylethylamino)phenyl]sulfonyl-2-phenoxybenzamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)OC=2C=CC=CC=2)=CC=C1NCCC1=CC=NC=C1 UCRZGSMIIVFPKF-UHFFFAOYSA-N 0.000 description 1
- FVXIQPQEXHFFKQ-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonyl-2-(2-phenylethoxy)benzamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)OCCC=2C=CC=CC=2)=CC=C1NCC1CCOCC1 FVXIQPQEXHFFKQ-UHFFFAOYSA-N 0.000 description 1
- VIXOUSKXJOQGGB-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonyl-2-(phenoxymethyl)benzamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)COC=2C=CC=CC=2)=CC=C1NCC1CCOCC1 VIXOUSKXJOQGGB-UHFFFAOYSA-N 0.000 description 1
- ZTMIHQVUBUBYDI-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonyl-2-phenylbenzamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)C=2C=CC=CC=2)=CC=C1NCC1CCOCC1 ZTMIHQVUBUBYDI-UHFFFAOYSA-N 0.000 description 1
- GHMJGYPEDLFHHB-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonyl-2-pyridin-3-yloxybenzamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)OC=2C=NC=CC=2)=CC=C1NCC1CCOCC1 GHMJGYPEDLFHHB-UHFFFAOYSA-N 0.000 description 1
- MEONLZRSNUGPON-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonyl-2-pyridin-4-yloxybenzamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)OC=2C=CN=CC=2)=CC=C1NCC1CCOCC1 MEONLZRSNUGPON-UHFFFAOYSA-N 0.000 description 1
- UNTPJYHBCXHSJJ-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonyl-2-quinolin-6-yloxybenzamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)OC=2C=C3C=CC=NC3=CC=2)=CC=C1NCC1CCOCC1 UNTPJYHBCXHSJJ-UHFFFAOYSA-N 0.000 description 1
- MGFZSBAKMNBEQZ-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonyl-2-quinolin-7-yloxybenzamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)OC=2C=C3N=CC=CC3=CC=2)=CC=C1NCC1CCOCC1 MGFZSBAKMNBEQZ-UHFFFAOYSA-N 0.000 description 1
- RFNMGWVQBKFXPF-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[3-nitro-4-(thiophen-2-ylmethylamino)phenyl]sulfonyl-2-phenoxybenzamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)OC=2C=CC=CC=2)=CC=C1NCC1=CC=CS1 RFNMGWVQBKFXPF-UHFFFAOYSA-N 0.000 description 1
- RKIHOVNIMDBFJX-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[3-nitro-4-[(1-quinolin-8-ylsulfonylpiperidin-4-yl)amino]phenyl]sulfonyl-2-phenoxybenzamide Chemical compound C=1C=C(NC2CCN(CC2)S(=O)(=O)C=2C3=NC=CC=C3C=CC=2)C([N+](=O)[O-])=CC=1S(=O)(=O)NC(=O)C1=CC=C(N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)C=C1OC1=CC=CC=C1 RKIHOVNIMDBFJX-UHFFFAOYSA-N 0.000 description 1
- LZYIVCJAVPIQSY-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-(2,4-dioxo-3-azabicyclo[3.2.0]heptan-3-yl)phenyl]sulfonyl-2-phenoxybenzamide Chemical compound C1=CC(Cl)=CC=C1C1=CC=CC=C1CN1CCN(C=2C=C(OC=3C=CC=CC=3)C(C(=O)NS(=O)(=O)C=3C=CC(=CC=3)N3C(C4CCC4C3=O)=O)=CC=2)CC1 LZYIVCJAVPIQSY-UHFFFAOYSA-N 0.000 description 1
- YNRDBBSAMYKPBD-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-(3-morpholin-4-ylpropylamino)-3-nitrophenyl]sulfonyl-2-naphthalen-2-yloxybenzamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)OC=2C=C3C=CC=CC3=CC=2)=CC=C1NCCCN1CCOCC1 YNRDBBSAMYKPBD-UHFFFAOYSA-N 0.000 description 1
- HDZUKPPZBFWBMK-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-(3-morpholin-4-ylpropylamino)-3-nitrophenyl]sulfonyl-2-phenoxybenzamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)OC=2C=CC=CC=2)=CC=C1NCCCN1CCOCC1 HDZUKPPZBFWBMK-UHFFFAOYSA-N 0.000 description 1
- VFRSNAQASXNCPC-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-(3-morpholin-4-ylpropylamino)-3-nitrophenyl]sulfonyl-2-pyridin-3-yloxybenzamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)OC=2C=NC=CC=2)=CC=C1NCCCN1CCOCC1 VFRSNAQASXNCPC-UHFFFAOYSA-N 0.000 description 1
- WVJAXJSOJWWUPR-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-(3-morpholin-4-ylpropylamino)phenyl]sulfonyl-2-phenoxybenzamide Chemical compound C1=CC(Cl)=CC=C1C1=CC=CC=C1CN1CCN(C=2C=C(OC=3C=CC=CC=3)C(C(=O)NS(=O)(=O)C=3C=CC(NCCCN4CCOCC4)=CC=3)=CC=2)CC1 WVJAXJSOJWWUPR-UHFFFAOYSA-N 0.000 description 1
- OLQVQUIHNOVTJY-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-(oxan-4-ylmethylamino)-3-(trifluoromethylsulfonyl)phenyl]sulfonyl-2-phenoxybenzamide Chemical compound FC(F)(F)S(=O)(=O)C1=CC(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)OC=2C=CC=CC=2)=CC=C1NCC1CCOCC1 OLQVQUIHNOVTJY-UHFFFAOYSA-N 0.000 description 1
- XBZYCOQBFHMASP-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-(oxan-4-ylmethylamino)phenyl]sulfonyl-2-phenylsulfanylbenzamide Chemical compound C1=CC(Cl)=CC=C1C1=CC=CC=C1CN1CCN(C=2C=C(SC=3C=CC=CC=3)C(C(=O)NS(=O)(=O)C=3C=CC(NCC4CCOCC4)=CC=3)=CC=2)CC1 XBZYCOQBFHMASP-UHFFFAOYSA-N 0.000 description 1
- GHEOYPVSKQWUCG-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-(oxan-4-ylmethylamino)phenyl]sulfonyl-2-pyridin-3-yloxybenzamide Chemical compound C1=CC(Cl)=CC=C1C1=CC=CC=C1CN1CCN(C=2C=C(OC=3C=NC=CC=3)C(C(=O)NS(=O)(=O)C=3C=CC(NCC4CCOCC4)=CC=3)=CC=2)CC1 GHEOYPVSKQWUCG-UHFFFAOYSA-N 0.000 description 1
- FEWLTCVXTVMUSR-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[(1-methylpiperidin-4-yl)amino]-3-nitrophenyl]sulfonyl-2-phenoxybenzamide Chemical compound C1CN(C)CCC1NC1=CC=C(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)OC=2C=CC=CC=2)C=C1[N+]([O-])=O FEWLTCVXTVMUSR-UHFFFAOYSA-N 0.000 description 1
- ZZTHVYGBHLPPNF-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[(1-methylpiperidin-4-yl)methylamino]-3-nitrophenyl]sulfonyl-2-phenoxybenzamide Chemical compound C1CN(C)CCC1CNC1=CC=C(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)OC=2C=CC=CC=2)C=C1[N+]([O-])=O ZZTHVYGBHLPPNF-UHFFFAOYSA-N 0.000 description 1
- PWAPPNLQNHZNMK-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[2-(4-methylpiperazin-1-yl)ethylamino]-3-nitrophenyl]sulfonyl-2-phenoxybenzamide Chemical compound C1CN(C)CCN1CCNC1=CC=C(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)OC=2C=CC=CC=2)C=C1[N+]([O-])=O PWAPPNLQNHZNMK-UHFFFAOYSA-N 0.000 description 1
- ACAPYGQFSJLDCS-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[2-(dimethylamino)ethylamino]-3-nitrophenyl]sulfonyl-2-phenoxybenzamide Chemical compound C1=C([N+]([O-])=O)C(NCCN(C)C)=CC=C1S(=O)(=O)NC(=O)C1=CC=C(N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)C=C1OC1=CC=CC=C1 ACAPYGQFSJLDCS-UHFFFAOYSA-N 0.000 description 1
- OVTAMWJLLDWNCW-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[3-(4-methylpiperazin-1-yl)propylamino]-3-nitrophenyl]sulfonyl-2-phenoxybenzamide Chemical compound C1CN(C)CCN1CCCNC1=CC=C(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)OC=2C=CC=CC=2)C=C1[N+]([O-])=O OVTAMWJLLDWNCW-UHFFFAOYSA-N 0.000 description 1
- FHHHWCSGDMVAHT-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[3-(dimethylamino)propoxy]-3-nitrophenyl]sulfonyl-2-phenoxybenzamide Chemical compound C1=C([N+]([O-])=O)C(OCCCN(C)C)=CC=C1S(=O)(=O)NC(=O)C1=CC=C(N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)C=C1OC1=CC=CC=C1 FHHHWCSGDMVAHT-UHFFFAOYSA-N 0.000 description 1
- ORJUWEAOLXMYPV-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[3-(dimethylamino)propyl-methylamino]-3-nitrophenyl]sulfonyl-2-phenoxybenzamide Chemical compound C1=C([N+]([O-])=O)C(N(C)CCCN(C)C)=CC=C1S(=O)(=O)NC(=O)C1=CC=C(N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)C=C1OC1=CC=CC=C1 ORJUWEAOLXMYPV-UHFFFAOYSA-N 0.000 description 1
- ANNCRDSCGJDZFH-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[3-(dimethylamino)propylamino]-3-(trifluoromethyl)phenyl]sulfonyl-2-phenoxybenzamide Chemical compound C1=C(C(F)(F)F)C(NCCCN(C)C)=CC=C1S(=O)(=O)NC(=O)C1=CC=C(N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)C=C1OC1=CC=CC=C1 ANNCRDSCGJDZFH-UHFFFAOYSA-N 0.000 description 1
- BPQUULCPOIUXMF-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[3-(dimethylamino)propylamino]-3-(trifluoromethylsulfonyl)phenyl]sulfonyl-2-(1h-indol-5-yloxy)benzamide Chemical compound C1=C(S(=O)(=O)C(F)(F)F)C(NCCCN(C)C)=CC=C1S(=O)(=O)NC(=O)C1=CC=C(N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)C=C1OC1=CC=C(NC=C2)C2=C1 BPQUULCPOIUXMF-UHFFFAOYSA-N 0.000 description 1
- QMTNYDPEIMSBMG-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[3-(dimethylamino)propylamino]-3-nitrophenyl]sulfonyl-2-(1h-indol-4-yloxy)benzamide Chemical compound C1=C([N+]([O-])=O)C(NCCCN(C)C)=CC=C1S(=O)(=O)NC(=O)C1=CC=C(N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)C=C1OC1=CC=CC2=C1C=CN2 QMTNYDPEIMSBMG-UHFFFAOYSA-N 0.000 description 1
- CRMUPZZTQKIZQP-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[3-(dimethylamino)propylamino]-3-nitrophenyl]sulfonyl-2-(1h-indol-5-yloxy)benzamide Chemical compound C1=C([N+]([O-])=O)C(NCCCN(C)C)=CC=C1S(=O)(=O)NC(=O)C1=CC=C(N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)C=C1OC1=CC=C(NC=C2)C2=C1 CRMUPZZTQKIZQP-UHFFFAOYSA-N 0.000 description 1
- NRBCHTCIIWAMSW-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[3-(dimethylamino)propylamino]-3-nitrophenyl]sulfonyl-2-(1h-indol-6-yloxy)benzamide Chemical compound C1=C([N+]([O-])=O)C(NCCCN(C)C)=CC=C1S(=O)(=O)NC(=O)C1=CC=C(N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)C=C1OC1=CC=C(C=CN2)C2=C1 NRBCHTCIIWAMSW-UHFFFAOYSA-N 0.000 description 1
- WUGWGQVLHLEPEX-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[3-(dimethylamino)propylamino]-3-nitrophenyl]sulfonyl-2-isoquinolin-5-yloxybenzamide Chemical compound C1=C([N+]([O-])=O)C(NCCCN(C)C)=CC=C1S(=O)(=O)NC(=O)C1=CC=C(N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)C=C1OC1=CC=CC2=CN=CC=C12 WUGWGQVLHLEPEX-UHFFFAOYSA-N 0.000 description 1
- UKFKBSSVQKMQRO-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[3-(dimethylamino)propylamino]-3-nitrophenyl]sulfonyl-2-isoquinolin-7-yloxybenzamide Chemical compound C1=C([N+]([O-])=O)C(NCCCN(C)C)=CC=C1S(=O)(=O)NC(=O)C1=CC=C(N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)C=C1OC1=CC=C(C=CN=C2)C2=C1 UKFKBSSVQKMQRO-UHFFFAOYSA-N 0.000 description 1
- PYXZMYZOQVAYKA-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[3-(dimethylamino)propylamino]-3-nitrophenyl]sulfonyl-2-naphthalen-2-yloxybenzamide Chemical compound C1=C([N+]([O-])=O)C(NCCCN(C)C)=CC=C1S(=O)(=O)NC(=O)C1=CC=C(N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)C=C1OC1=CC=C(C=CC=C2)C2=C1 PYXZMYZOQVAYKA-UHFFFAOYSA-N 0.000 description 1
- RSDVSEGQLQPBNE-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[3-(dimethylamino)propylamino]-3-nitrophenyl]sulfonyl-2-phenoxybenzamide Chemical compound C1=C([N+]([O-])=O)C(NCCCN(C)C)=CC=C1S(=O)(=O)NC(=O)C1=CC=C(N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)C=C1OC1=CC=CC=C1 RSDVSEGQLQPBNE-UHFFFAOYSA-N 0.000 description 1
- ITTWTZQEDOZWMI-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[3-(dimethylamino)propylamino]-3-nitrophenyl]sulfonyl-2-quinolin-6-yloxybenzamide Chemical compound C1=C([N+]([O-])=O)C(NCCCN(C)C)=CC=C1S(=O)(=O)NC(=O)C1=CC=C(N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)C=C1OC1=CC=C(N=CC=C2)C2=C1 ITTWTZQEDOZWMI-UHFFFAOYSA-N 0.000 description 1
- UNGQZYPSERXHSV-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[3-[methyl(propan-2-yl)amino]propylamino]-3-nitrophenyl]sulfonyl-2-phenoxybenzamide Chemical compound C1=C([N+]([O-])=O)C(NCCCN(C)C(C)C)=CC=C1S(=O)(=O)NC(=O)C1=CC=C(N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)C=C1OC1=CC=CC=C1 UNGQZYPSERXHSV-UHFFFAOYSA-N 0.000 description 1
- MGMYLLRHFHAWAH-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[4-(dimethylamino)butylamino]-3-nitrophenyl]sulfonyl-2-phenoxybenzamide Chemical compound C1=C([N+]([O-])=O)C(NCCCCN(C)C)=CC=C1S(=O)(=O)NC(=O)C1=CC=C(N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)C=C1OC1=CC=CC=C1 MGMYLLRHFHAWAH-UHFFFAOYSA-N 0.000 description 1
- ZTFVTCHOOJNCFA-RWYGWLOXSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[[(1s)-3-(dimethylamino)-1-thiophen-2-ylpropyl]amino]-3-nitrophenyl]sulfonyl-2-phenoxybenzamide Chemical compound N([C@@H](CCN(C)C)C=1SC=CC=1)C(C(=C1)[N+]([O-])=O)=CC=C1S(=O)(=O)NC(=O)C1=CC=C(N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)C=C1OC1=CC=CC=C1 ZTFVTCHOOJNCFA-RWYGWLOXSA-N 0.000 description 1
- JNQOOFMNPUFXHS-KXQOOQHDSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonyl-2-phenoxybenzamide Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C(=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)OC=1C=CC=CC=1)[N+]([O-])=O)SC1=CC=CC=C1 JNQOOFMNPUFXHS-KXQOOQHDSA-N 0.000 description 1
- AIOAGPOBFXULOX-UHFFFAOYSA-N 4-[4-[[2-(4-fluorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-4-yloxy)-n-[3-nitro-4-(3-pyrrolidin-1-ylpropylamino)phenyl]sulfonylbenzamide Chemical compound C=1C=C(F)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=3C=CNC=3C=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCCCN1CCCC1 AIOAGPOBFXULOX-UHFFFAOYSA-N 0.000 description 1
- OJAQHRAJVQPSHL-MAZIBIHTSA-N 4-[4-[[2-[5-[[(1r,5s)-8-azabicyclo[3.2.1]octan-8-yl]methyl]thiophen-2-yl]phenyl]methylidene]piperidin-1-yl]-n-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonyl-2-phenoxybenzamide Chemical compound N1([C@]2([H])CC[C@]1(CCC2)[H])CC(S1)=CC=C1C1=CC=CC=C1C=C(CC1)CCN1C(C=C1OC=2C=CC=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 OJAQHRAJVQPSHL-MAZIBIHTSA-N 0.000 description 1
- UMMRKRNLYBOQHR-ULNKKHRMSA-N 4-[4-[[2-[[(1r,5s)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl]amino]phenyl]methyl]piperazin-1-yl]-n-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonyl-2-phenoxybenzamide Chemical compound C([C@]1(CC[C@@](C2)(N1C)[H])[H])C2NC1=CC=CC=C1CN(CC1)CCN1C(C=C1OC=2C=CC=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 UMMRKRNLYBOQHR-ULNKKHRMSA-N 0.000 description 1
- SNGLUTGJHPJBMW-RKZGCHKJSA-N 4-[4-[[2-[[(1s,5r)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl]amino]phenyl]methyl]piperazin-1-yl]-n-[4-(3-morpholin-4-ylpropylamino)-3-nitrophenyl]sulfonyl-2-phenoxybenzamide Chemical compound C([C@]1(CC[C@@](C2)(N1C)[H])[H])C2NC1=CC=CC=C1CN(CC1)CCN1C(C=C1OC=2C=CC=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCCCN1CCOCC1 SNGLUTGJHPJBMW-RKZGCHKJSA-N 0.000 description 1
- FVSOTVSKPORIBG-MAZIBIHTSA-N 4-[4-[[3-[5-[[(1r,5s)-8-azabicyclo[3.2.1]octan-8-yl]methyl]thiophen-2-yl]phenyl]methyl]piperazin-1-yl]-n-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonyl-2-phenoxybenzamide Chemical compound N1([C@]2([H])CC[C@]1(CCC2)[H])CC(S1)=CC=C1C(C=1)=CC=CC=1CN(CC1)CCN1C(C=C1OC=2C=CC=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 FVSOTVSKPORIBG-MAZIBIHTSA-N 0.000 description 1
- LNKCZIXHBDSYJV-UHFFFAOYSA-N 4-[4-[[4,4-dimethyl-2-[3-(trifluoromethyl)phenyl]cyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-4-yloxy)-n-[3-nitro-4-(3-pyrrolidin-1-ylpropylamino)phenyl]sulfonylbenzamide Chemical compound C=1C=CC(C(F)(F)F)=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=3C=CNC=3C=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCCCN1CCCC1 LNKCZIXHBDSYJV-UHFFFAOYSA-N 0.000 description 1
- LEAVQDKFQREFPB-UHFFFAOYSA-N 4-[4-[[4,4-dimethyl-2-[4-(trifluoromethoxy)phenyl]cyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-4-yloxy)-n-[3-nitro-4-(3-pyrrolidin-1-ylpropylamino)phenyl]sulfonylbenzamide Chemical compound C=1C=C(OC(F)(F)F)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=3C=CNC=3C=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCCCN1CCCC1 LEAVQDKFQREFPB-UHFFFAOYSA-N 0.000 description 1
- LCCDNSYIOHNDML-UHFFFAOYSA-N 4-[4-[[4,4-dimethyl-2-[4-(trifluoromethyl)phenyl]cyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-4-yloxy)-n-[3-nitro-4-(3-pyrrolidin-1-ylpropylamino)phenyl]sulfonylbenzamide Chemical compound C=1C=C(C(F)(F)F)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=3C=CNC=3C=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCCCN1CCCC1 LCCDNSYIOHNDML-UHFFFAOYSA-N 0.000 description 1
- WVWYYMQXXPZBGE-UHFFFAOYSA-N 4-[4-[[4-(4-chlorophenyl)-1-(3-hydroxypropyl)-3,6-dihydro-2h-pyridin-5-yl]methyl]piperazin-1-yl]-2-(1h-indol-4-yloxy)-n-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonylbenzamide Chemical compound C1N(CCCO)CCC(C=2C=CC(Cl)=CC=2)=C1CN(CC1)CCN1C(C=C1OC=2C=3C=CNC=3C=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 WVWYYMQXXPZBGE-UHFFFAOYSA-N 0.000 description 1
- MKTOPOYZAJJQID-UHFFFAOYSA-N 4-[4-[[4-(4-chlorophenyl)-6,6-dimethyl-2,5-dihydropyran-3-yl]methyl]piperazin-1-yl]-2-(1h-indol-4-yloxy)-n-[4-[(1-methylpiperidin-4-yl)amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C1CN(C)CCC1NC1=CC=C(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3COC(C)(C)CC=3C=3C=CC(Cl)=CC=3)CC2)OC=2C=3C=CNC=3C=CC=2)C=C1[N+]([O-])=O MKTOPOYZAJJQID-UHFFFAOYSA-N 0.000 description 1
- DOUCQTBWNDOVHL-UHFFFAOYSA-N 4-[4-[[4-(4-chlorophenyl)-6,6-dimethyl-2,5-dihydropyran-3-yl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonylbenzamide Chemical compound C1OC(C)(C)CC(C=2C=CC(Cl)=CC=2)=C1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 DOUCQTBWNDOVHL-UHFFFAOYSA-N 0.000 description 1
- PONFIAVQDHUGMU-UHFFFAOYSA-N 4-[4-[[4-(4-chlorophenyl)-6,6-dimethyl-2,5-dihydropyran-3-yl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-[4-[(1-methylpiperidin-4-yl)amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C1CN(C)CCC1NC1=CC=C(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3COC(C)(C)CC=3C=3C=CC(Cl)=CC=3)CC2)OC=2C=C3C=CNC3=CC=2)C=C1[N+]([O-])=O PONFIAVQDHUGMU-UHFFFAOYSA-N 0.000 description 1
- LTHWFHWKVAQRJI-UHFFFAOYSA-N 4-[4-[[4-(4-chlorophenyl)-6-oxo-1-propan-2-ylpyridin-3-yl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonylbenzamide Chemical compound C=1C=C(Cl)C=CC=1C1=CC(=O)N(C(C)C)C=C1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 LTHWFHWKVAQRJI-UHFFFAOYSA-N 0.000 description 1
- ZCIMBYHIEFUAPC-UHFFFAOYSA-N 4-[4-[[4-(4-chlorophenyl)-6-propan-2-yloxypyridin-3-yl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonylbenzamide Chemical compound C1=NC(OC(C)C)=CC(C=2C=CC(Cl)=CC=2)=C1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 ZCIMBYHIEFUAPC-UHFFFAOYSA-N 0.000 description 1
- JZTNDGPIKYIMGD-UHFFFAOYSA-N 4-[4-[[4-tert-butyl-2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-[3-nitro-4-(oxan-4-ylmethoxy)phenyl]sulfonylbenzamide Chemical compound C=1C=C(Cl)C=CC=1C1=CC(C(C)(C)C)=CC=C1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1OCC1CCOCC1 JZTNDGPIKYIMGD-UHFFFAOYSA-N 0.000 description 1
- DULYXXGOKACFBD-UHFFFAOYSA-N 4-[4-[[4-tert-butyl-2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonylbenzamide Chemical compound C=1C=C(Cl)C=CC=1C1=CC(C(C)(C)C)=CC=C1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 DULYXXGOKACFBD-UHFFFAOYSA-N 0.000 description 1
- BJXNNZHPBIDJTA-UHFFFAOYSA-N 4-[4-[[4-tert-butyl-2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)-n-[3-nitro-4-[[1-(oxan-4-yl)piperidin-4-yl]amino]phenyl]sulfonylbenzamide Chemical compound C=1C=C(Cl)C=CC=1C1=CC(C(C)(C)C)=CC=C1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NC(CC1)CCN1C1CCOCC1 BJXNNZHPBIDJTA-UHFFFAOYSA-N 0.000 description 1
- ZHSKUOZOLHMKEA-UHFFFAOYSA-N 4-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid;hydron;chloride Chemical compound Cl.ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 ZHSKUOZOLHMKEA-UHFFFAOYSA-N 0.000 description 1
- HHFBDROWDBDFBR-UHFFFAOYSA-N 4-[[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1NC1=NC=C(CN=C(C=2C3=CC=C(Cl)C=2)C=2C(=CC=CC=2F)F)C3=N1 HHFBDROWDBDFBR-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- WUUGFSXJNOTRMR-IOSLPCCCSA-N 5'-S-methyl-5'-thioadenosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CSC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 WUUGFSXJNOTRMR-IOSLPCCCSA-N 0.000 description 1
- HUNAOTXNHVALTN-UHFFFAOYSA-N 5-(5-chloro-2,4-dihydroxyphenyl)-N-ethyl-4-(4-methoxyphenyl)pyrazole-3-carboxamide Chemical compound CCNC(=O)C1=NNC(C=2C(=CC(O)=C(Cl)C=2)O)=C1C1=CC=C(OC)C=C1 HUNAOTXNHVALTN-UHFFFAOYSA-N 0.000 description 1
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- 125000006043 5-hexenyl group Chemical group 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
- RREANTFLPGEWEN-MBLPBCRHSA-N 7-[4-[[(3z)-3-[4-amino-5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidin-2-yl]imino-5-fluoro-2-oxoindol-1-yl]methyl]piperazin-1-yl]-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylic acid Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(\N=C/3C4=CC(F)=CC=C4N(CN4CCN(CC4)C=4C(=CC=5C(=O)C(C(O)=O)=CN(C=5C=4)C4CC4)F)C\3=O)=NC=2)N)=C1 RREANTFLPGEWEN-MBLPBCRHSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- NKGPJODWTZCHGF-UHFFFAOYSA-N 9-[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purine-6-thione Chemical compound OC1C(O)C(CO)OC1N1C(NC=NC2=S)=C2N=C1 NKGPJODWTZCHGF-UHFFFAOYSA-N 0.000 description 1
- TUOSCZDRWRYPRS-UHFFFAOYSA-N 9-butyl-8-(3,4,5-trimethoxybenzyl)-9h-purin-6-amine Chemical compound N=1C2=C(N)N=CN=C2N(CCCC)C=1CC1=CC(OC)=C(OC)C(OC)=C1 TUOSCZDRWRYPRS-UHFFFAOYSA-N 0.000 description 1
- BUROJSBIWGDYCN-GAUTUEMISA-N AP 23573 Chemical compound C1C[C@@H](OP(C)(C)=O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 BUROJSBIWGDYCN-GAUTUEMISA-N 0.000 description 1
- GBJVVSCPOBPEIT-UHFFFAOYSA-N AZT-1152 Chemical compound N=1C=NC2=CC(OCCCN(CC)CCOP(O)(O)=O)=CC=C2C=1NC(=NN1)C=C1CC(=O)NC1=CC=CC(F)=C1 GBJVVSCPOBPEIT-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- MXPOCMVWFLDDLZ-NSCUHMNNSA-N Apaziquone Chemical compound CN1C(\C=C\CO)=C(CO)C(C2=O)=C1C(=O)C=C2N1CC1 MXPOCMVWFLDDLZ-NSCUHMNNSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 239000012664 BCL-2-inhibitor Substances 0.000 description 1
- QULDDKSCVCJTPV-UHFFFAOYSA-N BIIB021 Chemical compound COC1=C(C)C=NC(CN2C3=NC(N)=NC(Cl)=C3N=C2)=C1C QULDDKSCVCJTPV-UHFFFAOYSA-N 0.000 description 1
- 102100026596 Bcl-2-like protein 1 Human genes 0.000 description 1
- 229940123711 Bcl2 inhibitor Drugs 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- OWPKNLXIVUAVDD-UEOVJWFCSA-N CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NC[C@H]4CC[C@@H](CC4)C#N)c(c3)[N+]([O-])=O)c(Oc3cccc4[nH]cnc34)c2)=C(C1)c1ccc(Cl)cc1 Chemical compound CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NC[C@H]4CC[C@@H](CC4)C#N)c(c3)[N+]([O-])=O)c(Oc3cccc4[nH]cnc34)c2)=C(C1)c1ccc(Cl)cc1 OWPKNLXIVUAVDD-UEOVJWFCSA-N 0.000 description 1
- XGZZEDXPHWAXMM-YBEWYAPJSA-N CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@H]4CC[C@@H](CC4)N4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cccc4[nH]cnc34)c2)=C(C1)c1ccc(Cl)cc1 Chemical compound CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@H]4CC[C@@H](CC4)N4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cccc4[nH]cnc34)c2)=C(C1)c1ccc(Cl)cc1 XGZZEDXPHWAXMM-YBEWYAPJSA-N 0.000 description 1
- PJMQANDHUTXXOA-YBEWYAPJSA-N CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@H]4CC[C@@H](CC4)N4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cccc4[nH]ncc34)c2)=C(C1)c1ccc(Cl)cc1 Chemical compound CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@H]4CC[C@@H](CC4)N4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cccc4[nH]ncc34)c2)=C(C1)c1ccc(Cl)cc1 PJMQANDHUTXXOA-YBEWYAPJSA-N 0.000 description 1
- XNQGZKRRFOZQQK-GHAAWWQXSA-N CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3cnc(OC[C@H]4CC[C@H](O)CC4)c(Cl)c3)c(Oc3cccc4[nH]ncc34)c2)=C(C1)c1ccc(Cl)cc1 Chemical compound CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3cnc(OC[C@H]4CC[C@H](O)CC4)c(Cl)c3)c(Oc3cccc4[nH]ncc34)c2)=C(C1)c1ccc(Cl)cc1 XNQGZKRRFOZQQK-GHAAWWQXSA-N 0.000 description 1
- SIJOMEXEMDSFHW-FPJJVYJPSA-N CO[C@H]1CC[C@H](CNc2ccc(cc2[N+]([O-])=O)S(=O)(=O)NC(=O)c2ccc(cc2Oc2cccc3[nH]cnc23)N2CCN(CC3=C(CC(C)(C)CC3)c3ccc(Cl)cc3)CC2)CC1 Chemical compound CO[C@H]1CC[C@H](CNc2ccc(cc2[N+]([O-])=O)S(=O)(=O)NC(=O)c2ccc(cc2Oc2cccc3[nH]cnc23)N2CCN(CC3=C(CC(C)(C)CC3)c3ccc(Cl)cc3)CC2)CC1 SIJOMEXEMDSFHW-FPJJVYJPSA-N 0.000 description 1
- RATWQQRMJGYYLC-FPJJVYJPSA-N CO[C@H]1CC[C@H](CNc2ccc(cc2[N+]([O-])=O)S(=O)(=O)NC(=O)c2ccc(cc2Oc2cccc3[nH]ncc23)N2CCN(CC3=C(CC(C)(C)CC3)c3ccc(Cl)cc3)CC2)CC1 Chemical compound CO[C@H]1CC[C@H](CNc2ccc(cc2[N+]([O-])=O)S(=O)(=O)NC(=O)c2ccc(cc2Oc2cccc3[nH]ncc23)N2CCN(CC3=C(CC(C)(C)CC3)c3ccc(Cl)cc3)CC2)CC1 RATWQQRMJGYYLC-FPJJVYJPSA-N 0.000 description 1
- ZZRDDZVWTARSGV-ZGSWXILYSA-N CO[C@H]1CC[C@H](COc2ncc(cc2Cl)S(=O)(=O)NC(=O)c2ccc(cc2Oc2cccc3[nH]ncc23)N2CCN(CC3=C(CC(C)(C)CC3)c3ccc(Cl)cc3)CC2)CC1 Chemical compound CO[C@H]1CC[C@H](COc2ncc(cc2Cl)S(=O)(=O)NC(=O)c2ccc(cc2Oc2cccc3[nH]ncc23)N2CCN(CC3=C(CC(C)(C)CC3)c3ccc(Cl)cc3)CC2)CC1 ZZRDDZVWTARSGV-ZGSWXILYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 101100464175 Candida albicans (strain SC5314 / ATCC MYA-2876) PIR32 gene Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- SHHKQEUPHAENFK-UHFFFAOYSA-N Carboquone Chemical compound O=C1C(C)=C(N2CC2)C(=O)C(C(COC(N)=O)OC)=C1N1CC1 SHHKQEUPHAENFK-UHFFFAOYSA-N 0.000 description 1
- AOCCBINRVIKJHY-UHFFFAOYSA-N Carmofur Chemical compound CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O AOCCBINRVIKJHY-UHFFFAOYSA-N 0.000 description 1
- 229940123587 Cell cycle inhibitor Drugs 0.000 description 1
- 102100025832 Centromere-associated protein E Human genes 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 102100021906 Cyclin-O Human genes 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 101100481408 Danio rerio tie2 gene Proteins 0.000 description 1
- 102100033553 Delta-like protein 4 Human genes 0.000 description 1
- 108010002156 Depsipeptides Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 101000582926 Dictyostelium discoideum Probable serine/threonine-protein kinase PLK Proteins 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- SAMRUMKYXPVKPA-VFKOLLTISA-N Enocitabine Chemical compound O=C1N=C(NC(=O)CCCCCCCCCCCCCCCCCCCCC)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 SAMRUMKYXPVKPA-VFKOLLTISA-N 0.000 description 1
- 102000056372 ErbB-3 Receptor Human genes 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 1
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- RVAQIUULWULRNW-UHFFFAOYSA-N Ganetespib Chemical compound C1=C(O)C(C(C)C)=CC(C=2N(C(O)=NN=2)C=2C=C3C=CN(C)C3=CC=2)=C1O RVAQIUULWULRNW-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- JRZJKWGQFNTSRN-UHFFFAOYSA-N Geldanamycin Natural products C1C(C)CC(OC)C(O)C(C)C=C(C)C(OC(N)=O)C(OC)CCC=C(C)C(=O)NC2=CC(=O)C(OC)=C1C2=O JRZJKWGQFNTSRN-UHFFFAOYSA-N 0.000 description 1
- 102100032510 Heat shock protein HSP 90-beta Human genes 0.000 description 1
- 101000914247 Homo sapiens Centromere-associated protein E Proteins 0.000 description 1
- 101000897441 Homo sapiens Cyclin-O Proteins 0.000 description 1
- 101000872077 Homo sapiens Delta-like protein 4 Proteins 0.000 description 1
- 101001016856 Homo sapiens Heat shock protein HSP 90-beta Proteins 0.000 description 1
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
- 239000002144 L01XE18 - Ruxolitinib Substances 0.000 description 1
- UIARLYUEJFELEN-LROUJFHJSA-N LSM-1231 Chemical compound C12=C3N4C5=CC=CC=C5C3=C3C(=O)NCC3=C2C2=CC=CC=C2N1[C@]1(C)[C@](CO)(O)C[C@H]4O1 UIARLYUEJFELEN-LROUJFHJSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 101000988090 Leishmania donovani Heat shock protein 83 Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 102220595571 Major vault protein_R52A_mutation Human genes 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000008135 Mechanistic Target of Rapamycin Complex 1 Human genes 0.000 description 1
- 108010035196 Mechanistic Target of Rapamycin Complex 1 Proteins 0.000 description 1
- 102000009308 Mechanistic Target of Rapamycin Complex 2 Human genes 0.000 description 1
- 108010034057 Mechanistic Target of Rapamycin Complex 2 Proteins 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 108700011259 MicroRNAs Proteins 0.000 description 1
- VFKZTMPDYBFSTM-KVTDHHQDSA-N Mitobronitol Chemical compound BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-KVTDHHQDSA-N 0.000 description 1
- 101100481410 Mus musculus Tek gene Proteins 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- QTXLONKZCYYXEL-LZXZCVKDSA-N N-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonyl-2-phenoxy-4-[4-[[2-[(1S,7R)-8-tricyclo[5.2.1.02,6]dec-8-enyl]phenyl]methyl]piperazin-1-yl]benzamide Chemical compound C=1([C@]2([H])C[C@@](C3CCCC32)(C=1)[H])C1=CC=CC=C1CN(CC1)CCN1C(C=C1OC=2C=CC=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 QTXLONKZCYYXEL-LZXZCVKDSA-N 0.000 description 1
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 description 1
- KTDZCOWXCWUPEO-UHFFFAOYSA-N NS-398 Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1CCCCC1 KTDZCOWXCWUPEO-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- AFLXUQUGROGEFA-UHFFFAOYSA-N Nitrogen mustard N-oxide Chemical compound ClCC[N+]([O-])(C)CCCl AFLXUQUGROGEFA-UHFFFAOYSA-N 0.000 description 1
- MHQJUHSHQGQVTM-HNENSFHCSA-N Octadecyl fumarate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)\C=C/C(O)=O MHQJUHSHQGQVTM-HNENSFHCSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- SUDAHWBOROXANE-SECBINFHSA-N PD 0325901 Chemical compound OC[C@@H](O)CONC(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F SUDAHWBOROXANE-SECBINFHSA-N 0.000 description 1
- 101150045321 PIR3 gene Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 101100528525 Prochlorococcus marinus (strain SARG / CCMP1375 / SS120) rnc gene Proteins 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- AHHFEZNOXOZZQA-ZEBDFXRSSA-N Ranimustine Chemical compound CO[C@H]1O[C@H](CNC(=O)N(CCCl)N=O)[C@@H](O)[C@H](O)[C@H]1O AHHFEZNOXOZZQA-ZEBDFXRSSA-N 0.000 description 1
- 229940127361 Receptor Tyrosine Kinase Inhibitors Drugs 0.000 description 1
- 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- JHBIMJKLBUMNAU-UHFFFAOYSA-N SC-58125 Chemical compound C1=CC(S(=O)(=O)C)=CC=C1N1C(C=2C=CC(F)=CC=2)=CC(C(F)(F)F)=N1 JHBIMJKLBUMNAU-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-ZSJDYOACSA-N Sulfuric acid-d2 Chemical compound [2H]OS(=O)(=O)O[2H] QAOWNCQODCNURD-ZSJDYOACSA-N 0.000 description 1
- 108010000449 TNF-Related Apoptosis-Inducing Ligand Receptors Proteins 0.000 description 1
- 102000002259 TNF-Related Apoptosis-Inducing Ligand Receptors Human genes 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- 102000002938 Thrombospondin Human genes 0.000 description 1
- 108060008245 Thrombospondin Proteins 0.000 description 1
- IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 229930189037 Trapoxin Natural products 0.000 description 1
- YCPOZVAOBBQLRI-WDSKDSINSA-N Treosulfan Chemical compound CS(=O)(=O)OC[C@H](O)[C@@H](O)COS(C)(=O)=O YCPOZVAOBBQLRI-WDSKDSINSA-N 0.000 description 1
- 229940127507 Ubiquitin Ligase Inhibitors Drugs 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- OIRDTQYFTABQOQ-UHTZMRCNSA-N Vidarabine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O OIRDTQYFTABQOQ-UHTZMRCNSA-N 0.000 description 1
- 102220479829 Voltage-dependent L-type calcium channel subunit beta-2_R56K_mutation Human genes 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- LPTCUYGPZMAHMM-GPJOBVNKSA-L [(4r,5r)-5-(azanidylmethyl)-2-propan-2-yl-1,3-dioxolan-4-yl]methylazanide;platinum(4+);propanedioate Chemical compound [Pt+4].[O-]C(=O)CC([O-])=O.CC(C)C1O[C@H](C[NH-])[C@@H](C[NH-])O1 LPTCUYGPZMAHMM-GPJOBVNKSA-L 0.000 description 1
- XMYKNCNAZKMVQN-NYYWCZLTSA-N [(e)-(3-aminopyridin-2-yl)methylideneamino]thiourea Chemical compound NC(=S)N\N=C\C1=NC=CC=C1N XMYKNCNAZKMVQN-NYYWCZLTSA-N 0.000 description 1
- XSMVECZRZBFTIZ-UHFFFAOYSA-M [2-(aminomethyl)cyclobutyl]methanamine;2-oxidopropanoate;platinum(4+) Chemical compound [Pt+4].CC([O-])C([O-])=O.NCC1CCC1CN XSMVECZRZBFTIZ-UHFFFAOYSA-M 0.000 description 1
- HXELGNKCCDGMMN-UHFFFAOYSA-N [F].[Cl] Chemical compound [F].[Cl] HXELGNKCCDGMMN-UHFFFAOYSA-N 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940023476 agar Drugs 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 229940060515 aleve Drugs 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229940110282 alimta Drugs 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 229940098174 alkeran Drugs 0.000 description 1
- 125000004419 alkynylene group Chemical group 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229960000473 altretamine Drugs 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229940024545 aluminum hydroxide Drugs 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000002927 anti-mitotic effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000003080 antimitotic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 229950002465 apaziquone Drugs 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 239000005441 aurora Substances 0.000 description 1
- KLNFSAOEKUDMFA-UHFFFAOYSA-N azanide;2-hydroxyacetic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OCC(O)=O KLNFSAOEKUDMFA-UHFFFAOYSA-N 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- BYZFMXYCXMZVAH-UHFFFAOYSA-N benzyl 4-[[4-[[4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)benzoyl]sulfamoyl]-2-nitroanilino]methyl]piperidine-1-carboxylate Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC(CC1)CCN1C(=O)OCC1=CC=CC=C1 BYZFMXYCXMZVAH-UHFFFAOYSA-N 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 229940110331 bextra Drugs 0.000 description 1
- GPRLTFBKWDERLU-UHFFFAOYSA-N bicyclo[2.2.2]octane Chemical group C1CC2CCC1CC2 GPRLTFBKWDERLU-UHFFFAOYSA-N 0.000 description 1
- SHOMMGQAMRXRRK-UHFFFAOYSA-N bicyclo[3.1.1]heptane Chemical group C1C2CC1CCC2 SHOMMGQAMRXRRK-UHFFFAOYSA-N 0.000 description 1
- LPCWKMYWISGVSK-UHFFFAOYSA-N bicyclo[3.2.1]octane Chemical group C1C2CCC1CCC2 LPCWKMYWISGVSK-UHFFFAOYSA-N 0.000 description 1
- GNTFBMAGLFYMMZ-UHFFFAOYSA-N bicyclo[3.2.2]nonane Chemical group C1CC2CCC1CCC2 GNTFBMAGLFYMMZ-UHFFFAOYSA-N 0.000 description 1
- WNTGVOIBBXFMLR-UHFFFAOYSA-N bicyclo[3.3.1]nonane Chemical group C1CCC2CCCC1C2 WNTGVOIBBXFMLR-UHFFFAOYSA-N 0.000 description 1
- KVLCIHRZDOKRLK-UHFFFAOYSA-N bicyclo[4.2.1]nonane Chemical group C1C2CCC1CCCC2 KVLCIHRZDOKRLK-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- ACWZRVQXLIRSDF-UHFFFAOYSA-N binimetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1F ACWZRVQXLIRSDF-UHFFFAOYSA-N 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229960000455 brentuximab vedotin Drugs 0.000 description 1
- 229950004271 brostallicin Drugs 0.000 description 1
- RXOVOXFAAGIKDQ-UHFFFAOYSA-N brostallicin Chemical compound C1=C(C(=O)NCCN=C(N)N)N(C)C=C1NC(=O)C1=CC(NC(=O)C=2N(C=C(NC(=O)C=3N(C=C(NC(=O)C(Br)=C)C=3)C)C=2)C)=CN1C RXOVOXFAAGIKDQ-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- OMZCMEYTWSXEPZ-UHFFFAOYSA-N canertinib Chemical compound C1=C(Cl)C(F)=CC=C1NC1=NC=NC2=CC(OCCCN3CCOCC3)=C(NC(=O)C=C)C=C12 OMZCMEYTWSXEPZ-UHFFFAOYSA-N 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 229960002115 carboquone Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 229960003261 carmofur Drugs 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 229940047495 celebrex Drugs 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- IQCIQDNWBGEGRL-UHFFFAOYSA-N chembl1614651 Chemical compound O=C1C2=C(O)C=CC(O)=C2N2N=C(CNCCO)C3=CC=C(NCCCN)C1=C32 IQCIQDNWBGEGRL-UHFFFAOYSA-N 0.000 description 1
- ZFVRYNYOPQZKDG-MQMHXKEQSA-N chembl560895 Chemical compound O=C1CC(C)(C)CC2=C1C(C(F)(F)F)=NN2C(C=1)=CC=C(C(N)=O)C=1N[C@H]1CC[C@H](O)CC1 ZFVRYNYOPQZKDG-MQMHXKEQSA-N 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- WDDPHFBMKLOVOX-AYQXTPAHSA-N clofarabine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F WDDPHFBMKLOVOX-AYQXTPAHSA-N 0.000 description 1
- 229960000928 clofarabine Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 229950007276 conatumumab Drugs 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 229950006614 cytarabine ocfosfate Drugs 0.000 description 1
- YJTVZHOYBAOUTO-URBBEOKESA-N cytarabine ocfosfate Chemical compound O[C@H]1[C@H](O)[C@@H](COP(O)(=O)OCCCCCCCCCCCCCCCCCC)O[C@H]1N1C(=O)N=C(N)C=C1 YJTVZHOYBAOUTO-URBBEOKESA-N 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 229940070230 daypro Drugs 0.000 description 1
- 229960003603 decitabine Drugs 0.000 description 1
- 229960000958 deferoxamine Drugs 0.000 description 1
- 229960003314 deracoxib Drugs 0.000 description 1
- 229940051427 deramaxx Drugs 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 125000005959 diazepanyl group Chemical group 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- NYDXNILOWQXUOF-UHFFFAOYSA-L disodium;2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioate Chemical compound [Na+].[Na+].C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)NC(CCC([O-])=O)C([O-])=O)C=C1 NYDXNILOWQXUOF-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- 125000005411 dithiolanyl group Chemical group S1SC(CC1)* 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 229940072701 dolobid Drugs 0.000 description 1
- 238000004980 dosimetry Methods 0.000 description 1
- ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 description 1
- 229950005454 doxifluridine Drugs 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- VLCYCQAOQCDTCN-UHFFFAOYSA-N eflornithine Chemical compound NCCCC(N)(C(F)F)C(O)=O VLCYCQAOQCDTCN-UHFFFAOYSA-N 0.000 description 1
- 229960002759 eflornithine Drugs 0.000 description 1
- 229940121647 egfr inhibitor Drugs 0.000 description 1
- 229940120655 eloxatin Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 150000002081 enamines Chemical class 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 229950011487 enocitabine Drugs 0.000 description 1
- INVTYAOGFAGBOE-UHFFFAOYSA-N entinostat Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC(=O)OCC1=CC=CN=C1 INVTYAOGFAGBOE-UHFFFAOYSA-N 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 229950006835 eptaplatin Drugs 0.000 description 1
- 229940082789 erbitux Drugs 0.000 description 1
- 229960001842 estramustine Drugs 0.000 description 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 229960005293 etodolac Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229960005167 everolimus Drugs 0.000 description 1
- 230000028023 exocytosis Effects 0.000 description 1
- 229940065410 feldene Drugs 0.000 description 1
- 229950000133 filanesib Drugs 0.000 description 1
- LLXISKGBWFTGEI-FQEVSTJZSA-N filanesib Chemical compound C1([C@]2(CCCN)SC(=NN2C(=O)N(C)OC)C=2C(=CC=C(F)C=2)F)=CC=CC=C1 LLXISKGBWFTGEI-FQEVSTJZSA-N 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 150000003948 formamides Chemical class 0.000 description 1
- 229960004783 fotemustine Drugs 0.000 description 1
- YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical compound N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229940020967 gemzar Drugs 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 229940080856 gleevec Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229950011595 glufosfamide Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- QBKSWRVVCFFDOT-UHFFFAOYSA-N gossypol Chemical compound CC(C)C1=C(O)C(O)=C(C=O)C2=C(O)C(C=3C(O)=C4C(C=O)=C(O)C(O)=C(C4=CC=3C)C(C)C)=C(C)C=C21 QBKSWRVVCFFDOT-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 description 1
- 150000002373 hemiacetals Chemical class 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 125000005549 heteroarylene group Chemical group 0.000 description 1
- 125000006588 heterocycloalkylene group Chemical group 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
- 229960004171 hydroxychloroquine Drugs 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 229940124541 immunological agent Drugs 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000012444 intercalating antibiotic Substances 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229940084651 iressa Drugs 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000005929 isobutyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])OC(*)=O 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 125000005969 isothiazolinyl group Chemical group 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 238000001948 isotopic labelling Methods 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 125000003971 isoxazolinyl group Chemical group 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 229960004752 ketorolac Drugs 0.000 description 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
- BWHLPLXXIDYSNW-UHFFFAOYSA-N ketorolac tromethamine Chemical compound OCC(N)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 BWHLPLXXIDYSNW-UHFFFAOYSA-N 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229950000340 laromustine Drugs 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229950008991 lobaplatin Drugs 0.000 description 1
- 229940063718 lodine Drugs 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960000994 lumiracoxib Drugs 0.000 description 1
- 229940124302 mTOR inhibitor Drugs 0.000 description 1
- 229950000547 mafosfamide Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 229960005485 mitobronitol Drugs 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 1
- VFKZTMPDYBFSTM-GUCUJZIJSA-N mitolactol Chemical compound BrC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-GUCUJZIJSA-N 0.000 description 1
- 229950010913 mitolactol Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- VYGYNVZNSSTDLJ-HKCOAVLJSA-N monorden Natural products CC1CC2OC2C=C/C=C/C(=O)CC3C(C(=CC(=C3Cl)O)O)C(=O)O1 VYGYNVZNSSTDLJ-HKCOAVLJSA-N 0.000 description 1
- 229940072709 motrin Drugs 0.000 description 1
- ZTFBIUXIQYRUNT-MDWZMJQESA-N mubritinib Chemical compound C1=CC(C(F)(F)F)=CC=C1\C=C\C1=NC(COC=2C=CC(CCCCN3N=NC=C3)=CC=2)=CO1 ZTFBIUXIQYRUNT-MDWZMJQESA-N 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- SMFXSYMLJDHGIE-UHFFFAOYSA-N n-(3-aminopropyl)-n-[1-(5-benzyl-3-methyl-4-oxo-[1,2]thiazolo[5,4-d]pyrimidin-6-yl)-2-methylpropyl]-4-methylbenzamide Chemical compound N=1C=2SN=C(C)C=2C(=O)N(CC=2C=CC=CC=2)C=1C(C(C)C)N(CCCN)C(=O)C1=CC=C(C)C=C1 SMFXSYMLJDHGIE-UHFFFAOYSA-N 0.000 description 1
- XJQICOBDVKWHMO-UHFFFAOYSA-N n-[3-carbamoyl-4-(oxan-4-ylmethoxy)phenyl]sulfonyl-4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)benzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1C(N)=O)=CC=C1OCC1CCOCC1 XJQICOBDVKWHMO-UHFFFAOYSA-N 0.000 description 1
- GBRMEXCOMUAVCB-UHFFFAOYSA-N n-[3-chloro-4-[(4-fluorooxan-4-yl)methoxy]phenyl]sulfonyl-4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indazol-4-yloxy)benzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=3C=NNC=3C=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1Cl)=CC=C1OCC1(F)CCOCC1 GBRMEXCOMUAVCB-UHFFFAOYSA-N 0.000 description 1
- QWVPXCHNXRIFOQ-ACNXJJMFSA-N n-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonyl-2-phenoxy-4-[4-[3-phenylpropanoyl-[(1r,3s,4s,5s)-4,6,6-trimethyl-3-bicyclo[3.1.1]heptanyl]amino]piperidin-1-yl]benzamide Chemical compound C=1C=CC=CC=1CCC(=O)N([C@@H]1[C@@H](C)[C@@]2(C[C@](C1)(C2(C)C)[H])[H])C(CC1)CCN1C(C=C1OC=2C=CC=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 QWVPXCHNXRIFOQ-ACNXJJMFSA-N 0.000 description 1
- CMTJZWVSFKVXCF-MOBCKVDDSA-N n-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonyl-2-phenoxy-4-[4-[3-phenylpropyl-[(1r,3s,4s,5s)-4,6,6-trimethyl-3-bicyclo[3.1.1]heptanyl]amino]piperidin-1-yl]benzamide Chemical compound C1CN(C=2C=C(OC=3C=CC=CC=3)C(C(=O)NS(=O)(=O)C=3C=C(C(NCC4CCOCC4)=CC=3)[N+]([O-])=O)=CC=2)CCC1N([C@@H]1[C@@H](C)[C@@]2(C[C@](C1)(C2(C)C)[H])[H])CCCC1=CC=CC=C1 CMTJZWVSFKVXCF-MOBCKVDDSA-N 0.000 description 1
- MCXGCOULAVDBIT-VGRKJIIQSA-N n-[4-(3-morpholin-4-ylpropylamino)-3-nitrophenyl]sulfonyl-2-phenoxy-4-[4-[3-phenylpropanoyl-[(1r,3s,4s,5s)-4,6,6-trimethyl-3-bicyclo[3.1.1]heptanyl]amino]piperidin-1-yl]benzamide Chemical compound C=1C=CC=CC=1CCC(=O)N([C@@H]1[C@@H](C)[C@@]2(C[C@](C1)(C2(C)C)[H])[H])C(CC1)CCN1C(C=C1OC=2C=CC=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCCCN1CCOCC1 MCXGCOULAVDBIT-VGRKJIIQSA-N 0.000 description 1
- HNQALQPPDCVHCX-CZXJNUCUSA-N n-[4-(3-morpholin-4-ylpropylamino)-3-nitrophenyl]sulfonyl-2-phenoxy-4-[4-[3-phenylpropyl-[(1r,3s,4s,5s)-4,6,6-trimethyl-3-bicyclo[3.1.1]heptanyl]amino]piperidin-1-yl]benzamide Chemical compound C1CN(C=2C=C(OC=3C=CC=CC=3)C(C(=O)NS(=O)(=O)C=3C=C(C(NCCCN4CCOCC4)=CC=3)[N+]([O-])=O)=CC=2)CCC1N([C@@H]1[C@@H](C)[C@@]2(C[C@](C1)(C2(C)C)[H])[H])CCCC1=CC=CC=C1 HNQALQPPDCVHCX-CZXJNUCUSA-N 0.000 description 1
- SCVWFUKUBGBZMA-UHFFFAOYSA-N n-[4-[(1-acetylpiperidin-4-yl)amino]-3-nitrophenyl]sulfonyl-4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)benzamide Chemical compound C1CN(C(=O)C)CCC1NC1=CC=C(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3CCC(C)(C)CC=3C=3C=CC(Cl)=CC=3)CC2)OC=2C=C3C=CNC3=CC=2)C=C1[N+]([O-])=O SCVWFUKUBGBZMA-UHFFFAOYSA-N 0.000 description 1
- KIQBDADITBMUQU-UHFFFAOYSA-N n-[4-[(1-aminocyclohexyl)methylamino]-3-nitrophenyl]sulfonyl-4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)benzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1(N)CCCCC1 KIQBDADITBMUQU-UHFFFAOYSA-N 0.000 description 1
- VRJPVVVAAPUWFB-UHFFFAOYSA-N n-[4-[(2-aminocyclohexyl)amino]-3-nitrophenyl]sulfonyl-4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)benzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NC1CCCCC1N VRJPVVVAAPUWFB-UHFFFAOYSA-N 0.000 description 1
- PEBYWYUAUQCZLW-UHFFFAOYSA-N n-[4-[(4-acetylmorpholin-2-yl)methylamino]-3-nitrophenyl]sulfonyl-2-(1h-benzimidazol-4-yloxy)-4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]benzamide Chemical compound C1N(C(=O)C)CCOC1CNC1=CC=C(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3CCC(C)(C)CC=3C=3C=CC(Cl)=CC=3)CC2)OC=2C=3N=CNC=3C=CC=2)C=C1[N+]([O-])=O PEBYWYUAUQCZLW-UHFFFAOYSA-N 0.000 description 1
- FVQMLVZSDIYBOL-UHFFFAOYSA-N n-[4-[(4-aminooxan-4-yl)methylamino]-3-nitrophenyl]sulfonyl-4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)benzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1(N)CCOCC1 FVQMLVZSDIYBOL-UHFFFAOYSA-N 0.000 description 1
- IBLBCBMCZNDGTM-UHFFFAOYSA-N n-[4-[[1-(benzenesulfonyl)piperidin-4-yl]amino]-3-nitrophenyl]sulfonyl-4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-2-phenoxybenzamide Chemical compound [O-][N+](=O)C1=CC(S(=O)(=O)NC(=O)C=2C(=CC(=CC=2)N2CCN(CC=3C(=CC=CC=3)C=3C=CC(Cl)=CC=3)CC2)OC=2C=CC=CC=2)=CC=C1NC(CC1)CCN1S(=O)(=O)C1=CC=CC=C1 IBLBCBMCZNDGTM-UHFFFAOYSA-N 0.000 description 1
- QSPNYOYPCNYORQ-UHFFFAOYSA-N n-[5-bromo-6-(oxan-4-ylmethoxy)pyridin-3-yl]sulfonyl-4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-4-yloxy)benzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=3C=CNC=3C=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1Br)=CN=C1OCC1CCOCC1 QSPNYOYPCNYORQ-UHFFFAOYSA-N 0.000 description 1
- VBVVJCMIWMJWOH-UHFFFAOYSA-N n-[5-bromo-6-(oxan-4-ylmethoxy)pyridin-3-yl]sulfonyl-4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)benzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1Br)=CN=C1OCC1CCOCC1 VBVVJCMIWMJWOH-UHFFFAOYSA-N 0.000 description 1
- NCYLQVLHJWWNRW-UHFFFAOYSA-N n-[5-bromo-6-(oxan-4-ylmethylamino)pyridin-3-yl]sulfonyl-4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-5-yloxy)benzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1Br)=CN=C1NCC1CCOCC1 NCYLQVLHJWWNRW-UHFFFAOYSA-N 0.000 description 1
- NHEBRQDYIXTJOA-UHFFFAOYSA-N n-[5-chloro-6-(oxan-4-ylmethoxy)pyridin-3-yl]sulfonyl-4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indazol-4-yloxy)benzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=3C=NNC=3C=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1Cl)=CN=C1OCC1CCOCC1 NHEBRQDYIXTJOA-UHFFFAOYSA-N 0.000 description 1
- ORYCIHNPSVTTRW-UHFFFAOYSA-N n-[5-chloro-6-[(1-cyclopropylpiperidin-4-yl)amino]pyridin-3-yl]sulfonyl-4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indazol-4-yloxy)benzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=3C=NNC=3C=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1Cl)=CN=C1NC(CC1)CCN1C1CC1 ORYCIHNPSVTTRW-UHFFFAOYSA-N 0.000 description 1
- AKRJXOCVGNZMBS-JGCGQSQUSA-N n-[5-chloro-6-[(3r)-1-(2,2-difluoroethyl)pyrrolidin-3-yl]oxypyridin-3-yl]sulfonyl-4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indazol-4-yloxy)benzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=3C=NNC=3C=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1Cl)=CN=C1O[C@@H]1CCN(CC(F)F)C1 AKRJXOCVGNZMBS-JGCGQSQUSA-N 0.000 description 1
- JZVOHBDETKRCAT-UHFFFAOYSA-N n-[5-chloro-6-[(4-fluorooxan-4-yl)methoxy]pyridin-3-yl]sulfonyl-4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indol-4-yloxy)benzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=3C=CNC=3C=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1Cl)=CN=C1OCC1(F)CCOCC1 JZVOHBDETKRCAT-UHFFFAOYSA-N 0.000 description 1
- BIGFZWFFVCNYSU-UHFFFAOYSA-N n-[5-chloro-6-[2-(oxolan-2-yl)ethoxy]pyridin-3-yl]sulfonyl-4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1h-indazol-4-yloxy)benzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=3C=NNC=3C=CC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1Cl)=CN=C1OCCC1CCCO1 BIGFZWFFVCNYSU-UHFFFAOYSA-N 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960004270 nabumetone Drugs 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229950007221 nedaplatin Drugs 0.000 description 1
- IXOXBSCIXZEQEQ-UHTZMRCNSA-N nelarabine Chemical compound C1=NC=2C(OC)=NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O IXOXBSCIXZEQEQ-UHTZMRCNSA-N 0.000 description 1
- 229960000801 nelarabine Drugs 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960001420 nimustine Drugs 0.000 description 1
- VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- XHWRWCSCBDLOLM-UHFFFAOYSA-N nolatrexed Chemical compound CC1=CC=C2NC(N)=NC(=O)C2=C1SC1=CC=NC=C1 XHWRWCSCBDLOLM-UHFFFAOYSA-N 0.000 description 1
- 229950000891 nolatrexed Drugs 0.000 description 1
- ZCYXXKJEDCHMGH-UHFFFAOYSA-N nonane Chemical compound CCCC[CH]CCCC ZCYXXKJEDCHMGH-UHFFFAOYSA-N 0.000 description 1
- UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical group C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 description 1
- JFNLZVQOOSMTJK-KNVOCYPGSA-N norbornene Chemical group C1[C@@H]2CC[C@H]1C=C2 JFNLZVQOOSMTJK-KNVOCYPGSA-N 0.000 description 1
- BKIMMITUMNQMOS-UHFFFAOYSA-N normal nonane Natural products CCCCCCCCC BKIMMITUMNQMOS-UHFFFAOYSA-N 0.000 description 1
- 229950006584 obatoclax Drugs 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical class CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 125000005963 oxadiazolidinyl group Chemical group 0.000 description 1
- 125000005882 oxadiazolinyl group Chemical group 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 229960002739 oxaprozin Drugs 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000005968 oxazolinyl group Chemical group 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- 229960004662 parecoxib Drugs 0.000 description 1
- TZRHLKRLEZJVIJ-UHFFFAOYSA-N parecoxib Chemical compound C1=CC(S(=O)(=O)NC(=O)CC)=CC=C1C1=C(C)ON=C1C1=CC=CC=C1 TZRHLKRLEZJVIJ-UHFFFAOYSA-N 0.000 description 1
- WVUNYSQLFKLYNI-AATRIKPKSA-N pelitinib Chemical compound C=12C=C(NC(=O)\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC1=CC=C(F)C(Cl)=C1 WVUNYSQLFKLYNI-AATRIKPKSA-N 0.000 description 1
- 229950003819 pelitrexol Drugs 0.000 description 1
- 229960003349 pemetrexed disodium Drugs 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000008039 phosphoramides Chemical class 0.000 description 1
- 125000000612 phthaloyl group Chemical group C(C=1C(C(=O)*)=CC=CC1)(=O)* 0.000 description 1
- IIMIOEBMYPRQGU-UHFFFAOYSA-L picoplatin Chemical compound N.[Cl-].[Cl-].[Pt+2].CC1=CC=CC=N1 IIMIOEBMYPRQGU-UHFFFAOYSA-L 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- MREOOEFUTWFQOC-UHFFFAOYSA-M potassium;5-chloro-4-hydroxy-1h-pyridin-2-one;4,6-dioxo-1h-1,3,5-triazine-2-carboxylate;5-fluoro-1-(oxolan-2-yl)pyrimidine-2,4-dione Chemical compound [K+].OC1=CC(=O)NC=C1Cl.[O-]C(=O)C1=NC(=O)NC(=O)N1.O=C1NC(=O)C(F)=CN1C1OCCC1 MREOOEFUTWFQOC-UHFFFAOYSA-M 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000003331 prothrombotic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- AECPBJMOGBFQDN-YMYQVXQQSA-N radicicol Chemical compound C1CCCC(=O)C[C@H]2[C@H](Cl)C(=O)CC(=O)[C@H]2C(=O)O[C@H](C)C[C@H]2O[C@@H]21 AECPBJMOGBFQDN-YMYQVXQQSA-N 0.000 description 1
- 229930192524 radicicol Natural products 0.000 description 1
- 229960004432 raltitrexed Drugs 0.000 description 1
- 229960002185 ranimustine Drugs 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 108091006082 receptor inhibitors Proteins 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 229940087462 relafen Drugs 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- OAKGNIRUXAZDQF-TXHRRWQRSA-N retaspimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(O)C1=CC(O)=C2NCC=C OAKGNIRUXAZDQF-TXHRRWQRSA-N 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 1
- 229960000311 ritonavir Drugs 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 description 1
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 description 1
- 229960000215 ruxolitinib Drugs 0.000 description 1
- 229960000953 salsalate Drugs 0.000 description 1
- 229960005399 satraplatin Drugs 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229950000055 seliciclib Drugs 0.000 description 1
- CYOHGALHFOKKQC-UHFFFAOYSA-N selumetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl CYOHGALHFOKKQC-UHFFFAOYSA-N 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 229940071138 stearyl fumarate Drugs 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229950007866 tanespimycin Drugs 0.000 description 1
- 229940120982 tarceva Drugs 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229960001674 tegafur Drugs 0.000 description 1
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- 125000005304 thiadiazolidinyl group Chemical group 0.000 description 1
- 125000005305 thiadiazolinyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000002769 thiazolinyl group Chemical group 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 229960003723 tiazofurine Drugs 0.000 description 1
- FVRDYQYEVDDKCR-DBRKOABJSA-N tiazofurine Chemical compound NC(=O)C1=CSC([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=N1 FVRDYQYEVDDKCR-DBRKOABJSA-N 0.000 description 1
- MIMJSJSRRDZIPW-UHFFFAOYSA-N tilmacoxib Chemical compound C=1C=C(S(N)(=O)=O)C(F)=CC=1C=1OC(C)=NC=1C1CCCCC1 MIMJSJSRRDZIPW-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229960001017 tolmetin Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 229940019127 toradol Drugs 0.000 description 1
- AKCRNFFTGXBONI-UHFFFAOYSA-N torin 1 Chemical compound C1CN(C(=O)CC)CCN1C1=CC=C(N2C(C=CC3=C2C2=CC(=CC=C2N=C3)C=2C=C3C=CC=CC3=NC=2)=O)C=C1C(F)(F)F AKCRNFFTGXBONI-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 108010060597 trapoxin A Proteins 0.000 description 1
- 229940066958 treanda Drugs 0.000 description 1
- 229960003181 treosulfan Drugs 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 229960005526 triapine Drugs 0.000 description 1
- PCFIPYFVXDCWBW-UHFFFAOYSA-N tricyclo[3.3.1.03,7]nonane Chemical compound C1C(C2)C3CC2CC1C3 PCFIPYFVXDCWBW-UHFFFAOYSA-N 0.000 description 1
- 229960001099 trimetrexate Drugs 0.000 description 1
- NOYPYLRCIDNJJB-UHFFFAOYSA-N trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-N 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical class [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical class [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical class CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 229960002004 valdecoxib Drugs 0.000 description 1
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 1
- 229960000604 valproic acid Drugs 0.000 description 1
- 229960003636 vidarabine Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229940087652 vioxx Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 229940063674 voltaren Drugs 0.000 description 1
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 1
- 229960000237 vorinostat Drugs 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229940053867 xeloda Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
- C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/32—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
Claims (15)
1. Forbindelse med formel II
eller terapeutisk acceptabelt salt deraf, hvor R100 er R50, OR50, SR50, S(0)R50, S02R5°, C(0)R50, C0(0)R50, 0C(0)R50, 0C(0)0R50, NH2, NHR50, N(R50)2j C(0)NH2jC(0)NHR50, C(O)N(R50)2j C(0)NH0H, C(0)NH0R50, C(0)NHS02R50, C(0)NR55S02R50, S02NH2, S02NHR50, SO2N(R50)2j CF3,CF2CF3,C(0)H, C(0)0H, C(N)NH2j C(N)NHR50, C(N)N(R50)2i OH, (O), CN, N3, N02i CF3i CF2CF3i OCF3i OCF2CF3i F, Cl, Br eller I; n erO, 1,2 eller 3; A1 er N eller C(A2); en eller to eller tre eller hver af A2, B1, D1 og E1 er udvalgt uafhængigt blandt R1, OR1, SR1, S(0)R1, S02R1, C(0)R1, C(0)0R1, 0C(0)R1 NHC1, N(R1)2j C(0)NHR1, C(0)N(R1)2, NHC(0)R1, NHC(0)0R1, NR1C(0)NHR1, NR1C(0)N(R1)2, S02NHR1, S02N(R1)2, NHS02R1, NHS02NHR1 og N(CH3)S02N(CH3)R1, og de resterende af A2, B1, D1 og E1 er udvalgt uafhængigt blandt H, F, Cl, Br, I, CN, CF3, C(0)0H, C(0)NH2 og C(0)0R1A; Y1 er H, CN, N02, C(0)0H, F, Cl, Br, I, CF3, OCF3, CF2CF3, OCF2CF3, R17, OR17, C(0)R17, C(0)0R17, SR17, NH2, NHR17, N(R17)2 NHC(0)R17, C(0)NH2, C(0)NHR17, C(0)N(R17)2, NHS(0)R17 eller NHS02R17; R1 er R2, R3, R4 eller R5; R1A er CrCe-alkyl, C3-C6-alkenyl eller C3-C6-alkynyl; R2 er phenyl, der er ufusioneret eller fusioneret med aren, heteroaren eller R2A; R2A er cycloalkan eller heterocycloalkan; R3 er heteroaryl, der er ufusioneret eller fusioneret med benzen, heteroaren eller R3A; R3A er cycloalkan eller heterocycloalkan; R4 er cycloalkyl, cycloalkenyl, heterocycloalkyl eller heterocycloalkenyl, der hver er ufusioneret eller fusioneret med aren, heteroaren eller R4A; R4A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R5 er alkyl, alkenyl eller alkynyl, der hver er usubstitueret eller substitueret med en eller to eller tre uafhængigt udvalgte R6, R7, OR7, SR7, S(0)R7, S02R7, NHR7, N(R7)2, C(0)R7, C(0)NH2i C(0)NHR7, NHC(0)R7, NHS02R7, NHC(0)0R7, S02NH2, S02NHR7, S02N(R7)2, NHC(0)NH2, NHC(0)NHR7, NHC(0)CH(CH3)NHC(0)CH(CH3)NH2, NHC(0)CH(CH3)NHC(0)CH(CH3)NHR1, OH, (O), C(0)0H, (O), N3, CN, NH2j CF3j CF2CF3j F, Cl, Br eller I substituenter; R6 er C2-C5-spiroalkyl, der hver er usubstitueret eller substitueret med OH, (O), N3, CN, CF3, CF2CF3j F, Cl, Br, I, NH2, NH(CH3) eller N(CH3)2; R7 er R8, R9, R10 eller R11; R8 er phenyl, der er ufusioneret eller fusioneret med aren, heteroaren eller R8A; R8A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R9 er heteroaryl, der er ufusioneret eller fusioneret med aren, heteroaren eller R9A; RØA gr cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R10 er C3-C10-cycloalkyl eller C4-C10-cycloalkenyl, der hver har en eller to CH2-dele, der er usubstitueret eller substitueret med uafhængigt udvalgte O, C(O), CNOH, CNOCH3, S, S(O), S02 eller NH, og en eller to CH-dele, der er usubstitueret eller substitueret med N, og hver er disse er ufusioneret eller fusioneret med aren, heteroaren eller R10A; R10A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R11 er alkyl, alkenyl eller alkynyl, der hver er usubstitueret eller substitueret med en eller to eller tre uafhængigt udvalgte R12, OR12, NHR12, N(R12)2, C(0)NH2, C(0)NHR12, C(0)N(R12)2, OH, (O), C(0)0H, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br eller I substituenter; R12 er R13, R14, R15 eller R16; R13 er phenyl, der er ufusioneret eller fusioneret med aren, heteroaren eller R13A; R13A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R14 er heteroaryl, der hver er ufusioneret eller fusioneret med aren, heteroaren eller R14A; R14A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R15 er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken, der hver er ufusioneret eller fusioneret med aren, heteroaren eller R15A; R15A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R16 er alkyl, alkenyl eller alkynyl; R17 er R18, R19, R20 eller R21; R18 er phenyl, der er ufusioneret eller fusioneret med aren, heteroaren eller R18A; R18A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R19 er heteroaryl, der er ufusioneret eller fusioneret med aren, heteroaren eller R19A; risa er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R20 er C3-Ci0-cycloalkyl eller C4-Ci0-cycloalkenyl, der hver har en eller to CH2-dele, der er usubstitueret eller substitueret med uafhængigt udvalgte O, C(O), CNOH, CNOCH3, S, S(O), S02 eller NH, og en eller to CH-dele, der er usubstitueret eller substitueret med N, og hver er disse er ufusioneret eller fusioneret med aren, heteroaren eller R20A; R20A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R21 er alkyl, alkenyl eller alkynyl, der hver er usubstitueret eller substitueret med en eller to eller tre uafhængigt udvalgte R22, OR22, NHR22, N(R22)2, C(0)NH2, C(0)NHR22, C(0)N(R22)2, OH, (O), C(0)0H, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br eller I substituenter; R22 er R23, R24 eller R25; R23 er phenyl, der er ufusioneret eller fusioneret med aren, heteroaren eller R23A- r23a er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R24 er heteroaren, der er ufusioneret eller fusioneret med aren, heteroaren eller R24A; r24a er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R25 er C3-C6-cycloalkyl eller C4-C6-cycloalkenyl, der hver har en eller to CH2-dele, der er usubstitueret eller substitueret med uafhængigt udvalgte O, C(O), CNOH, CNOCH3, S, S(O), S02 eller NH, og en eller to CH-dele, der er usubstitueret eller substitueret med N, og hver er disse er ufusioneret eller fusioneret med aren, heteroaren eller R25A; R25A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R30 er cycloalkyl eller cycloalkenyl, der hver har en eller to CH2-dele, der er usubstitueret eller substitueret med uafhængigt udvalgte O, C(O), CNOH, CNOCH3, S, S(O), S02 eller NH, og en eller to CH-dele, der er usubstitueret eller substitueret med N, og hver er disse er ufusioneret eller fusioneret med aren, heteroaren eller R30A; R30A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; der hver er substitueret med F, Cl, Br, I, CH2R37, CH(R31)(R37), C(R31)(R31A)(R37), C(0)R37, OR37, SR37, S(0)R37, S02R37, NHR37 eller N(R32)R37; R31 og R31A uafhængigt er F, Cl, Br eller alkyl eller sammen er C2-C5-spiroalkyl; R32 er R33, C(0)R33 eller C(0)0R33; R33 er R34 eller R35; R34 er phenyl, der er ufusioneret eller fusioneret med aryl, heteroaryl eller R34A; R34A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R35 er alkyl, der er usubstitueret eller substitueret med R36; R36 er phenyl, der er ufusioneret eller fusioneret med aren, heteroaren eller R36A; r36a er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R37 er R38, R39 eller R40, der hver er substitueret med F, Cl, Br, I, R41, OR41, NHR41, N(R41)2, NHC(0)0R41, SR41, S(0)R41 eller S02R41; R38 er phenyl, der er ufusioneret eller fusioneret med aren, heteroaren eller R38A- r38a er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R39 er heteroaryl, der er ufusioneret eller fusioneret med aren, heteroaren eller R39A- r39a er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R40 er C3-C8-cycloalkyl eller C4-C8-cycloalkenyl, der hver har en eller to CH2-dele, der er usubstitueret eller substitueret med uafhængigt udvalgte O, C(O), CNOH, CNOCH3, S, S(O), S02 eller NH, og en eller to CH-dele, der er usubstitueret eller substitueret med N, og hver er disse er ufusioneret eller fusioneret med aren, heteroaren eller R40A; R40A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R41 er R42 R43, R44 eller R45; R42 er phenyl, der er ufusioneret eller fusioneret med aren, heteroaren eller R42A- r42a er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R43 er heteroaryl, der er ufusioneret eller fusioneret med aren, heteroaren eller R43A- r43a er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R44 er C3-C9-cycloalkyl eller C4-C7-cycloalkenyl, der hver har en eller to CH2-dele, der er usubstitueret eller substitueret med uafhængigt udvalgte O, C(O), CNOH, CNOCH3, S, S(O), S02 eller NH, og en eller to CH-dele, der er usubstitueret eller substitueret med N, og hver er disse er ufusioneret eller fusioneret med aren, heteroaren eller R44A; R44A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R45 er alkyl, alkenyl eller alkynyl, der hver er usubstitueret eller substitueret med en eller to uafhængigt udvalgte R46, OR46, NHR46, N(R46)2, C(0)NH2, C(0)NHR46, C(0)N(R46)2, OH, (O), C(0)0H, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br eller I substituenter; R46 er R47, R48 eller R49; R47 er phenyl, der er ufusioneret eller fusioneret med aren, heteroaren eller R47A; r47a er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R48 er heteroaryl eller R48A; R48A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R49 er C3-C6-cycloalkyl eller C4-C6-cycloalkenyl, der hver har en eller to CH2-dele, der er usubstitueret eller substitueret med uafhængigt udvalgte O, C(O), CNOH, CNOCH3, S, S(O), S02 eller NH, og en eller to CH-dele, der er usubstitueret eller substitueret med N, og hver er disse er ufusioneret eller fusioneret med aren, heteroaren eller R49A; R49A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; hvor dele som vist ved R2, R3, R4, R6, R6C, R8, R8A, R9, R10, R13, R14, R15, R18, R19 R20, R23_ R24j R25j R26j R27j R28j R29 R30j R34j R36j R38 R39j R40j R42_ R43j R44j R47, R48 og R49 uafhængigt er usubstitueret, yderligere usubstitueret, substitueret eller yderligere substitueret med en eller to eller tre eller fire eller fem uafhængigt udvalgte R50, OR50, SR50, S(0)R5°, S02R5°, C(0)R5°, C0(0)R5°, 0C(0)R5°, 0C(0)0R5°, NH2, NHR50, N(R50)2, C(0)NH2, C(0)NHR50, C(O)N(R50)2, C(0)NH0H, C(0)NH0R50, C(0)NHS02R50, C(O)NR50SO2R50, S02NH2S02NHR50, SO2N(R50)2, CF3j CF2CF3j C(0)H, C(0)0H, C(N)NH2j C(N)NHR50, C(N)N(R50)2, OH, (O), CN, N3, N02, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br eller I substituenter; R50 er R51, R52, R53 eller R54; R51 er phenyl, der er ufusioneret eller fusioneret med aren, heteroaren eller R51B- r5ib er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R52 er heteroaryl; R53 er C3-C6-cycloalkyl eller C4-C6-cycloalkenyl, der hver har en eller to CH2-dele, der er usubstitueret eller substitueret med uafhængigt udvalgte O, C(O), CNOH, CNOCH3, S, S(O), S02 eller NH, og en eller to CH-dele, der er usubstitueret eller substitueret med N, og hver er disse er ufusioneret eller fusioneret med aren, heteroaren eller R53B; hvor R53B er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R54 er alkyl, alkenyl eller alkynyl, der hver er usubstitueret eller substitueret med en eller to eller tre uafhængigt udvalgte R55, OR55, SR55, S(0)R55, S02R55, NHR55, N(R55)2, C(0)R55, C(0)NH2, C(0)NHR55, NHC(0)R55, NHS02R55, NHC(0)0R55, S02NH2, S02NHR55, S02N(R55)2, NHC(0)NH2, NHC(0)NHR55, OH, (O), C(0)0H, (O), N3, CN, NH2, CF3, OCF3, CF2CF3, OCF2CF3, F, Cl, Br eller I substituenter; R55 er alkyl, alkenyl, alkynyl, phenyl, heteroaryl eller R56; hvor alkyl, alkenyl, alkynyl er usubstitueret eller substitueret med OCH3; og R56 er C3-C8-cycloalkyl eller C4-C6-cycloalkenyl, der hver har en eller to CH2-dele, der er usubstitueret eller substitueret med uafhængigt udvalgte O, C(O), CNOH, CNOCH3, S, S(O), S02 eller NH, og en eller to CH-dele, der er usubstitueret eller substitueret med N.
2. Forbindelse med formel III
eller terapeutisk acceptabelt salt deraf, hvor R100 er R50, OR50, SR50, S(0)R50, S02R5°, C(0)R50, C0(0)R50, 0C(0)R50, 0C(0)0R50, NH2, NHR50, N(R50)2j C(0)NH2j C(0)NHR50, C(O)N(R50)2j C(0)NH0H, C(0)NH0R5°, C(0)NHS02R50, C(0)NR55S02R50, S02NH2, S02NHR50, SO2N(R50)2i CF3i CF2CF3i C(0)H, C(0)0H, C(N)NH2i C(N)NHR50, C(N)N(R50)2j OH, (O), CN, N3, N02j CF3j CF2CF3j OCF3j OCF2CF3j F, Cl, Br eller I; n erO, 1,2 eller 3; A1 er N eller C(A2); en eller to eller tre eller hver af A2, B1, D1 og E1 er udvalgt uafhængigt blandt R1, OR1, SR1, S(0)R1, S02R1, C(0)R1, C(0)0R1, 0C(0)R1, NHR1, N(R1)2, C(0)NHR1, C(0)N(R1)2, NHC(0)R1, NHC(0)0R1, NR1C(0)NHR1, NR1C(0)N(R1)2, S02NHR1, S02N(R1)2 NHS02R1, NHS02NHR1 og N(CH3)S02N(CH3)R1, og de resterende af A2, B1, D1 og E1 er udvalgt uafhængigt blandt H, F, Cl, Br, I, CN, CF3, C(0)0H, C(0)NH2 og C(0)0R1A Y1 er H, CN, N02, C(0)0H, F, Cl, Br, I, CF3, OCF3, CF2CF3, OCF2CF3, R17, OR17, C(0)R17, C(0)0R17, SR17, NH2, NHR17, N(R17)2, NHC(0)R17, C(0)NH2, C(0)NHR17, C(0)N(R17)2, NHS(0)R17 eller NHS02R17; R1 er R2, R3, R4 eller R5; R1A er Ci-C6-alkyl, C3-C6-alkenyl eller C3-C6-alkynyl; R2 er phenyl, der er ufusioneret eller fusioneret med aren, heteroaren eller R2A; R2A er cycloalkan eller heterocycloalkan; R3 er heteroaryl, der er ufusioneret eller fusioneret med benzen, heteroaren eller R3A; R3A er cycloalkan eller heterocycloalkan; R4 er cycloalkyl, cycloalkenyl, heterocycloalkyl eller heterocycloalkenyl, der hver er ufusioneret eller fusioneret med aren, heteroaren eller R4A; R4A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R5 er alkyl, alkenyl eller alkynyl, der hver er usubstitueret eller substitueret med en eller to eller tre uafhængigt udvalgte R6, R7, OR7, SR7, S(0)R7, S02R7, NHR7, N(R7)2, C(0)R7, C(0)NH2, C(0)NHR7, NHC(0)R7, NHS02R7, NHC(0)0R7, S02NH2S02NHR7, S02N(R7)2i NHC(0)NH2i NHC(0)NHR7, NHC(0)CH(CH3)NHC(0)CH(CH3)NH2, NHC(0)CH(CH3)NHC(0)CH(CH3)NHR1, OH, (O), C(0)0H, (O), N3, CN, NH2j CF3j CF2CF3j F, Cl, Br eller I substituenter; R6 er C2-C5-spiroalkyl, der hver er usubstitueret eller substitueret med OH, (O), N3, CN, CF3, CF2CF3, F, Cl, Br, I, NH2, NH(CH3) eller N(CH3)2; R7 er R8, R9, R10 eller R11; R8 er phenyl, der er ufusioneret eller fusioneret med aren, heteroaren eller R8A; R8A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R9 er heteroaryl, der er ufusioneret eller fusioneret med aren, heteroaren eller R9A; R9A gr cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R10 er C3-C10-cycloalkyl eller C4-C10-cycloalkenyl, der hver har en eller to CH2-dele, der er usubstitueret eller substitueret med uafhængigt udvalgte O, C(O), CNOH, CNOCH3, S, S(O), S02 eller NH, og en eller to CH-dele, der er usubstitueret eller substitueret med N, og hver er disse er ufusioneret eller fusioneret med aren, heteroaren eller R10A; R10A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R11 er alkyl, alkenyl eller alkynyl, der hver er usubstitueret eller substitueret med en eller to eller tre uafhængigt udvalgte R12, OR12, NHR12, N(R12)2, C(0)NH2, C(0)NHR12, C(0)N(R12)2, OH, (O), C(0)0H, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br eller I substituenter; R12 er R13, R14, R15 eller R16; R13 er phenyl, der er ufusioneret eller fusioneret med aren, heteroaren eller R13A; R13A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R14 er heteroaryl, der hver er ufusioneret eller fusioneret med aren, heteroaren eller R14A; R14A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R15 er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken, der hver er ufusioneret eller fusioneret med aren, heteroaren eller R15A; R15A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R16 er alkyl, alkenyl eller alkynyl; R17 er R18, R19, R20 eller R21; R18 er phenyl, der er ufusioneret eller fusioneret med aren, heteroaren eller R18A; R18A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R19 er heteroaryl, der er ufusioneret eller fusioneret med aren, heteroaren eller R19A; R19A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R20 er C3-C10-cycloalkyl eller C4-C10-cycloalkenyl, der hver har en eller to CH2-dele, der er usubstitueret eller substitueret med uafhængigt udvalgte O, C(O), CNOH, CNOCH3, S, S(O), S02 eller NH, og en eller to CH-dele, der er usubstitueret eller substitueret med N, og hver er disse er ufusioneret eller fusioneret med aren, heteroaren eller R20A; R20A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R21 er alkyl, alkenyl eller alkynyl, der hver er usubstitueret eller substitueret med en eller to eller tre uafhængigt udvalgte R22, OR22, NHR22, N(R22)2, C(0)NH2, C(0)NHR22, C(0)N(R22)2 OH, (O), C(0)0H, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br eller I substituenter; R22 er R23, R24 eller R25; R23 er phenyl, der er ufusioneret eller fusioneret med aren, heteroaren eller R23A- r23a er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R24 er heteroaren, der er ufusioneret eller fusioneret med aren, heteroaren eller R24A- r24a er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R25 er C3-C6-cycloalkyl eller C4-C6-cycloalkenyl, der hver har en eller to CH2-dele, der er usubstitueret eller substitueret med uafhængigt udvalgte O, C(O), CNOH, CNOCH3, S, S(O), S02 eller NH, og en eller to CH-dele, der er usubstitueret eller substitueret med N, og hver er disse er ufusioneret eller fusioneret med aren, heteroaren eller R25A; R25A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R30 er cycloalkyl eller cycloalkenyl, der hver har en eller to CH2-dele, der er usubstitueret eller substitueret med uafhængigt udvalgte O, C(O), CNOH, CNOCH3, S, S(O), S02 eller NH, og en eller to CH-dele, der er usubstitueret eller substitueret med N, og hver er disse er ufusioneret eller fusioneret med aren, heteroaren eller R30A; R30A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; der hver er substitueret med F, Cl, Br, I, CH2R37, CH(R31)(R37), C(R31)(R31A)(R37), C(0)R37, OR37, SR37, S(0)R37, S02R37, NHR37 eller N(R32)R37; R31 og R31A uafhængigt er F, Cl, Br eller alkyl eller sammen er C2-C5-spiroalkyl; R32 er R33, C(0)R33 eller C(0)0R33; R33 er R34 eller R35; R34 er phenyl, der er ufusioneret eller fusioneret med aryl, heteroaryl eller R34A; R34A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R35 er alkyl, der er usubstitueret eller substitueret med R36; R36 er phenyl, der er ufusioneret eller fusioneret med aren, heteroaren eller R36A- r36a er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R37 er R38, R39 eller R40, der hver er substitueret med F, Cl, Br, I, R41, OR41, NHR41, N(R41)2, NHC(0)0R41, SR41, S(0)R41 eller S02R41; R38 er phenyl, der er ufusioneret eller fusioneret med aren, heteroaren eller R38A- r38a er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R39 er heteroaryl, der er ufusioneret eller fusioneret med aren, heteroaren eller R39A- r39a er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R40 er C3-C8-cycloalkyl eller C4-C8-cycloalkenyl, der hver har en eller to CH2-dele, der er usubstitueret eller substitueret med uafhængigt udvalgte O, C(O), CNOH, CNOCH3, S, S(O), S02 eller NH, og en eller to CH-dele, der er usubstitueret eller substitueret med N, og hver er disse er ufusioneret eller fusioneret med aren, heteroaren eller R40A; R40A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R41 er R42, R43, R44 eller R45; R42 er phenyl, der er ufusioneret eller fusioneret med aren, heteroaren eller R42A; R42A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R43 er heteroaryl, der er ufusioneret eller fusioneret med aren, heteroaren eller R43A- r43a er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R44 er C3-C9-cycloalkyl eller C4-C7-cycloalkenyl, der hver har en eller to CH2-dele, der er usubstitueret eller substitueret med uafhængigt udvalgte O, C(O), CNOH, CNOCH3, S, S(O), S02 eller NH, og en eller to CH-dele, der er usubstitueret eller substitueret med N, og hver er disse er ufusioneret eller fusioneret med aren, heteroaren eller R44A; R44A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R45 er alkyl, alkenyl eller alkynyl, der hver er usubstitueret eller substitueret med en eller to uafhængigt udvalgte R46, OR46, NHR46, N(R46)2, C(0)NH2, C(0)NHR46, C(0)N(R46)2, OH, (O), C(0)0H, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br eller I substituenter; R46 er R47, R48 eller R49; R47 er phenyl, der er ufusioneret eller fusioneret med aren, heteroaren eller R47A; r47a er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R48 er heteroaryl eller R48A; R48A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R49 er C3-C6-cycloalkyl eller C4-C6-cycloalkenyl, der hver har en eller to CH2-dele, der er usubstitueret eller substitueret med uafhængigt udvalgte O, C(O), CNOH, CNOCH3, S, S(O), S02 eller NH, og en eller to CH-dele, der er usubstitueret eller substitueret med N, og hver er disse er ufusioneret eller fusioneret med aren, heteroaren eller R49A; R49A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; hvor dele som vist ved R2, R3, R4, R6, R6C, R8, R8A, R9, R10, R13, R14, R15, R18, R19, R20, R23, R24, R25, R26, R27, R28, R29, R30, R34, R36, R38, R39, R40, R42, R43, R44, R47, R48, R19, R20, R23, R24, R25, R26, R27, R28, R29, R30, R34, R36, R38, R39, R40, R42, R43, R44, R47, R48 og R49 uafhængigt er usubstitueret, yderligere usubstitueret, substitueret eller yderligere substitueret med en eller to eller tre eller fire eller fem uafhængigt udvalgte R50, OR50, SR50, S(0)R5°, S02R5°, C(0)R5°, C0(0)R5°, 0C(0)R5°, 0C(0)0R5°, NH2, NHR50, N(R50)2, C(0)NH2, C(0)NHR50, C(O)N(R50)2, C(0)NH0H, C(0)NH0R50, C(0)NHS02R50, C(O)NR50SO2R50, S02NH2, S02NHR50, SO2N(R50)2j CF3j CF2CF3j C(0)H, C(0)0H, C(N)NH2, C(N)NHR50, C(N)N(R50)2j OH, (O), CN, n3, no2, cf3, CF2CF3j OCF3j OCF2CF3j F, Cl, Br eller I substituenter; R50 er R51, R52, R53 eller R54; R51 er phenyl, der er ufusioneret eller fusioneret med aren, heteroaren eller R51B; R51B er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R52 er heteroaryl; R53 er C3-C6-cycloalkyl eller C4-C6-cycloalkenyl, der hver har en eller to CH2-dele, der er usubstitueret eller substitueret med uafhængigt udvalgte O, C(O), CNOH, CNOCH3, S, S(O), S02 eller NH, og en eller to CH-dele, der er usubstitueret eller substitueret med N, og hver er disse er ufusioneret eller fusioneret med aren, heteroaren eller R53B; hvor R53B er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R54 er alkyl, alkenyl eller alkynyl, der hver er usubstitueret eller substitueret med en eller to eller tre uafhængigt udvalgte R55, OR55, SR55, S(0)R55, S02R55, NHR55, N(R55)2, C(0)R55, C(0)NH2, C(0)NHR55, NHC(0)R55, NHS02R55, NHC(0)0R55 S02NH2, S02NHR55, S02N(R55)2, NHC(0)NH2, NHC(0)NHR55, OH, (O), C(0)0H, (O), N3, CN, NH2, CF3, OCF3, CF2CF3, OCF2CF3, F, Cl, Br eller I substituenter; R55 er alkyl, alkenyl, alkynyl, phenyl, heteroaryl eller R56; hvor alkyl, alkenyl, alkynyl er usubstitueret eller substitueret med OCH3; og R56 er C3-C8-cycloalkyl eller C4-C6-cycloalkenyl, der hver har en eller to CH2-dele, der er usubstitueret eller substitueret med uafhængigt udvalgte O, C(O), CNOH, CNOCH3, S, S(O), S02 eller NH, og en eller to CH-dele, der er usubstitueret eller substitueret med N.
3. Forbindelse med formel IV
eller terapeutisk acceptabelt salt deraf, hvor R100 er R50, OR50, SR50, S(0)R50, S02R5°, C(0)R50, C0(0)R50, 0C(0)R50, 0C(0)0R50, NH2, NHR50, N(R50)2j C(0)NH2j C(0)NHR50, C(O)N(R50)2j C(0)NH0H, C(0)NH0R50, C(0)NHS02R50, C(0)NR55S02R50, S02NH2, S02NHR50, SO2N(R50)2j CF3j CF2CF3j C(0)H, C(0)0H, C(N)NH2j C(N)NHR50, C(N)N(R50)2j OH, (O), CN, N3, N02j CF3j CF2CF3j OCF3j OCF2CF3j F, Cl, Br eller I; n erO, 1,2 eller 3; A1 er N eller 0(Α2}; en eller to eller tre eller hver af A2, B1, D1 og E1 er udvalgt uafhængigt blandt R1, OR1, SR1, S(0)R1, S02R1, C(0)R1, C(0)0R1, 0C(0)R1, NHR1, N(R1)2, C(0)NHR1, C(0)N(R1)2, NHC(0)R1, NHC(0)0R1, NR1C(0)NHR1, NR1C(0)N(R1)2, S02NHR1, S02N(R1)2, NHS02R1, NHS02NHR1 og N(CH3)S02N(CH3)R1, og de resterende af A2, B1, D1 og E1 er udvalgt uafhængigt blandt H, F, Cl, Br, I, CN, CF3, C(0)0H, C(0)NH2 og C(0)0R1A; Y1 er H, CN, N02, C(0)0H, F, Cl, Br, I, CF3, OCF3, CF2CF3, OCF2CF3, R17, OR17, C(0)R17, C(0)0R17, SR17, NH2, NHR17, N(R17)2, NHC(0)R17, C(0)NH2, C(0)NHR17, C(0)N(R17)2, NHS(0)R17 eller NHS02R17; R1 er R2, R3, R4 eller R5; R1A er CrCe-alkyl, C3-C6-alkenyl eller C3-C6-alkynyl; R2 er phenyl, der er ufusioneret eller fusioneret med aren, heteroaren eller R2A; R2A er cycloalkan eller heterocycloalkan; R3 er heteroaryl, der er ufusioneret eller fusioneret med benzen, heteroaren eller R3A; R3A er cycloalkan eller heterocycloalkan; R4 er cycloalkyl, cycloalkenyl, heterocycloalkyl eller heterocycloalkenyl, der hver er ufusioneret eller fusioneret med aren, heteroaren eller R4A; R4A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R5 er alkyl, alkenyl eller alkynyl, der hver er usubstitueret eller substitueret med en eller to eller tre uafhængigt udvalgte R6, R7, OR7, SR7, S(0)R7, S02R7, NHR7, N(R7)2, C(0)R7, C(0)NH2, C(0)NHR7, NHC(0)R7, NHS02R7, NHC(0)0R7, S02NH2, S02NHR7, S02N(R7)2, NHC(0)NH2, NHC(0)NHR7, NHC(0)CH(CH3)NHC(0)CH(CH3)NH2, NHC(0)CH(CH3)NHC(0)CH(CH3)NHR1, OH, (O), C(0)0H, (O), N3> CN, NH2j CF3j CF2CF3j F, Cl, Br eller I substituenter; R6 er C2-C5-spiroalkyl, der hver er usubstitueret eller substitueret med OH, (O), N3, CN, CF3, CF2CF3, F, Cl, Br, I, NH2, NH(CH3) eller N(CH3)2; R7 er R8, R9, R10 eller R11; R8 er phenyl, der er ufusioneret eller fusioneret med aren, heteroaren eller R8A; R8A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R9 er heteroaryl, der er ufusioneret eller fusioneret med aren, heteroaren eller R9A; R9A gr cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R10 er C3-Ci0-cycloalkyl eller C4-Ci0-cycloalkenyl, der hver har en eller to CH2-dele, der er usubstitueret eller substitueret med uafhængigt udvalgte O, C(O), CNOH, CNOCH3, S, S(O), S02 eller NH, og en eller to CH-dele, der er usubstitueret eller substitueret med N, og hver er disse er ufusioneret eller fusioneret med aren, heteroaren eller R10A; R10A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R11 er alkyl, alkenyl eller alkynyl, der hver er usubstitueret eller substitueret med en eller to eller tre uafhængigt udvalgte R12, OR12, NHR12, N(R12)2, C(0)NH2, C(0)NHR12, C(0)N(R12)2, OH, (O), C(0)0H, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br eller I substituenter; R12 er R13, R14, R15 eller R16; R13 er phenyl, der er ufusioneret eller fusioneret med aren, heteroaren eller R13A; R13A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R14 er heteroaryl, der hver er ufusioneret eller fusioneret med aren, heteroaren eller R14A; R14A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R15 er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken, der hver er ufusioneret eller fusioneret med aren, heteroaren eller R15A; R15A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R16 er alkyl, alkenyl eller alkynyl; R17 er R18, R19, R20 eller R21; R18 er phenyl, der er ufusioneret eller fusioneret med aren, heteroaren eller R18A; risa er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R19 er heteroaryl, der er ufusioneret eller fusioneret med aren, heteroaren eller R19A; R19A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R20 er C3-C10-cycloalkyl eller C4-C10-cycloalkenyl, der hver har en eller to CH2-dele, der er usubstitueret eller substitueret med uafhængigt udvalgte O, C(O), CNOH, CNOCH3, S, S(O), S02 eller NH, og en eller to CH-dele, der er usubstitueret eller substitueret med N, og hver er disse er ufusioneret eller fusioneret med aren, heteroaren eller R20A; R20A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R21 er alkyl, alkenyl eller alkynyl, der hver er usubstitueret eller substitueret med en eller to eller tre uafhængigt udvalgte R22, OR22, NHR22, N(R22)2, C(0)NH2, C(0)NHR22, C(0)N(R22)2, OH, (O), C(0)0H, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br eller I substituenter; R22 er R23, R24 eller R25; R23 er phenyl, der er ufusioneret eller fusioneret med aren, heteroaren eller R23A- r23a er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R24 er heteroaren, der er ufusioneret eller fusioneret med aren, heteroaren eller R24A- r24a er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R25 er C3-C6-cycloalkyl eller C4-C6-cycloalkenyl, der hver har en eller to CH2-dele, der er usubstitueret eller substitueret med uafhængigt udvalgte O, C(O), CNOH, CNOCH3, S, S(O), S02 eller NH, og en eller to CH-dele, der er usubstitueret eller substitueret med N, og hver er disse er ufusioneret eller fusioneret med aren, heteroaren eller R25A; R25A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R30 er cycloalkyl eller cycloalkenyl, der hver har en eller to CH2-dele, der er usubstitueret eller substitueret med uafhængigt udvalgte O, C(O), CNOH, CNOCH3, S, S(O), S02 eller NH, og en eller to CH-dele, der er usubstitueret eller substitueret med N, og hver er disse er ufusioneret eller fusioneret med aren, heteroaren eller R30A; R30A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; der hver er substitueret med F, Cl, Br, I, CH2R37, CH(R31)(R37), C(R31)(R31A)(R37), C(0)R37, OR37, SR37, S(0)R37, S02R37, NHR37 eller N(R32)R37; R31 og R31A uafhængigt er F, Cl, Br eller alkyl eller sammen er C2-C5-spiroalkyl; R32 er R33, C(0)R33 eller C(0)0R33; R33 er R34 eller R35; R34 er phenyl, der er ufusioneret eller fusioneret med aryl, heteroaryl eller R34A; R34A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R35 er alkyl, der er usubstitueret eller substitueret med R36; R36 er phenyl, der er ufusioneret eller fusioneret med aren, heteroaren eller R36A; r36a er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R37 er R38, R39 eller R40, der hver er substitueret med F, Cl, Br, I, R41, OR41, NHR41, N(R41)2, NHC(0)0R41, SR41, S(0)R41 eller S02R41; R38 er phenyl, der er ufusioneret eller fusioneret med aren, heteroaren eller R38A- R38A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R39 er heteroaryl, der er ufusioneret eller fusioneret med aren, heteroaren eller R39A- r39a er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R40 er C3-C8-cycloalkyl eller C4-C8-cycloalkenyl, der hver har en eller to CH2-dele, der er usubstitueret eller substitueret med uafhængigt udvalgte O, C(O), CNOH, CNOCH3, S, S(O), S02 eller NH, og en eller to CH-dele, der er usubstitueret eller substitueret med N, og hver er disse er ufusioneret eller fusioneret med aren, heteroaren eller R40A; R40A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R41 er R42, R43, R44 eller R45; R42 er phenyl, der er ufusioneret eller fusioneret med aren, heteroaren eller R42A; R42A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R43 er heteroaryl, der er ufusioneret eller fusioneret med aren, heteroaren eller R43A- r43a er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R44 er C3-C9-cycloalkyl eller C4-C7-cycloalkenyl, der hver har en eller to CH2-dele, der er usubstitueret eller substitueret med uafhængigt udvalgte O, C(O), CNOH, CNOCH3, S, S(O), S02 eller NH, og en eller to CH-dele, der er usubstitueret eller substitueret med N, og hver er disse er ufusioneret eller fusioneret med aren, heteroaren eller R44A; R44A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R45 er alkyl, alkenyl eller alkynyl, der hver er usubstitueret eller substitueret med en eller to uafhængigt udvalgte R46, OR46, NHR46, N(R46)2, C(0)NH2, C(0)NHR46, C(0)N(R46)2, OH, (O), C(0)0H, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br eller I substituenter; R46 er R47, R48 eller R49; R47 er phenyl, der er ufusioneret eller fusioneret med aren, heteroaren eller R47A- r47a er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R48 er heteroaryl eller R48A; R48A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R49 er C3-C6-cycloalkyl eller C4-C6-cycloalkenyl, der hver har en eller to CH2-dele, der er usubstitueret eller substitueret med uafhængigt udvalgte O, C(O), CNOH, CNOCH3, S, S(O), S02 eller NH, og en eller to CH-dele, der er usubstitueret eller substitueret med N, og hver er disse er ufusioneret eller fusioneret med aren, heteroaren eller R49A; R49A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; hvor dele som vist ved R2, R3, R4, R6, R6c, R8, R8A, R9, R10, R13, R14, R15, R18, R19, R20, R23, R24, R25, R26, R27, R28, R29, R30, R34, R36, R38, R39, R40, R42, R43, R44, R47, R48 og R49 uafhængigt er usubstitueret, yderligere usubstitueret, substitueret eller yderligere substitueret med en eller to eller tre eller fire eller fem uafhængigt udvalgte R50, OR50, SR50, S(0)R5°, S02R5°, C(0)R5°, C0(0)R5°, 0C(0)R5°, 0C(0)0R5°, NH2, NHR50, N(R50)2, C(0)NH2, C(0)NHR50, C(O)N(R50)2, C(0)NH0H, C(0)NH0R5°, C(0)NHS02R50, C(0)NR50S02R50, S02NH2, S02NHR50, SO2N(R50)2j CFs, CF2CF3j C(0)H, C(0)0H, C(N)NH2j C(N)NHR50, C(N)N(R50)2, OH, (O), CN, N3, N02, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br eller I substituenter; R50 er R51, R52, R53 eller R54; R51 er phenyl, der er ufusioneret eller fusioneret med aren, heteroaren eller R51B; R51B er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R52 er heteroaryl; R53 er C3-C6-cycloalkyl eller C4-C6-cycloalkenyl, der hver har en eller to CH2-dele, der er usubstitueret eller substitueret med uafhængigt udvalgte 0, C(O), CNOH, CNOCH3, S, S(O), S02 eller NH, og en eller to CH-dele, der er usubstitueret eller substitueret med N, og hver er disse er ufusioneret eller fusioneret med aren, heteroaren eller R53B; hvor R53B er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R54 er alkyl, alkenyl eller alkynyl, der hver er usubstitueret eller substitueret med en eller to eller tre uafhængigt udvalgte R55, OR55, SR55, S(0)R55, S02R55, NHR55, N(R55)2, C(0)R55, C(0)NH2, C(0)NHR55, NHC(0)R55, NHS02R55, NHC(0)0R55, S02NH2j S02NHR55, S02N(R55)2j NHC(0)NH2j NHC(0)NHR55, OH, (O), C(0)0H, (O), N3> CN, NH2j CF3j OCF3j CF2CF3j OCF2CF3j F, Cl, Br eller I substituenter; R55 er alkyl, alkenyl, alkynyl, phenyl, heteroaryl eller R56; hvor alkyl, alkenyl, alkynyl er usubstitueret eller substitueret med OCH3; og R56 er C3-C8-cycloalkyl eller C4-C6-cycloalkenyl, der hver har en eller to CH2-dele, der er usubstitueret eller substitueret med uafhængigt udvalgte O, C(O), CNOH, CNOCH3, S, S(O), S02 eller NH, og en eller to CH-dele, der er usubstitueret eller substitueret med N.
4. Forbindelse med formel V
eller terapeutisk acceptabelt salt deraf, hvor R100 er R50, OR50, SR50, S(0)R50, S02R50, C(0)R50, C0(0)R50, 0C(0)R50, 0C(0)0R50, NH2, NHR50, N(R50)2, C(0)NH2, C(0)NHR50, C(O)N(R50)2, C(0)NH0H, C(0)NH0R50, C(0)NHS02R50, C(0)NR55S02R50, S02NH2, S02NHR50, SO2N(R50)2j CF3j CF2CF3j C(0)H, C(0)0H, C(N)NH2j C(N)NHR50, C(N)N(R50)2i OH, (O), CN, N3, N02i CF3i CF2CF3i OCF3i OCF2CF3i F, Cl, Br eller I; n erO, 1,2 eller 3; A1 er N eller C(A2); en eller to eller tre eller hver af A2, B1, D1 og E1 er udvalgt uafhængigt blandt R1, OR1, SR1, S(0)R1, S02R1, C(0)R1, C(0)0R1, 0C(0)R1, NHR1, N(R1)2j C(0)NHR1, C(0)N(R1)2, NHC(0)R1, NHC(0)0R1, NR1C(0)NHR1, NR1C(0)N(R1)2j S02NHR1, S02N(R1)2j NHS02R1, NHS02NHR1 og N(CH3)S02N(CH3)R1, og de resterende af A2, B1, D1 og E1 er udvalgt uafhængigt blandt H, F, Cl, Br, I, CN, CF3, C(0)0H, C(0)NH2 og C(0)0R1A; Y1 er H, CN, N02, C(0)0H, F, Cl, Br, I, CF3, OCF3, CF2CF3, OCF2CF3, R17, OR17, C(0)R17, C(0)0R17, SR17, NH2, NHR17, N(R17)2, NHC(0)R17, C(0)NH2, C(0)NHR17, C(0)N(R17)2, NHS(0)R17 eller NHS02R17; R1 er R2, R3, R4 eller R5; R1A er CrCe-alkyl, C3-C6-alkenyl eller C3-C6-alkynyl; R2 er phenyl, der er ufusioneret eller fusioneret med aren, heteroaren eller R2A; R2A er cycloalkan eller heterocycloalkan; R3 er heteroaryl, der er ufusioneret eller fusioneret med benzen, heteroaren eller R3A; R3A er cycloalkan eller heterocycloalkan; R4 er cycloalkyl, cycloalkenyl, heterocycloalkyl eller heterocycloalkenyl, der hver er ufusioneret eller fusioneret med aren, heteroaren eller R4A; R4A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R5 er alkyl, alkenyl eller alkynyl, der hver er usubstitueret eller substitueret med en eller to eller tre uafhængigt udvalgte R6, R7, OR7, SR7, S(0)R7, S02R7, NHR7, N(R7)2, C(0)R7, C(0)NH2, C(0)NHR7, NHC(0)R7, NHS02R7, NHC(0)0R7, S02NH2, S02NHR7, S02N(R7)2, NHC(0)NH2i NHC(0)NHR7, NHC(0)CH(CH3)NHC(0)CH(CH3)NH2, NHC(0)CH(CH3)NHC(0)CH(CH3)NHR1, OH, (O), C(0)0H, (O), N3, CN, NH2, CF3, CF2CF3, F, Cl, Br eller I substituenter; R6 er C2-C5-spiroalkyl, der hver er usubstitueret eller substitueret med OH, (O), N3, CN, CF3, CF2CF3j F, Cl, Br, I, NH2, NH(CH3) eller N(CH3)2; R7 er R8, R9, R10 eller R11; R8 er phenyl, der er ufusioneret eller fusioneret med aren, heteroaren eller R8A; R8A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R9 er heteroaryl, der er ufusioneret eller fusioneret med aren, heteroaren eller R9A; R9A gr cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R10 er C3-C10-cycloalkyl eller C4-C10-cycloalkenyl, der hver har en eller to CH2-dele, der er usubstitueret eller substitueret med uafhængigt udvalgte O, C(O), CNOH, CNOCH3, S, S(O), S02 eller NH, og en eller to CH-dele, der er usubstitueret eller substitueret med N, og hver er disse er ufusioneret eller fusioneret med aren, heteroaren eller R10A; R10A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R11 er alkyl, alkenyl eller alkynyl, der hver er usubstitueret eller substitueret med en eller to eller tre uafhængigt udvalgte R12, OR12, NHR12, N(R12)2, C(0)NH2, C(0)NHR12, C(0)N(R12)2, OH, (O), C(0)0H, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br eller I substituenter; R12 er R13, R14, R15 eller R16; R13 er phenyl, der er ufusioneret eller fusioneret med aren, heteroaren eller R13A; risa er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R14 er heteroaryl, der hver er ufusioneret eller fusioneret med aren, heteroaren eller R14A; R14A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R15 er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken, der hver er ufusioneret eller fusioneret med aren, heteroaren eller R15A; R15A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R16 er alkyl, alkenyl eller alkynyl; R17 er R18, R19, R20 eller R21; R18 er phenyl, der er ufusioneret eller fusioneret med aren, heteroaren eller R18A; risa er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R19 er heteroaryl, der er ufusioneret eller fusioneret med aren, heteroaren eller R19A; R19A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R20 er C3-Ci0-cycloalkyl eller C4-Ci0-cycloalkenyl, der hver har en eller to CH2-dele, der er usubstitueret eller substitueret med uafhængigt udvalgte O, C(O), CNOH, CNOCH3, S, S(O), S02 eller NH, og en eller to CH-dele, der er usubstitueret eller substitueret med N, og hver er disse er ufusioneret eller fusioneret med aren, heteroaren eller R20A; R20A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R21 er alkyl, alkenyl eller alkynyl, der hver er usubstitueret eller substitueret med en eller to eller tre uafhængigt udvalgte R22, OR22, NHR22, N(R22)2, C(0)NH2, C(0)NHR22, C(0)N(R22)2, OH, (O), C(0)0H, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br eller I substituenter; R22 er R23, R24 eller R25; R23 er phenyl, der er ufusioneret eller fusioneret med aren, heteroaren eller R23A- r23a er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R24 er heteroaren, der er ufusioneret eller fusioneret med aren, heteroaren eller R24A- r24a er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R25 er C3-C6-cycloalkyl eller C4-C6-cycloalkenyl, der hver har en eller to CH2-dele, der er usubstitueret eller substitueret med uafhængigt udvalgte O, C(O), CNOH, CNOCH3, S, S(O), S02 eller NH, og en eller to CH-dele, der er usubstitueret eller substitueret med N, og hver er disse er ufusioneret eller fusioneret med aren, heteroaren eller R25A; R25A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R30 er cycloalkyl eller cycloalkenyl, der hver har en eller to CH2-dele, der er usubstitueret eller substitueret med uafhængigt udvalgte O, C(O), CNOH, CNOCH3, S, S(O), S02 eller NH, og en eller to CH-dele, der er usubstitueret eller substitueret med N, og hver er disse er ufusioneret eller fusioneret med aren, heteroaren eller R30A; R30A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; der hver er substitueret med F, Cl, Br, I, CH2R37, CH(R31)(R37), C(R31)(R31A)(R37), C(0)R37, OR37, SR37, S(0)R37, S02R37, NHR37 eller N(R32)R37; R31 og R31A uafhængigt er F, Cl, Br eller alkyl eller sammen er C2-C5-spiroalkyl; R32 er R33, C(0)R33 eller C(0)0R33; R33 er R34 eller R35; R34 er phenyl, der er ufusioneret eller fusioneret med aryl, heteroaryl eller R34A; R34A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R35 er alkyl, der er usubstitueret eller substitueret med R36; R36 er phenyl, der er ufusioneret eller fusioneret med aren, heteroaren eller R36A- r36a er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R37 er R38, R39 eller R40, der hver er substitueret med F, Cl, Br, I, R41, OR41, NHR41, N(R41)2, NHC(0)0R41, SR41, S(0)R41 eller S02R41; R38 er phenyl, der er ufusioneret eller fusioneret med aren, heteroaren eller R38A- r38a er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R39 er heteroaryl, der er ufusioneret eller fusioneret med aren, heteroaren eller R39A- r39a er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R40 er C3-C8-cycloalkyl eller C4-C8-cycloalkenyl, der hver har en eller to CH2-dele, der er usubstitueret eller substitueret med uafhængigt udvalgte O, C(O), CNOH, CNOCH3, S, S(O), S02 eller NH, og en eller to CH-dele, der er usubstitueret eller substitueret med N, og hver er disse er ufusioneret eller fusioneret med aren, heteroaren eller R40A; R40A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R41 er R42, R43, R44 eller R45; R42 er phenyl, der er ufusioneret eller fusioneret med aren, heteroaren eller R42A; R42A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R43 er heteroaryl, der er ufusioneret eller fusioneret med aren, heteroaren eller R43A- r43a er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R44 er C3-C9-cycloalkyl eller C4-C7-cycloalkenyl, der hver har en eller to CH2-dele, der er usubstitueret eller substitueret med uafhængigt udvalgte O, C(O), CNOH, CNOCH3, S, S(O), S02 eller NH, og en eller to CH-dele, der er usubstitueret eller substitueret med N, og hver er disse er ufusioneret eller fusioneret med aren, heteroaren eller R44A; R44A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R45 er alkyl, alkenyl eller alkynyl, der hver er usubstitueret eller substitueret med en eller to uafhængigt udvalgte R46, OR46, NHR46, N(R46)2, C(0)NH2, C(0)NHR46, C(0)N(R46)2, OH, (O), C(0)0H, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br eller I substituenter; R46 er R47, R48 eller R49; R47 er phenyl, der er ufusioneret eller fusioneret med aren, heteroaren eller R47A. r47a er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R48 er heteroaryl eller R48A; R48A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R49 er C3-C6-cycloalkyl eller C4-C6-cycloalkenyl, der hver har en eller to CH2-dele, der er usubstitueret eller substitueret med uafhængigt udvalgte O, C(O), CNOH, CNOCH3, S, S(O), S02 eller NH, og en eller to CH-dele, der er usubstitueret eller substitueret med N, og hver er disse er ufusioneret eller fusioneret med aren, heteroaren eller R49A; R49A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; hvor dele som vist ved R2, R3, R4, R6, R6C, R8, R8A, R9, R10, R13, R14, R15, R18, R19, R20, R23, R24, R25, R26, R27, R28, R29, R30, R34, R36, R38, R39, R40, R42, R43, R44, R47, R48 og R49 uafhængigt er usubstitueret, yderligere usubstitueret, substitueret eller yderligere substitueret med en eller to eller tre eller fire eller fem uafhængigt udvalgte R50, OR50, SR50, S(0)R5°, S02R5°, C(0)R5°, C0(0)R5°, 0C(0)R5°, 0C(0)0R5°, NH2, NHR50, N(R50)2, C(0)NH2, C(0)NHR50, C(O)N(R50)2, C(0)NH0H, C(0)NH0R5°, C(0)NHS02R50, C(0)NR50S02R50, S02NH2, S02NHR50, SO2N(R50)2j CF3j CF2CF3j C(0)H, C(0)0H, C(N)NH2j C(N)NHR50, C(N)N(R50)2, OH, (O), CN, N3> N02, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br eller I substituenter; R50 er R51, R52, R53 eller R54; R51 er phenyl, der er ufusioneret eller fusioneret med aren, heteroaren eller R51B; R51B er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R52 er heteroaryl; R53 er C3-C6-cycloalkyl eller C4-C6-cycloalkenyl, der hver har en eller to CH2-dele, der er usubstitueret eller substitueret med uafhængigt udvalgte O, C(O), CNOH, CNOCH3, S, S(O), S02 eller NH, og en eller to CH-dele, der er usubstitueret eller substitueret med N, og hver er disse er ufusioneret eller fusioneret med aren, heteroaren eller R53B; hvor R53B er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R54 er alkyl, alkenyl eller alkynyl, der hver er usubstitueret eller substitueret med en eller to eller tre uafhængigt udvalgte R55, OR55, SR55, S(0)R55, S02R55, NHR55, N(R55)2, C(0)R55, C(0)NH2, C(0)NHR55, NHC(0)R55, NHS02R55, NHC(0)0R55, S02NH2, S02NHR55, S02N(R55)2, NHC(0)NH2, NHC(0)NHR55, OH, (O), C(0)0H, (O), N3, CN, NH2, CF3, OCF3, CF2CF3, OCF2CF3, F, Cl, Br eller I substituenter; R55 er alkyl, alkenyl, alkynyl, phenyl, heteroaryl eller R56; hvor alkyl, alkenyl, alkynyl er usubstitueret eller substitueret med OCH3; og R56 er C3-C8-cycloalkyl eller C4-C6-cycloalkenyl, der hver har en eller to CH2-dele, der er usubstitueret eller substitueret med uafhængigt udvalgte O, C(O), CNOH, CNOCH3, S, S(O), S02 eller NH, og en eller to CH-dele, der er usubstitueret eller substitueret med N.
5. Forbindelse eller terapeutisk acceptabelt salt ifølge et hvilket som helst af kravene 1-4, hvor A1 er C(A2); og A2 erH.
6. Forbindelse eller terapeutisk acceptabelt salt ifølge et hvilket som helst af kravene 1-4, hvor A1 er C(A2) eller N; A2 er Fl; og B1 erNHR1.
7. Forbindelse eller terapeutisk acceptabelt salt ifølge et hvilket som helst af kravene 1-4, hvor A1 er C(A2) eller N; A2 er H; B1 erNHR1; og D1 erH.
8. Forbindelse eller terapeutisk acceptabelt salt ifølge et hvilket som helst af kravene 1-4, hvor A1 er C(A2) eller N; A2 er H; B1 erNHR1; D1 er H; og E1 erH.
9. Forbindelse eller terapeutisk acceptabelt salt ifølge et hvilket som helst af kravene 1-4, hvor A1 er C(A2) eller N; A2 er H; B1 erNHR1; D1 er Η; E1 er H; og Y1 er N02.
10. Forbindelse ifølge krav 1 eller terapeutisk acceptabelt salt deraf, hvor forbindelsen er udvalgt blandt: 4-(4-((2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)- N-((4-((1-cyclopentylpiperidin-4-yl)annino)-3-nitrophenyl)sulfonyl)-2-(1H-indol-5- yloxy)benzamid; 4-(4-((4'-chlor-1,1'-biphenyl-2-yl)methyl)piperazin-1-yl)-2-(1 H-indol-5-yloxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzannid; 4-(4-((4'-chlor-1,1'-biphenyl-2-yl)methyl)piperazin-1-yl)-N-((4-((3-(dimethylamino)propyl)amino)-3-nitrophenyl)sulfonyl )-2-(1 H-indol-5-yloxy)benzamid; 4-(4-((2-(4-chlorphenyl)-5,5-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)- 2-(1 H-indol-5-yloxy)-N-((4-((3-morpholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)benzamid; 4-(4-((2-(4-chlorphenyl)-5,5-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-N-((4-((3-(dimethylamino)propyl)annino)-3-nitrophenyl)sulfonyl)-2-(1 H-indol-5-yloxy)benzamid; 4-(4-((2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)- 2-(1H-indol-5-yloxy)-N-((4-((3-morpholin-4-ylpropyl)amino)-3- nitrophenyl)sulfonyl)benzamid; 4-(4-((2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)- N-((4-((3-(dimethylamino)propyl)amino)-3-nitrophenyl)sulfonyl)-2-(1H-indol-5- yloxy)benzamid; 4-(4-((4'-chlor-1,1'-biphenyl-2-yl)methyl)piperazin-1-yl)-2-(1 H-indol-5-yloxy)-N- ((4-((3-morpholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)benzannid; 4-(4-((4'-chlor-1,1'-biphenyl-2-yl)methyl)piperazin-1-yl)-2-(1H-indol-5-yloxy)-N- ((4-((tetrahydro-2H-pyran-4-ylmethyl)amino)-3- ((trifluormethyl)sulfonyl)phenyl)sulfonyl)benzannid; 4-(4-((4'-chlor-1,1'-biphenyl-2-yl)methyl)piperazin-1-yl)-N-((4-((3-(dimethylamino)propyl)amino)-3-((trifluormethyl)sulfonyl)phenyl)sulfonyl)-2-(1 H-indol-5-yloxy)benzamid; N-((3-((chlor(difluor)methyl)sulfonyl)-4-((3- (dimethylamino)propyl)amino)phenyl)sulfonyl)-4-(4-((2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-(1 H-indol-5-yloxy)benzamid; N-((3-((chlor(difluor)methyl)sulfonyl)-4-((1-methylpiperidin-4-yl)amino)phenyl)sulfonyl)-4-(4-((2-(4-chlorphenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1 -yl)-2-(1 H-indol-5-yloxy)benzamid; 4-(4-((2-(4-chlorphenyl)cyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-((4-((1-methylpiperidin-4-yl)annino)-3-nitrophenyl)sulfonyl)benzannid; 4-(4-((2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-((4-((1 -methylpiperidin-4-yl)amino)-3-((trifluormethyl)sulfonyl)phenyl)sulfonyl)benzamid; 4-(4-((2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-((4-((2-(4-methylpiperazin-1-yl)ethyl)amino)-3-nitrophenyl)sulfonyl)benzamid; 4-(4-((2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-((4-((3-(4-methylpiperazin-1-yl)propyl)amino)-3-nitrophenyl)sulfonyl)benzamid; 4-(4-((2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-((3-nitro-4-((3-pyrrolidin-1 -ylpropyl)amino)phenyl)sulfonyl)benzamid; 4-(4-((2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-((4-((1 -methylpiperidin-4-yl)annino)-3-nitrophenyl)sulfonyl)benzamid; 4-(4-((2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)- N-((4-(3-(dimethylamino)propoxy)-3-nitrophenyl)sulfonyl)-2-(1H-indol-5- yloxy)benzamid; 4-(4-((2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-((4-(((1-methylpiperidin-4-yl)nnethyl)annino)-3-nitrophenyl)sulfonyl)benzamid; 4-(4-((2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-((4-(4-methylpiperazin-1 -yl)-3-nitrophenyl)sulfonyl)benzamid; 4-(4-((2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-N-((4-(((4-(dimethylamino)-1-methylpiperidin-4-yl)methyl)amino)-3-nitrophenyl)sulfonyl)-2-(1 H-indol-5-yloxy)benzamid; 4-(4-((4'-chlor-4-(2-(dimethylamino)ethoxy)-1,1'-biphenyl-2-yl)methyl)piperazin-1-yl)-2-(1 H-indol-5-yloxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzannid; 4-(4-((4'-chlor-4-(2-morpholin-4-ylethoxy)-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzannid; 4-(4-((4'-chlor-3-(2-(dimethylamino)ethoxy)-1,1'-biphenyl-2-yl)methyl)piperazin- 1-yl)-2-(1H-indol-5-yloxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzannid; 4-(4-((4'-chlor-3-(2-morpholin-4-ylethoxy)-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamid; 4-(4-((4'-chlor-3-(2-(dimethylamino)ethoxy)-1,1'-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-((3-nitro-4-((3-pyrrolidin-1 -ylpropyl)amino)phenyl)sulfonyl)benzamid; 4-(4-((4'-chlor-4-(2-(dimethylamino)ethoxy)-1,1'-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-((3-nitro-4-((3-pyrrolidin-1 -ylpropyl)amino)phenyl)sulfonyl)benzamid; 4-(4-((4'-chlor-4-(2-morpholin-4-ylethoxy)-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-((3-nitro-4-((3-pyrrolidin-1 -ylpropyl)amino)phenyl)sulfonyl)benzamid; 4- (4-((4'-chlor-1,1'-biphenyl-2-yl)methyl)piperazin-1-yl)-2-(2,3-dihydro-1H-indol- 5- yloxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzannid; 4-(4-((4-(4-chlorphenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl)methyl)piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-((4-((1 -methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)benzamid; 4-(4-((2-(4-chlorphenyl)cyclohept-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-((4-((1-methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfc>nyl)benzannid; 4-(4-((2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-N-((4-((3-(dimethylamino)propyl)amino)-3- ((trifluormethyl)sulfonyl)phenyl)sulfonyl)-2-(1H-indol-5-yloxy)benzamid; 4-(4-((2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-N-((4-((3-(dimethylamino)propyl)amino)-3-(trifluormethyl)phenyl)sulfonyl )-2-(1 H-indol-5-yloxy)benzamid; 4-(4-((2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-N-((3-cyano-4-((3-(dimethylamino)propyl)annino)phenyl)sulfonyl)-2-(1 H-indol-5-yloxy)benzamid; 4-(4-((2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-/V-((3-nitro-4-((1-tetrahydro-2/-/-pyran-4-ylpiperidin-4-yl)amino)phenyl)sulfonyl)benzamid; 4-(4-((2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-/V-((4-((4-methylpiperazin-1 -yl)amino)-3-nitrophenyl)sulfonyl)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)benzannid; trans-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin- 1-yl)-2-(1H-indol-5-yloxy)-N-({4-[(4-morpholin-4-ylcyclohexyl)amino]-3- nitrophenyl}sulfonyl)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2- (1H-indol-5-yloxy)-N-({4-[(2-methoxyethyl)amino]-3- nitrophenyl}sulfonyl)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-[(3-nitro-4-{[(3S)-tetrahydro-2H-pyran-3-ylmethyl]amino}phenyl)sulfonyl]benzannid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-[(3-nitro-4-{[(3R)-tetrahydro-2H-pyran-3-ylmethyl]amino}phenyl)sulfonyl]benzannid; 4-(4-{[4-(4-chlorphenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-1-yl)-2-(1 H-indol-5-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-[(4-{[(4-hydroxy-1-methylpiperidin-4-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1 H-indol-5-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-3-fluor-2-(1 H-indol-5-yloxy)-N-({4-[(1-methylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-3-fluor-2-(1 H-indol-5-yloxy)-N-({3-nitro-4-[(1-tetrahydro-2H-pyran-4-ylpiperidin-4-yl)amino]phenyl}sulfonyl)benzamid; N-[(4-{[(3S,4R)-1-benzyl-3-hydroxypiperidin-4-yl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)benzamid; N-[(4-{[(4-aminotetrahydro-2H-pyran-4-yl)methyl]annino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-[(4-{[1-(2-methoxyethyl)piperidin-4-yl]annino}-3-nitrophenyl)sulfonyl]benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-5-fluor-2-(1 H-indol-5-yloxy)-N-({4-[(1-methylpiperidin-4-yl)annino]-3-nitrophenyl}sulfonyl)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-5-fluor-2-(1 H-indol-5-yloxy)-N-({3-nitro-4-[(1-tetrahydro-2H-pyran-4-ylpiperidin-4-yl)amino]phenyl}sulfonyl)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)- N-[(4-{[1-(3-hydroxypropyl)piperidin-4-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H- indol-5-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)- N-[(4-{[4-(diethylamino)cyclohexyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-indol-5- yloxy)benzamid; 4- (4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-{[4-({[4-(dimethylamino)tetrahydro-2H-pyran-4-yl]methyl}annino)-3-nitrophenyl]sulfonyl}-2-(1H-indol-5-yloxy)benzamid; N-({4-[(2-aminocyclohexyl)amino]-3-nitrophenyl}sulfonyl)-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol- 5- yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-[(4-{[2-(4-hydroxy-1-methylpiperidin-4-yl)ethyl]amino}-3-nitrophenyl)sulfonyl]-2-(1 H-indol-5-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-[(3-nitro-4-{[1 -(1,3-thiazol-2-yl)piperidin-4-yl]amino}phenyl)sulfonyl]benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)- N-[(4-{[1-(cyclopropylmethyl)pipehdin-4-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H- indol-5-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2- (1H-indol-5-yloxy)-N-[(3-nitro-4-{[1-(4,4,4-trifluorbutyl)piperidin-4- yl]amino}phenyl)sulfonyl]benzamid; 4-[4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl-3-(hydroxymethyl)piperazin-l -yl]-2-(1 H-indol-5-yloxy)-N-({4-[1 -methylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)benzamid; 4-[4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}-3-(hydroxymethyl)piperazin-l -yl]-2-(1 H-indol-5-yloxy)-N-({3-nitro-4-[(1 -tetrahydro-2H-pyran-4-ylpiperidin-4-yl)amino]phenyl}sulfonyl)benzannid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-({4-[(4-methylpiperazin-1 -yl)amino]-3-[(trifluormethyl)sulfonyl]phenyl}sulfonyl)benzannid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-[(3-nitro-4-{[3-(3-oxopiperazin-1 -yl)propyl]amino}phenyl)sulfonyl]benzamid; 4-(4-{[2-(4-chlorphenyl)-5-hydroxycyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-({4-[(1 -methylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)benzamid; 4-(4-{[2-(4-chlorphenyl)-5-hydroxycyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-({3-nitro-4-[(1-tetrahydro-2H-pyran-4-ylpiperidin-4-yl)amino]phenyl}sulfonyl)benzamid; 4-(4-{[2-(4-chlorphenyl)-5-hydroxycyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-({4-[(4-methylpiperazin-1 -yl)amino]-3-nitrophenyl}sulfonyl)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-[(4-{[1 -(2,3-dihydro-1 H-inden-2-yl)piperidin-4-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1 H-indol-5-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-[(4-{[(1-morpholin-4-ylcyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-[(3-nitro-4-{[1 -(1,3-thiazol-2-ylmethyl)piperidin-4-yl]amino}phenyl)sulfonyl]benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-[(3-nitro-4-{[1 -(1,3-thiazol-4-ylmethyl)piperidin-4-yl]amino}phenyl)sulfonyl]benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-{[4-({[4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1 H-indol-5-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-[(4-{[4-(2-hydroxyethyl)piperazin-1-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1 H-indol-5-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-[(4-{[(3S)-1-methylpyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]benzamid; 4- (4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-[(4-{[1 -(3-fluorpropyl)piperidin-4-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1 H-indol- 5- yloxy)benzamid; 4-[4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}-3-(hydroxymethyl)piperazin-1-yl]-2-(1 H-indol-5-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)benzannid; N-[(4-{[(4-aminotetrahydro-2H-pyran-4-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-4-[4-{[2-(4-chlorphenyl )-4,4-dimethylcyclohex-1-en-1-yl]methyl}-3-(hydroxymethyl)piperazin-l -yl]-2-(1 H-indol-5-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-[(4-{[(1-hydroxycyclohexyl)methyl]amino-3-nitrophenyl)sulfonyl]-2-(1H-indol-5-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-[(4-{[4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1 H-indol-5-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-({4-[(2-hydroxy-1-tetrahydro-2H-pyran-4-ylethyl)amino]-3-nitrophenyl}sulfonyl)-2-(1 H-indol-5-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-{[3-nitro-4-({1 -[2-(1 H-pyrazol-1 -yl)ethyl]piperidin-4-yl}amino)phenyl]sulfonyl}benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-{[4-(methylamino)-3-nitrophenyl]sulfonyl}benzannid; 4-(4-{[2-(4-chlorphenyl)-5-hydroxycyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)benzannid; 4- (4-{[2-(4-chlorphenyl)-5-morpholin-4-ylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-2-(1H-indol-5-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)benzannid; N-[(4-{[(1-aminocyclohexyl)methyl]annino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol- 5- yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-[(3-nitro-4-{[2-(2-oxopyrrolidin-1 -yl)ethyl]amino}phenyl)sulfonyl]benzamid; 4-{4-[1-(4'-chlor-1,1'-biphenyl-2-yl)ethyl]piperazin-1-yl}-2-(1H-indol-5-yloxy)-N- ({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)benzannid; 4-(4-{1 -[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]ethyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)benzamid; 4-(4-{1 -[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]ethyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-({4-[(4-methylpiperazin-1 -yl)amino]-3-nitrophenyl}sulfonyl)benzamid; 4-(4-{1 -[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]ethyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-({4-[(3-morpholin-4-ylpropyl)amino]-3-nitrophenyl}sulfonyl)benzamid; 4-(4-{1 -[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]ethyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-({3-nitro-4-[(1-tetrahydro-2H-pyran-4-ylpiperidin-4-yl)amino]phenyl}sulfonyl)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)- N-({4-[(cyclohexylmethyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-indol-5- yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-{[4-(morpholin-4-ylamino)-3-nitrophenyl]sulfonyl}benzannid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-3-ylmethyl)amino]phenyl}sulfonyl)benzannid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2- (1H-indol-5-yloxy)-N-{[3-nitro-4-(tetrahydro-2H-pyran-4- ylamino)phenyl]sulfonyl}benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2- (1H-indol-5-yloxy)-N-[(4-{[(3-methyloxetan-3-yl)methyl]annino}-3- nitrophenyl)sulfonyl]benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-({4-[(4-methoxycyclohexyl)amino]-3-nitrophenyl}sulfonyl)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-[(4-{[3-(1,1-dioxidothiomorpholin-4-yl)propyl]amino}-3-nitrophenyl)sulfonyl]-2-(1 H-indol-5-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-[(3-nitro-4-{[2-(2-oxopiperidin-1 -yl)ethyl]amino}phenyl)sulfonyl]benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-[(3-nitro-4-{[2-(2-oxoimidazolidin-1 -yl)ethyl]amino}phenyl)sulfonyl]benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-({3-nitro-4-[(2-pyridin-4-ylethyl)amino]phenyl}sulfonyl)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-[(4-morpholin-4-yl-3-nitrophenyl)sulfonyl]benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-{[4-(4-methoxypiperidin-1 -yl)-3-nitrophenyl]sulfonyl}benzamid; 4-(4-{[2-(4-chlorphenyl)-5-pyrrolidin-1 -ylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)benzannid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-[(3-nitro-4-{[2-(3-oxopiperazin-1 -yl)ethyl]amino}phenyl)sulfonyl]benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-[(4-{[(1,1-dioxidotetrahydrothien-3-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1 H-indol-5-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-({4-[(1,1 -dioxidotetrahydrothien-3-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1 H-indol-5-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-{[4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]-3-(thfluormethyl)phenyl]sulfonyl}benzannid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)- N-({4-[2-(1,3-dioxolan-2-yl)ethyl]-3-nitrophenyl}sulfonyl)-2-(1H-indol-5- yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-{[3-nitro-4-(tetrahydro-2H-pyran-4-ylmethoxy)phenyl]sulfonyl}benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-({4-[(1-methyl-5-oxopyrrolidin-3-yl)amino]-3-nitrophenyl}sulfonyl)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-({4-[(1-methyl-6-oxopiperidin-3-yl)amino]-3-nitrophenyl}sulfonyl)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-{[3-nitro-4-(piperidin-1-ylamino)phenyl]sulfonyl}benzannid; 4-(4-{[4-(4-chlorphenyl)-1 -methyl-1 H-pyrazol-5-yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-({4-[(3-methyloxetan-3-yl)methoxy]-3-nitrophenyl}sulfonyl)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-[(3-nitro-4-{[(1-oxidotetrahydro-2H-thiopyran-4-yl)methyl]amino}phenyl)sulfonyl]benzannid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-({3-nitro-4-[(1,3-thiazol-5-ylmethyl)amino]phenyl}sulfonyl)benzannid; 4-(4-{[2-(4-chlorphenyl)-5,5-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2- (1H-indol-5-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl}sulfonyl)benzannid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-({3-nitro-4-[(2-tetrahydro-2H-pyran-4-ylethyl)amino]phenyl}sulfonyl)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-{[3-nitro-4-(2-tetrahydro-2H-pyran-4-ylethyl)phenyl]sulfonyl}benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-{[4-(1,4-dioxan-2-ylmethoxy)-3-nitrophenyl]sulfonyl}-2-(1 H-indol-5-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-[(4-{[2-(2-methoxyethoxy)ethyl]amino}-3-nitrophenyl)sulfonyl]benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-[(3-nitro-4-{[2-(trifluormethoxy)ethyl]annino}phenyl)sulfonyl]benzannid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-({4-[(2,2-difluorethyl)amino]-3-nitrophenyl}sulfonyl)-2-(1 H-indol-5-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2- (1H-indol-5-yloxy)-N-({4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]-3- [(trifluormethyl)sulfonyl]phenyl}sulfonyl)benzannid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-({4-[(4,4-difluorcyclohexyl)amino]-3-nitrophenyl}sulfonyl)-2-(1 H-indol-5-yloxy)benzamid; 4-(4-{[4-(4-chlorphenyl)-1-isopropyl-6-oxo-1,6-dihydropyridin-3-yl]methyl}piperazin-1-yl)-2-(1 H-indol-5-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)benzannid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-[(4-{[(tetrahydro-2H-pyran-4-ylmethyl)amino]carbonyl}phenyl)sulfonyl]benzannid; 4- (4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-[(4-{[(4-hydroxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1 H-indol- 5- yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2- (1H-indol-5-yloxy)-N-[(4-{[(4-methoxycyclohexyl)methyl]annino}-3- nitrophenyl)sulfonyl]benzamid; 4-(4-[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-[(4-{[(4-hydroxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1 H-indol-5-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-[(4-{[(4-methoxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-({4-[(2-methoxyethyl)amino]-3-[(trifluormethyl)sulfonyl]phenyl}sulfonyl)benzannid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-({4-[(3-methoxypropyl)amino]-3-nitrophenyl}sulfonyl)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-({4-[(2-cyanoethyl)amino]-3-nitrophenyl}sulfonyl)-2-(1 H-indol-5-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-{[4-({[(3R)-4-hydroxy-1-adamantyl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1 H-indol-5-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-{[4-({[(3R)-4-hydroxy-1-adamantyl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1 H-indol-5-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-({3-nitro-4-[(3,3,3-trifluorpropyl)amino]phenyl}sulfonyl)benzannid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-({4-[(4-fluortetrahydro-2H-pyran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1 H-indol-5-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-({4-(methylamino)-3-[(trifluormethyl)sulfonyl]phenyl}sulfonyl)benzannid; N-{[5-brom-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl}-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)benzamid; 4-(4-{[4-(4-chlorphenyl)-6-isopropoxypyridin-3-yl]methyl}piperazin-1-yl)-2-(1 H- indol-5-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl}sulfonyl)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-{[6-(tetrahydro-2H-pyran-4-ylmethoxy)-5-(1,3-thiazol-2-yl)pyridin-3-yl]sulfonyl}benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-[(4-{[(2- methoxyethyl)amino]carbonyl}phenyl)sulfonyl]benzannid; 4- (4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-{[5-cyano-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl}-2-(1 H-indol-5-yloxy)benzamid; N-({4-[(1-acetylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol- 5- yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2- (1H-indol-5-yloxy)-N-[(4-{[1-(methylsulfonyl)piperidin-4-yl]amino}-3- nitrophenyl)sulfonyl]benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-({4-[(1,4-dioxan-2-ylmethyl)amino]-3-nitrophenyl}sulfonyl)-2-(1 H-indol-5-yloxy)benzamid; 4-(4-{[4'-chlor-5-(trifluormethyl)-1,1 '-biphenyl-2-yl]methyl}piperazin-1 -yl)-2-(1 H- indol-5-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl}sulfonyl)benzannid; 4-(4-{[4'-chlor-5-(trifluormethyl)-1,1 '-biphenyl-2-yl]methyl}piperazin-1 -yl)-2-(1 H- indol-5-yloxy)-N-{[3-nitro-4-(tetrahydro-2H-pyran-4- ylmethoxy)phenyl]sulfonyl}benzamid; 4-{4-[(5-tert-butyl-4'-chlor-1,1 '-biphenyl-2-yl)methyl]piperazin-1 -yl}-2-(1 H-indol-5- yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl}sulfonyl)benzannid; 4-{4-[(5-tert-butyl-4'-chlor-1,1 '-biphenyl-2-yl)methyl]piperazin-1 -yl}-2-(1 H-indol-5- yloxy)-N-{[3-nitro-4-(tetrahydro-2H-pyran-4- ylmethoxy)phenyl]sulfonyl}benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-({3-nitro-4-[(2,2,2-trifluorethyl)amino]phenyl}sulfonyl)benzannid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-[(3-{[(tetrahydro-2H-pyran-4-ylmethyl)amino]carbonyl}phenyl)sulfonyl]benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-({4-[(2R)-1,4-dioxan-2-ylmethoxy]-3-nitrophenyl}sulfonyl)-2-(1 H-indol-5-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-({4-[(2S)-1,4-dioxan-2-ylmethoxy]-3-nitrophenyl}sulfonyl)-2-(1 H-indol-5-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-({4-[(3-morpholin-4-ylpropyl)amino]-3-[(trifluormethyl)sulfonyl]phenyl}sulfonyl)benzannid; N-({5-brom-6-[(tetrahydro-2H-pyran-4-ylmethyl)annino]pyndin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl )-2-(1 H-indol-5-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-({4-[(2-morpholin-4-ylethyl)amino]-3-[(thfluormethyl)sulfonyl]phenyl}sulfonyl)benzannid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-({5-cyano-6-[(tetrahydro-2H-pyran-4-ylmethyl)amino]pyridin-3-yl}sulfonyl)-2-(1 H-indol-5-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-({4-[(1 -methylpiperidin-4-yl)oxy]-3-nitrophenyl}sulfonyl)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-({4-[(1 -methylpiperidin-4-yl)nnethoxy]-3-nitrophenyl}sulfonyl)benzamid; benzyl-4-({[4-({[4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1-en-1- yl]methyl}piperazin-1-yl)-2-(1H-indol-5-yloxy)benzoyl]amino}sulfonyl)-2- nitrophenyl]amino}methyl)piperidin-1-carboxylat; N-{[3-(aminocarbonyl)-4-(tetrahydro-2H-pyran-4-ylmethoxy)phenyl]sulfonyl}-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)benzamid; 4-(4-{[4'-chlor-5-(trifluormethyl)-1,1 '-biphenyl-2-yl]methyl}piperazin-1 -yl)-2-(1 H- indol-5-yloxy)-N-({3-nitro-4-[(1-tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl}sulfonyl)benzamid; 4-{4-[(5-tert-butyl-4'-chlor-1,1 '-biphenyl-2-yl)methyl]piperazin-1 -yl}-2-(1 H-indol-5- yloxy)-N-({3-nitro-4-[(1-tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl}sulfonyl)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methylpiperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-[(4-{[(1 -methyl-1 H-imidazol-5-yl)methyl]amino}-3-nitrophenyl)sulfonyl]benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-{[4-(morpholin-4-ylsulfonyl)phenyl]sulfonyl}benzamid; 4- (4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-({4-[(1,1 -dioxidothiomorpholin-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1 H-indol- 5- yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-({4-[(4-morpholin-4-ylcyclohexyl)amino]-3-nitrophenyl}sulfonyl)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-({3-cyano-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1 H-indol-5-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)- N-({4-[(3,3-dimethylbutyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-indol-5- yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-[(4-{[(1S)-1-(hydroxymethyl )-3-methylbutyl]amino}-3-nitrophenyl)sulfonyl]-2-(1 H-indol-5-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-[(3-nitro-4-{[(2R)-tetrahydrofuran-2-ylmethyl]amino}phenyl)sulfonyl]benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-[(4-{[(1 R)-1-(hydroxymethyl)-2-methylpropyl]amino}-3-nitrophenyl)sulfonyl]-2-(1 H-indol-5-yloxy)benzamid; 4- (4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-({4-[(4-methoxyphenyl)amino]-3-nitrophenyl}sulfonyl)benzamid; N-[(4-{[2-(1,3-benzodioxol-5-yl)ethyl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol- 5- yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-[(3-nitro-4-{[3-(2-oxopyrrolidin-1 -yl)propyl]amino}phenyl)sulfonyl]benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-({4-[(4-hydroxyphenyl)amino]-3-nitrophenyl}sulfonyl)-2-(1 H-indol-5-yloxy)benzamid; N-{[4-({2-[4-(aminosulfonyl)phenyl]ethyl}amino)-3-nitrophenyl]sulfonyl}-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-[(4-{[3-(1 H-imidazol-1 -yl)propyl]amino}-3-nitrophenyl)sulfonyl]-2-(1 H-indol-5-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-[(3-nitro-4-{[(1 S)-1 -phenylethyl]amino}phenyl)sulfonyl]benzamid; N-({2-chlor-5-fluor-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-[(4-{[2-(2-methoxyethoxy)ethyl]thio}-3-nitrophenyl)sulfonyl]benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1H-indol-5-yloxy)-N-{[4-(methylsulfonyl)phenyl]sulfonyl}benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-({4-[(2,2-dimethyltetrahydro-2H-pyran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1 H-indol-5-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-({5-cyano-6-[(4-fluortetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-2-(1 H-indol-5-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)- N-{[5-cyano-6-(2-morpholin-4-ylethoxy)pyridin-3-yl]sulfonyl}-2-(1H-indol-5- yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-({3-nitro-4-[(1-tetrahydro-2H-pyran-4-ylpiperidin-4-yl)oxy]phenyl}sulfonyl)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-({4-[(4-morpholin-4-ylbut-2-ynyl)oxy]-3-nitrophenyl}sulfonyl)benzamid; og 4- (4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-({4-[(3-hydroxy-4-methoxyphenyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-indol- 5- yloxy)benzamid.
11. Forbindelse ifølge krav 2 eller terapeutisk acceptabelt salt deraf, hvor forbindelsen er udvalgt blandt: 4-(4-((4'-chlor-4-(pyrrolidin-1 -ylmethyl)-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzannid; 4-(4-((4'-chlor-4-(2-pyrrolidin-1 -ylethyl)-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzannid; 4-(4-((4'-chlor-1,1'-biphenyl-2-yl)methyl)piperazin-1-yl)-2-(1H-indol-4-yloxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamid; 4-(4-((4'-chlor-1,1'-biphenyl-2-yl)methyl)piperazin-1-yl)-N-((4-((3-(dimethylamino)propyl)annino)-3-nitrophenyl)sulfonyl )-2-(1 H-indol-4-yloxy)benzamid; 4-(4-((2-(4-chlorphenyl)-5,5-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-((4-((3-morpholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)benzamid; 4-(4-((2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-((4-((3-morpholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)benzamid; 4-(4-((2-(4-chlorphenyl)-5,5-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-N-((4-((3-(dimethylamino)propyl)annino)-3-nitrophenyl)sulfonyl)-2-(1 H-indol-4-yloxy)benzamid; 4-(4-((2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-N-((4-((3-(dimethylamino)propyl)annino)-3-nitrophenyl)sulfonyl)-2-(1 H-indol-4-yloxy)benzamid; 4-(4-((4'-chlor-1,1'-biphenyl-2-yl)methyl)piperazin-1-yl)-2-(1H-indol-4-yloxy)-N- ((4-((3-morpholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)benzannid; 4-(4-((4'-chlor-1,1'-biphenyl-2-yl)methyl)piperazin-1-yl)-2-(1H-indol-4-yloxy)-N- ((4-((tetrahydro-2H-pyran-4-ylmethyl)amino)-3- ((trifluormethyl)sulfonyl)phenyl)sulfonyl)benzamid; 4-(4-((4'-chlor-1,1'-biphenyl-2-yl)methyl)piperazin-1-yl)-2-(1H-indol-4-yloxy)-N- ((4-((3-morpholin-4-ylpropyl)amino)-3- ((trifluormethyl)sulfonyl)phenyl)sulfonyl)benzannid; 2-(1 H-indol-4-yloxy)-4-(4-((2-(4-methoxyphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-N-((3-nitro-4-((3-pyrrolidin-1 -ylpropyl)amino)phenyl)sulfonyl)benzamid; 4-(4-((4,4-dimethyl-2-(4-(thfluormethyl)phenyl)cydohex-1-en-1-yl)methyl)piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-((3-nitro-4-((3-pyrrolidin-1 -ylpropyl)amino)phenyl)sulfonyl)benzamid; 4-(4-((4,4-dimethyl-2-(4-(thfluormethoxy)phenyl)cydohex-1-en-1-yl)methyl)piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-((3-nitro-4-((3-pyrrolidin-1 -ylpropyl)amino)phenyl)sulfonyl)benzamid; 4-(4-((4,4-dimethyl-2-(3-(thfluormethyl)phenyl)cydohex-1-en-1-yl)methyl)piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-((3-nitro-4-((3-pyrrolidin-1 -ylpropyl)amino)phenyl)sulfonyl)benzamid; 4-(4-((2-(3-fluorphenyl)-4,4-dimethylcydohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-((3-nitro-4-((3-pyrrolidin-1 -ylpropyl)amino)phenyl)sulfonyl)benzamid; 4-(4-((2-(4-fluorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-((3-nitro-4-((3-pyrrolidin-1 -ylpropyl)amino)phenyl)sulfonyl)benzamid; 4-(4-((2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-((4-((3-(4-methylpiperazin-1-yl)propyl)amino)-3-nitrophenyl)sulfonyl)benzamid; 4-(4-((2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-((4-((2-(4-methylpiperazin-1-yl)ethyl)amino)-3-nitrophenyl)sulfonyl)benzamid; 4-(4-((2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-((3-nitro-4-((3-pyrrolidin-1 -ylpropyl)amino)phenyl)sulfonyl)benzamid; 4-(4-((2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-((4-((1 -methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)benzamid; 4-(4-((2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-((4-(((1-methylpiperidin-4-yl)methyl)amino)-3-nitrophenyl)sulfonyl)benzamid; 4-(4-((2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-N-((4-(3-(dimethylamino)propoxy)-3-nitrophenyl)sulfonyl)-2-(1 H-indol-4-yloxy)benzamid; 4-(4-((2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)- 2-(1H-indol-4-yloxy)-N-((3-nitro-4-((1-(2,2,2-trifluorethyl)piperidin-4- yl)amino)phenyl)sulfonyl)benzamid; 4-(4-((4'-chlor-4-(2-(dimethylamino)ethoxy)-1,1'-biphenyl-2-yl)nnethyl)piperazin-1-yl)-2-(1 H-indol-4-yloxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzannid; 4-(4-((4'-chlor-3-(2-(dimethylamino)ethoxy)-1,1'-biphenyl-2-yl)methyl)piperazin- 1-yl)-2-(1H-indol-4-yloxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzannid; 4-(4-((4'-chlor-4-(2-morpholin-4-ylethoxy)-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamid; 4-(4-((4'-chlor-3-(2-morpholin-4-ylethoxy)-1,1 '-biphenyl-2-y)methyl)piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamid; 4-(4-((2-(4-chlorphenyl)cyclohept-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-((3-nitro-4-((3-pyrrolidin-1-ylpropyl)amino)phenyl)sulfonyl)benzamid; 4-(4-((2-(4-chlorphenyl)cyclooct-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-((3-nitro-4-((3-pyrrolidin-1-ylpropyl)amino)phenyl)sulfonyl)benzamid; 4-(4-((2-(4-chlorphenyl)cyclopent-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-((3-nitro-4-((3-pyrrolidin-1-ylpropyl)amino)phenyl)sulfonyl)benzamid; 4-(4-((2-(4-chlorphenyl)-4,4-dimethylcyclopent-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-((4-((1 -methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)benzamid; 4-(4-((4-(4-chlorphenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl)methyl)piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-((4-((1 -methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)benzamid; 4-(4-((2-(4-chlorphenyl)cyclooct-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-((4-((1-methylpiperidin-4-yl)annino)-3-nitrophenyl)sulfonyl)benzannid; 4-(4-((2-(4-chlorphenyl)cyclohept-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-((4-((1-methylpiperidin-4-yl)annino)-3-nitrophenyl)sulfonyl)benzannid; 4-(4-((2-(4-chlorphenyl)cyclopent-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-((4-((1-methylpiperidin-4-yl)annino)-3-nitrophenyl)sulfonyl)benzannid; 4-(4-((2-(4-chlorphenyl)cyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-((4-((1-methylpiperidin-4-yl)annino)-3-nitrophenyl)sulfonyl)benzannid; 4-(4-(1 -(4'-chlor-1,1 '-biphenyl-2-yl)ethyl)piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamid; N-((4-(((4-aminotetrahydro-2/-/-pyran-4-yl)methyl)annino)-3-nitrophenyl)sulfonyl)-4-(4-((2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-(1 H-indol-4-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-[(4-{[(4-hydroxy-1-methylpiperidin-4-yl)methyl]annino}-3-nitrophenyl)sulfonyl]-2-(1 H-indol-4-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-({4-[(4-methylpiperazin-1 -yl)amino]-3-nitrophenyl}sulfonyl)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)- N-[(4-{[1-(2-hydroxyethyl)piperidin-4-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H- indol-4-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-[(4-{[1-(2-methoxyethyl)piperidin-4-yl]amino}-3-nitrophenyl)sulfonyl]benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-[(4-{[1-(3-hydroxypropyl)piperidin-4-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1 H-indol-4-yloxy)benzamid; 4-[4-({4'-chlor-3-[3-(dimethylamino)propyl]-1,1 '-biphenyl-2-yl}methyl)piperazin-1 - yl]-2-(1H-indol-4-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl}sulfonyl)benzannid; 4-{4-[(4'-chlor-4-morpholin-4-yl-1,1 '-biphenyl-2-yl)methyl]piperazin-1 -yl}-2-(1 H- indol-4-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl}sulfonyl)benzamid; 4-[4-({4'-chlor-3-[2-(dimethylamino)ethoxy]-1,1'-biphenyl-2-yl}methyl)piperazin-1 -yl]-2-(1 H-indol-4-yloxy)-N-({3-nitro-4-[(1 -tetrahydro-2H-pyran-4-ylpiperidin-4-yl)amino]phenyl}sulfonyl)benzamid; 4-{4-[1-(4'-chlor-1,1'-biphenyl-2-yl)ethyl]piperazin-1-yl}-2-(1H-indol-4-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)benzannid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-[(4-{[4-(dimethylamino)cyclohexyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-indol-4-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)- N-[(4-{[4-(diethylamino)cyclohexyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-indol-4- yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-({4-[(4-morpholin-4-ylcyclohexyl)amino]-3-nitrophenyl}sulfonyl)benzamid; 4-[4-({4'-chlor-3-[2-(dimethylamino)ethoxy]-1,1'-biphenyl-2-yl}methyl)piperazin-1 -yl]-2-(1 H-indol-4-yloxy)-N-({4-[(1 -methylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)benzamid; 4-{4-[1-(4'-chlor-1,1'-biphenyl-2-yl)ethyl]piperazin-1-yl}-2-(1H-indol-4-yloxy)-N-({4-[(1-methylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)benzannid; 4-[4-({4'-chlor-4-[3-(dimethylamino)prop-1 -ynyl]-1,1 '-biphenyl-2-yl}methyl)piperazin-1-yl]-2-(1H-indol-4-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)benzamid; 4-(4- {[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)- 2-(1H-indol-4-yloxy)-N-[(3-nitro-4-{[1-(4,4,4-trifluorbutyl)piperidin-4- yl]amino}phenyl)sulfonyl]benzamid; 4-(4-{[4'-chlor-4-(2-hydroxyethoxy)-1,1'-biphenyl-2-yl]methyl}piperazin-1-yl)-2-(1 H-indol-4-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-({4-[(4-methylpiperazin-1 -yl)amino]-3-[(trifluormethyl)sulfonyl]phenyl}sulfonyl)benzannid; 4-{4-[1-(4'-chlor-1,1'-biphenyl-2-yl)ethyl]piperazin-1-yl}-2-(1H-indol-4-yloxy)-N-({4-[(4-methylpiperazin-1-yl)amino]-3-nitrophenyl}sulfonyl)benzannid; 4-(4-{[4'-chlor-4-(2-hydroxyethoxy)-1,1'-biphenyl-2-yl]methyl}piperazin-1-yl)-2-(1 H-indol-4-yloxy)-N-({4-[(1 -methylpiperidin-4-yl)annino]-3-nitrophenyl}sulfonyl)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-[(3-nitro-4-{[3-(3-oxopiperazin-1 -yl)propyl]amino}phenyl)sulfonyl]benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-[(4-{[1 -(2,3-dihydro-1 H-inden-2-yl)piperidin-4-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1 H-indol-4-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-({4-[(2-methoxyethyl)amino]-3-nitrophenyl}sulfonyl)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)- N-[(4-{[4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl]amino}-3- nitrophenyl)sulfonyl]-2-(1H-indol-4-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)benzannid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-{[4-(methylamino)-3-nitrophenyl]sulfonyl}benzannid; 4-{4-[1-(4'-chlor-1,1'-biphenyl-2-yl)ethyl]piperazin-1-yl}-2-(1H-indol-4-yloxy)-N-({4-[(3-morpholin-4-ylpropyl)amino]-3-nitrophenyl}sulfonyl)benzamid; 4-{4-[(1 R)-1 -(4'-chlor-1,1'-biphenyl-2-yl)ethyl]piperazin-1 -yl}-2-(1 H-indol-4- yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl}sulfonyl)benzannid; 4-{4-[(1 S)-1 -(4'-chlor-1,1 '-biphenyl-2-yl)ethyl]piperazin-1 -yl}-2-(1 H-indol-4- yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl}sulfonyl)benzannid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1H-indol-4-yloxy)-N-{[4-(morpholin-4-ylamino)-3-nitrophenyl]sulfonyl}benzannid; 4-[4-({4'-chlor-4-[2-(dimethylamino)ethoxy]-1,1'-biphenyl-2-yl}methyl)piperazin-1 -yl]-2-(1 H-indol-4-yloxy)-N-({4-[(4-methylpiperazin-1 -yl)amino]-3-nitrophenyl}sulfonyl)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-[(3-nitro-4-{[2-(3-oxopiperazin-1 -yl)ethyl]amino}phenyl)sulfonyl]benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-{[3-nitro-4-(piperidin-1-ylamino)phenyl]sulfonyl}benzannid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-{[3-nitro-4-(tetrahydro-2H-pyran-4-ylmethoxy)phenyl] sulfonyl} benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-[(3-nitro-4-{[2-(trifluormethoxy)ethyl]annino}phenyl)sulfonyl]benzannid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-[(4-{[2-(2-methoxyethoxy)ethyl]amino}-3-nitrophenyl)sulfonyl]benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-[(4-{[3-(methylsulfonyl)propyl]amino}-3-nitrophenyl)sulfonyl]benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-[(4-{[3-(1,1-dioxidothiomorpholin-4-yl)propyl]amino}-3-nitrophenyl)sulfonyl]-2-(1 H-indol-4-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-({4-[(1,1 -dioxidotetrahydrothien-3-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1 H-indol-4-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-[(4-{[(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1 H-indol-4-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-({4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]-3-[(thfluormethyl)sulfonyl]phenyl}sulfonyl)benzannid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-({4-[(4-fluortetrahydro-2H-pyran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1 H-indol-4-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-({4-[(2-methoxyethyl)amino]-3-[(trifluormethyl)sulfonyl]phenyl}sulfonyl)benzannid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-{[3-nitro-4-(2-tetrahydro-2H-pyran-4-ylethoxy)phenyl]sulfonyl}benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2- (1H-indol-4-yloxy)-N-({4-[3-(methylsulfonyl)propoxy]-3- nitrophenyl}sulfonyl)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-({4-[(3-methoxypropyl)amino]-3-nitrophenyl}sulfonyl)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-({4-[(2-cyanoethyl)amino]-3-nitrophenyl}sulfonyl)-2-(1 H-indol-4-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2- (1H-indol-4-yloxy)-N-({3-nitro-4·!^^- trifluorpropyl)amino]phenyl}sulfonyl)benzannid; N-({5-brom-6-[(tetrahydro-2H-pyran-4-ylmethyl)amino]pyndin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl )-2-(1 H-indol-4-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-[(4-{[(1,1-dioxidotetrahydrothien-3-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1 H-indol-4-yloxy)benzamid; N-({4-[(1-acetylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-4-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-[(4-{[1-(methylsulfonyl)piperidin-4-yl]amino}-3-nitrophenyl)sulfonyl]benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-({3-nitro-4-[(2,2,2-trifluorethyl)amino]phenyl}sulfonyl)benzannid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-({4-[(3-morpholin-4-ylpropyl)amino]-3-[(trifluormethyl)sulfonyl]phenyl}sulfonyl)benzannid; 4-(4-{[4-(4-chlorphenyl)-1-(3-hydroxypropyl)-1,2,5,6-tetrahydropyridin-3-yl]methyl}piperazin-1-yl)-2-(1 H-indol-4-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)benzannid; N-{[5-brom-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl}-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-4-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-{[6-[(tetrahydro-2H-pyran-4-ylmethyl)amino]-5-(1,3-thiazol-2-yl)pyridin-3-yl]sulfonyl}benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-({3-cyano-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1 H-indol-4-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-[(4-{[2-(2-methoxyethoxy)ethyl]thio}-3-nitrophenyl)sulfonyl]benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-{[4-(methylsulfonyl)phenyl]sulfonyl}benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-{[5-cyano-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl}-2-(1 H-indol-4-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-{[5-chlor-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl}-2-(1 H-indol-4-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-{[5-ethynyl-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl}-2-(1 H-indol-4-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)- N-{[5-cyano-6-(2-morpholin-4-ylethoxy)pyridin-3-yl]sulfonyl}-2-(1H-indol-4- yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-({5-cyano-6-[(4-fluortetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-2-(1 H-indol-4-yloxy)benzamid; og N-({5-chlor-6-[(4-fluortetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-4-yloxy)benzamid.
12. Forbindelse ifølge krav 3 eller terapeutisk acceptabelt salt deraf, hvor forbindelsen er udvalgt blandt: 2-(1 H-benzimidazol-4-yloxy)-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1- en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl}sulfonyl)benzannid; 2-(1 H-benzimidazol-4-yloxy)-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1-en-1 -yl]methyl}piperazin-1 -yl)-N-[(4-{[(3R)-1 -(2,2-difluorethyl)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]benzamid; 2- (1 H-benzimidazol-4-yloxy)-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({4-[(4-fluortetrahydro-2H-pyran-4-yl)methoxy]- 3- nitrophenyl}sulfonyl)benzamid; 2-(1H-benzimidazol-4-yloxy)-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1- en-1-yl]methyl}piperazin-1-yl)-N-{[4-({[4-(2,2-difluorethyl)morpholin-2- yl]methyl}amino)-3-nitrophenyl]sulfonyl}benzamid; 2-(1 H-benzimidazol-4-yloxy)-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1-en-1 -yl]methyl}piperazin-1 -yl)-N-({3-nitro-4-[(1 -tetrahydro-2H-pyran-4-ylpiperidin-4-yl)amino]phenyl}sulfonyl)benzamid; 2-(1 H-benzimidazol-4-yloxy)-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1-en-1 -yl]methyl}piperazin-1 -yl)-N-({4-[(1 -methylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)benzamid; 2-(1 H-benzimidazol-4-yloxy)-N-[(5-chlor-6-{[(2S)-4-(N,N-dimethylglycyl)morpholin-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)benzamid; 2-(1 H-benzimidazol-4-yloxy)-N-[(5-chlor-6-{[(2R)-4-(N,N-dimethylglycyl)morpholin-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)benzamid; 2-(1H-benzimidazol-4-yloxy)-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1-en-1 -yl]methyl}piperazin-1 -yl)-N-[(4-{[(3R)-1 -(cyanomethyl)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]benzamid; 2-(1H-benzimidazol-4-yloxy)-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1-en-1 -yl]methyl}piperazin-1 -yl)-N-{[4-({(3R)-1 -[2-(2- methoxyethoxy)ethyl]pyrrolidin-3-yl}amino)-3-nitrophenyl]sulfonyl}benzannid; 2-(1 H-benzimidazol-4-yloxy)-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1-en-1 -yl]methyl}piperazin-1 -yl)-N-[(4-{[(3R)-1 -(N,N-dimethylglycyl)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]benzamid; 2-(1 H-benzimidazol-4-yloxy)-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1- en-1-yl]methyl}piperazin-1-yl)-N-{[4-({[4-(cyanomethyl)nnorpholin-2- yl]methyl}amino)-3-nitrophenyl]sulfonyl}benzamid; 2-(1 H-benzimidazol-4-yloxy)-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1- en-1-yl]methyl}piperazin-1-yl)-N-[(4-{[(4-cyclopropylmorpholin-2- yl)methyl]amino}-3-nitrophenyl)sulfonyl]benzamid; 2-(1 H-benzimidazol-4-yloxy)-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1- en-1-yl]methyl}piperazin-1-yl)-N-[(3-nitro-4-{[(4-oxetan-3-ylmorpholin-2- yl)methyl]amino}phenyl)sulfonyl]benzamid; 2-(1H-benzimidazol-4-yloxy)-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1- en-1-yl]methyl}piperazin-1-yl)-N-{[4-({[(2R)-4-(N,N-dimethylglycyl)morpholin-2- yl]methyl}amino)-3-nitrophenyl]sulfonyl}benzamid; 2-(1 H-benzimidazol-4-yloxy)-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1- en-1-yl]methyl}piperazin-1-yl)-N-{[4-({[(2S)-4-(N,N-dimethylglycyl)morpholin-2- yl]methyl}amino)-3-nitrophenyl]sulfonyl}benzamid; 2-(1 H-benzimidazol-4-yloxy)-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1- en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydrofuran-3- ylmethyl)amino]phenyl}sulfonyl)benzamid; trans-2-(1 H-benzimidazol-4-yloxy)-4-(4-{[2-(4-chlorphenyl)-4,4- dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-[(4-{[(4- methoxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]benzamid; 2-(1 H-benzimidazol-4-yloxy)-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1- en-1-yl]methyl}piperazin-1-yl)-N-[(4-{[(4-fluortetrahydro-2H-pyran-4- yl)methyl]amino}-3-nitrophenyl)sulfonyl]benzamid; 2-(1H-benzimidazol-4-yloxy)-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1- en-1-yl]methyl}piperazin-1-yl)-N-({5-fluor-6-[(4-fluortetrahydro-2H-pyran-4- yl)methoxy]pyridin-3-yl}sulfonyl)benzamid; 2-(1H-benzimidazol-4-yloxy)-N-({5-chlor-6-[(4-fluortetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)benzamid; 2-(1 H-benzimidazol-4-yloxy)-N-({5-chlor-6-[(1-cyclopropylpiperidin-4-yl)amino]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1-en-1 -yl]methyl}piperazin-1 -yl)benzamid; 2-(1 H-benzimidazol-4-yloxy)-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1-en-1 -yl]methyl}piperazin-1 -yl)-N-({4-[(1,4-dioxan-2-ylmethyl)amino]-3-nitrophenyl}sulfonyl)benzamid; 2-(1 H-benzimidazol-4-yloxy)-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1-en-1 -yl]methyl}piperazin-1 -yl)-N-({4-[(1 -cyclopropylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)benzamid; trans-2-(1 H-benzimidazol-4-yloxy)-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-({4-[(4-morpholin-4-ylcydohexyl)amino]-3-nitrophenyl}sulfonyl)benzamid; 2-(1H-benzimidazol-4-yloxy)-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1-en-1 -yl]methyl}piperazin-1 -yl)-N-({4-[(4-methylpiperazin-1 -yl)amino]-3-nitrophenyl}sulfonyl)benzamid; 2-(1 H-benzimidazol-4-yloxy)-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1-en-1 -yl]methyl}piperazin-1 -yl)-N-[(4-{[(1 -methylpiperidin-4-yl)methyl]amino}-3-nitrophenyl)sulfonyl]benzamid; 2-(1 H-benzimidazol-4-yloxy)-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1-en-1 -yl]methyl}piperazin-1 -yl)-N-({4-[({(2R)-4-[2-(2-methoxyethoxy)ethyl]morpholin-2-yl}methyl)amino]-3-nitrophenyl}sulfonyl)benzamid; 2-(1 H-benzimidazol-4-yloxy)-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1- en-1-yl]methyl}piperazin-1-yl)-N-[(4-{[(4,4-difluorcyclohexyl)methyl]amino}-3- nitrophenyl)sulfonyl]benzamid; N-[(4-{[(4-acetylmorpholin-2-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1 H- benzimidazol-4-yloxy)-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1-en-1- yl]methyl}piperazin-1-yl)benzamid; 2-(1 H-benzimidazol-4-yloxy)-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1- en-1-yl]methyl}piperazin-1-yl)-N-{[4-({[4-(methylsulfonyl)morpholin-2- yl]methyl}amino)-3-nitrophenyl]sulfonyl}benzamid; trans-2-(1 H-benzimidazol-4-yloxy)-4-(4-{[2-(4-chlorphenyl)-4,4- dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-[(4-{[(4- cyanocyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]benzannid; og 2-(1H-benzimidazol-4-yloxy)-N-({5-chlor-6-[(4,4- difluorcyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)benzamid.
13. Forbindelse ifølge krav 4 eller terapeutisk acceptabelt salt deraf, hvor forbindelsen er udvalgt blandt: N-({5-chlor-6-[(4-fluortetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indazol-4-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-({5-cyano-6-[(4-fluortetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-2-(1 H-indazol-4-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-[(4-{[(4-fluortetrahydro-2H-pyran-4-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1 H-indazol-4-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)- N-{[6-[(4-fluortetrahydro-2H-pyran-4-yl)methoxy]-5-(trifluormethyl)pyridin-3- yl]sulfonyl}-2-(1H-indazol-4-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-[(4-{[(4-cyclopropylmorpholin-2-yl)methyl]annino}-3-nitrophenyl)sulfonyl]-2-(1 H-indazol-4-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-[(4-{[(4,4-difluorcyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1 H-indazol-4-yloxy)benzamid; N-[(5-chlor-6-{[(4-fluortetrahydro-2H-pyran-4-yl)methyl]amino}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1 -yl)-2-(1 H-indazol-4-yloxy)benzamid; trans-N-({5-chlor-6-[(4-methoxycyclohexyl)methoxy]pyridin-3-yl}sulfonyl )-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl )-2-(1 H-indazol-4-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-({5-fluor-6-[(4-fluortetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-2-(1 H-indazol-4-yloxy)benzamid; N-[(5-chlor-6-{[1-(cyanomethyl)-4-fluorpiperidin-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1 -yl)-2-(1 H-indazol-4-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-{[5-chlor-6-(tetrahydrofuran-3-ylmethoxy)pyridin-3-yl]sulfonyl}-2-(1 H-indazol-4-yloxy)benzamid; trans-N-({5-chlor-6-[(4-hydroxycyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl )-2-(1 H-indazol-4-yloxy)benzamid; N-[(5-chlor-6-{[(3R)-1-(2,2-difluorethyl)pyrrolidin-3-yl]oxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indazol-4-yloxy)benzamid; N-[(5-chlor-6-{[(2S)-4-(N,N-dimethylglycyl)morpholin-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1 -yl)-2-(1 H-indazol-4-yloxy)benzamid; N-[(5-chlor-6-{[(2R)-4-(N,N-dimethylglycyl)morpholin-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1 -yl)-2-(1 H-indazol-4-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-{[5-chlor-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl}-2-(1 H-indazol-4-yloxy)benzamid; N-{[5-chlor-6-({(3R)-1-[2-fluor-1-(fluormethyl)ethyl]pyrrolidin-3-yl}oxy)pyridin-3-yl]sulfonyl}-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1 -yl)-2-(1 H-indazol-4-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-{[4-({(3R)-1-[2-fluor-1-(fluormethyl)ethyl]pyrrolidin-3-yl}amino)-3-nitrophenyl]sulfonyl}-2-(1 H-indazol-4-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-({4-[(1-cyclopropylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl )-2-(1 H-indazol-4-yloxy)benzamid; N-{[5-chlor-6-({(3R)-1-[2-fluor-1-(fluormethyl)ethyl]pyrrolidin-3-yl}methoxy)pyridin-3-yl]sulfonyl}-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indazol-4-yloxy)benzamid; N-[(5-chlor-6-{[(3R)-1-(2,2-difluorethyl)pyrrolidin-3-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1 -yl)-2-(1 H-indazol-4-yloxy)benzamid; trans-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-2-(1 H-indazol-4-yloxy)-N-[(4-{[(4-methoxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-{[4-(1,4-dioxan-2-ylmethoxy)-3-nitrophenyl]sulfonyl}-2-(1 H-indazol-4-yloxy)benzamid; N-({5-chlor-6-[(1-cyclopropylpiperidin-4-yl)amino]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indazol-4-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-{[6-({4-fluor-1-[2-fluor-1-(fluornnethyl)ethyl]piperidin-4-yl}nnethoxy)-5-(trifluormethyl)pyridin-3-yl]sulfonyl}-2-(1 H-indazol-4-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-{[5-chlor-6-(2-tetrahydrofuran-2-ylethoxy)pyridin-3-yl]sulfonyl}-2-(1H-indazol-4-yloxy)benzamid; N-({3-chlor-4-[(4-fluortetrahydro-2H-pyran-4-yl)methoxy]phenyl}sulfonyl)-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl )-2-(1 H-indazol-4-yloxy)benzamid; N-({5-chlor-6-[(4-fluortetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[4-(4-chlorphenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-1 -yl)-2-(1 H-indazol-4-yloxy)benzamid; og 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-{[5-cyano-6-(2-tetrahydro-2H-pyran-4-ylethoxy)pyridin-3-yl]sulfonyl}-2-(1 H-indazol-4-yloxy)benzamid.
14. Sammensætning til anvendelse til behandling af blærecancer, hjernecancer, brystcancer, knoglemarvscancer, cervikal cancer, kronisk lymfocytisk leukæmi, kolorektal cancer, øsofageal cancer, hepatocellulær cancer, lymfoblastisk leukæmi, follikulært lymfom, en lymfoid malignitet af T-celle- eller B-celle-oprindelse, melanom, myeloid leukæmi, myelom, oral cancer, ovariecancer, ikke-småcellet lungecancer, prostatacancer, småcellet lungecancer eller miltcancer, hvilken sammensætning omfatter et excipiens og en terapeutisk effektiv mængde af forbindelsen eller det terapeutisk acceptable salt ifølge et hvilket som helst af kravene 1-13.
15. Forbindelse eller terapeutisk acceptabelt salt ifølge et hvilket som helst af kravene 1-13 til anvendelse til behandling af blærecancer, hjernecancer, brystcancer, knoglemarvscancer, cervikal cancer, kronisk lymfocytisk leukæmi, kolorektal cancer, øsofageal cancer, hepatocellulær cancer, lymfoblastisk leukæmi, follikulært lymfom, en lymfoid malignitet af T-celle- eller B-celle-oprindelse, melanom, myeloid leukæmi, myelom, oral cancer, ovariecancer, ikke-småcellet lungecancer, prostatacancer, småcellet lungecancer eller miltcancer hos en patient.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12027508P | 2008-12-05 | 2008-12-05 | |
US18118009P | 2009-05-26 | 2009-05-26 | |
PCT/US2009/066790 WO2010065865A2 (en) | 2008-12-05 | 2009-12-04 | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2376480T3 true DK2376480T3 (da) | 2016-09-12 |
Family
ID=41786218
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK09795606.4T DK2376480T3 (da) | 2008-12-05 | 2009-12-04 | Sulfonamidderivater som bcl-2-selektive apoptoseinducerende midler til behandling af cancer og immunsygdomme |
Country Status (38)
Country | Link |
---|---|
EP (3) | EP2376480B1 (da) |
JP (2) | JP5684720B2 (da) |
KR (2) | KR101692705B1 (da) |
CN (2) | CN102307872B (da) |
AR (1) | AR074510A1 (da) |
AU (1) | AU2009322219B2 (da) |
BR (1) | BRPI0922771A2 (da) |
CA (1) | CA2744711C (da) |
CL (1) | CL2011001313A1 (da) |
CO (1) | CO6390038A2 (da) |
CR (2) | CR20160269A (da) |
CY (1) | CY1117929T1 (da) |
DK (1) | DK2376480T3 (da) |
DO (1) | DOP2011000152A (da) |
EC (1) | ECSP11011174A (da) |
ES (1) | ES2588374T3 (da) |
HK (1) | HK1162031A1 (da) |
HR (1) | HRP20161085T1 (da) |
HU (1) | HUE029289T2 (da) |
IL (2) | IL212960A (da) |
LT (1) | LT2376480T (da) |
ME (1) | ME02642B (da) |
MX (2) | MX2011005922A (da) |
MY (1) | MY158932A (da) |
NZ (2) | NZ614305A (da) |
PE (2) | PE20120119A1 (da) |
PH (1) | PH12015502581B1 (da) |
PL (1) | PL2376480T3 (da) |
PT (1) | PT2376480T (da) |
RS (1) | RS55176B1 (da) |
RU (2) | RU2497822C2 (da) |
SG (1) | SG10201500767RA (da) |
SI (1) | SI2376480T1 (da) |
SM (1) | SMT201600313B (da) |
TW (2) | TWI600652B (da) |
UY (2) | UY32305A (da) |
WO (1) | WO2010065865A2 (da) |
ZA (1) | ZA201103806B (da) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100160322A1 (en) | 2008-12-04 | 2010-06-24 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
US8557983B2 (en) | 2008-12-04 | 2013-10-15 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
US8563735B2 (en) | 2008-12-05 | 2013-10-22 | Abbvie Inc. | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
US8586754B2 (en) | 2008-12-05 | 2013-11-19 | Abbvie Inc. | BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
NZ593593A (en) | 2009-01-19 | 2013-11-29 | Abbvie Inc | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
HUE027698T2 (en) | 2009-05-26 | 2016-10-28 | Abbvie Bahamas Ltd | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
US9034875B2 (en) | 2009-05-26 | 2015-05-19 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
US20220315555A1 (en) | 2009-05-26 | 2022-10-06 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
TWI520960B (zh) * | 2010-05-26 | 2016-02-11 | 艾伯維有限公司 | 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑 |
TWI535712B (zh) * | 2010-08-06 | 2016-06-01 | 阿斯特捷利康公司 | 化合物 |
UA113500C2 (xx) * | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
CA3152557A1 (en) | 2010-10-29 | 2012-05-03 | Abbvie Inc. | Solid dispersions containing an apoptosis-inducing agent |
MY191300A (en) * | 2010-11-23 | 2022-06-14 | Abbvie Ireland Unlimited Co | Methods of treatment using selective bcl-2 inhibitors |
JP6141188B2 (ja) | 2010-11-23 | 2017-06-07 | アッヴィ・インコーポレイテッド | アポトーシス誘導剤の塩および結晶の形態 |
CN103987711B (zh) | 2011-10-14 | 2016-08-24 | 艾伯维公司 | 作为用于治疗癌症和免疫性和自身免疫性疾病的凋亡诱导剂的8-氨基甲酰基-2-(2,3-二取代吡啶-6-基)-1,2,3,4-四氢异喹啉衍生物 |
WO2013185202A1 (en) * | 2012-06-14 | 2013-12-19 | Beta Pharma Canada Inc | Apoptosis inducers |
ES2800026T3 (es) | 2012-08-09 | 2020-12-23 | Celgene Corp | Tratamiento de enfermedades inmunitarias e inflamatorias |
US20150038511A1 (en) | 2012-08-09 | 2015-02-05 | Celgene Corporation | Treatment of immune-related and inflammatory diseases |
US20140275082A1 (en) | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
TWI745271B (zh) | 2014-05-19 | 2021-11-11 | 美商西建公司 | 全身紅斑性狼瘡之治療 |
CN104402778B (zh) * | 2014-12-03 | 2017-04-05 | 青岛蓝帆新材料有限公司 | 一种苄磺酰胺取代的丙烯酰胺衍生物 |
US10195213B2 (en) | 2015-03-13 | 2019-02-05 | Unity Biotechnology, Inc. | Chemical entities that kill senescent cells for use in treating age-related disease |
CN105198789B (zh) * | 2015-10-26 | 2018-06-05 | 山东大学 | 取代3-吲哚类Bcl-2蛋白抑制剂及制备方法和应用 |
US11111259B2 (en) | 2015-12-18 | 2021-09-07 | Unity Biotechnology, Inc. | Acylsulfonamide derivatives for treating senescence-associated diseases and disorders |
EP4129999A1 (en) | 2016-08-05 | 2023-02-08 | The Regents Of The University Of Michigan | N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors |
US11053239B2 (en) | 2017-01-07 | 2021-07-06 | Fochon Pharmaceuticals, Ltd. | Compounds as BLC-2-selective apoptosis-inducing agents |
JOP20190191A1 (ar) | 2017-02-22 | 2019-08-08 | Astrazeneca Ab | وحدات شجرية علاجية |
CN110546151B (zh) | 2017-04-18 | 2023-04-28 | 重庆复创医药研究有限公司 | 凋亡诱导剂 |
ES2971457T3 (es) | 2017-08-23 | 2024-06-05 | Guangzhou Lupeng Pharmaceutical Company Ltd | Inhibidores de BCL-2 |
AU2019207608B2 (en) * | 2018-01-10 | 2024-03-28 | Recurium Ip Holdings, Llc | Benzamide compounds |
WO2019185025A1 (zh) * | 2018-03-30 | 2019-10-03 | 正大天晴药业集团股份有限公司 | 三氟甲基取代的磺酰胺类选择性bcl-2抑制剂 |
CA3098348A1 (en) | 2018-04-29 | 2019-11-07 | Beigene, Ltd. | Bcl-2 inhibitors |
CA3095699A1 (en) | 2018-07-31 | 2020-02-06 | Ascentage Pharma (Suzhou) Co., Ltd. | Combination product of bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases |
KR20210003731A (ko) | 2018-07-31 | 2021-01-12 | 어센테지 파마 (쑤저우) 컴퍼니 리미티드 | Bcl-2 억제제와 MDM2 억제제의 병용 제품 및 질환의 예방 및/또는 치료에 있어서 이의 용도 |
US11554127B2 (en) | 2018-07-31 | 2023-01-17 | Ascentage Pharma (Suzhou) Co., Ltd. | Synergistic antitumor effect of Bcl-2 inhibitor combined with rituximab and/or bendamustine or Bcl-2 inhibitor combined with CHOP |
CN110772521A (zh) | 2018-07-31 | 2020-02-11 | 苏州亚盛药业有限公司 | Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途 |
US11903950B2 (en) | 2018-08-22 | 2024-02-20 | Newave Pharmaceutical Inc. | BCL-2 inhibitors |
KR20210086680A (ko) * | 2018-10-29 | 2021-07-08 | 치아타이 티안큉 파마수티컬 그룹 주식회사 | Bcl-2-선택적 억제제로서의 트리플루오로메틸-치환된 술폰아미드 |
CN109384764B (zh) * | 2018-12-12 | 2021-09-03 | 中国科学院上海有机化学研究所 | 苯基噻吩磺酰胺类化合物、药物组合物、其制备方法和应用 |
CN109851535A (zh) * | 2019-01-30 | 2019-06-07 | 天津现代职业技术学院 | 一种制备4-氟-3-(三氟甲磺酰基)苯磺酰胺的方法 |
WO2020238785A1 (zh) | 2019-05-24 | 2020-12-03 | 正大天晴药业集团股份有限公司 | 包括甲基和三氟甲基的双取代磺酰胺类选择性bcl-2抑制剂 |
US20230174528A1 (en) | 2020-04-29 | 2023-06-08 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Crystal of trifluoromethyl/chloro disubstituted sulfonamide selective bcl-2 inhibitor |
CN111848607B (zh) * | 2020-07-22 | 2023-03-17 | 长沙创新药物工业技术研究院有限公司 | 一种新型bcl-2/bcl-xl抑制剂、药物组合物及用途 |
JP2024504542A (ja) * | 2021-02-01 | 2024-02-01 | アセンテージ ファーマ(スーチョウ)カンパニー,リミティド | Bcl-2阻害剤としてのスルホニルベンズアミド誘導体 |
EP4353722A1 (en) | 2021-06-04 | 2024-04-17 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phosphate of trifluoromethyl-substituted sulfonamide compound |
KR20230144443A (ko) | 2022-04-06 | 2023-10-16 | 한국과학기술원 | MCL-1 및 BCL-xL에 동시에 결합하는 단백질 및 이의 용도 |
WO2024012557A1 (en) * | 2022-07-15 | 2024-01-18 | Berrybio (Hong Kong) Limited | Anti-apoptotic bcl-2 family protein degraders, pharmaceutical compositions, and therapeutic applications |
WO2024032776A1 (en) * | 2022-08-12 | 2024-02-15 | Fochon Biosciences, Ltd. | Compounds as bcl-2 inhibitors |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4215878A1 (de) * | 1992-05-14 | 1993-11-18 | Bayer Ag | Sulfonylierte Carbonsäureamide |
GB9203798D0 (en) * | 1992-02-21 | 1992-04-08 | Fujisawa Pharmaceutical Co | Quinolylbenzofuran derivatives,processes for preparation thereof and pharmaceutical composition comprising the same |
MY115155A (en) | 1993-09-09 | 2003-04-30 | Upjohn Co | Substituted oxazine and thiazine oxazolidinone antimicrobials. |
ATE257829T1 (de) | 1995-09-15 | 2004-01-15 | Upjohn Co | Aminoaryl oxazolidinone n-oxide |
US20030220234A1 (en) | 1998-11-02 | 2003-11-27 | Selvaraj Naicker | Deuterated cyclosporine analogs and their use as immunodulating agents |
RU2208609C2 (ru) * | 1998-02-04 | 2003-07-20 | Новартис Аг | Сульфониламинопроизводные, которые ингибируют разлагающие матрикс металлопротеиназы |
DE19830430A1 (de) * | 1998-07-08 | 2000-01-13 | Hoechst Marion Roussel De Gmbh | Schwefelsubstituierte Sulfonylamino-carbonsäure-N-arylamide, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
GB9918037D0 (en) | 1999-07-30 | 1999-09-29 | Biochemie Gmbh | Organic compounds |
ES2249270T3 (es) * | 1999-08-12 | 2006-04-01 | Pharmacia Italia S.P.A. | Derivados de 3(5)-aminopirazol, procedimiento para su preparacion y su uso como agentes antitumorales. |
PL365444A1 (en) * | 2000-03-21 | 2005-01-10 | The Procter & Gamble Company | Heterocyclic side chain containing, n-substituted metalloprotease inhibitors |
AR031130A1 (es) * | 2000-09-20 | 2003-09-10 | Abbott Lab | N-acilsulfonamidas promotoras de la apoptosis |
US6720338B2 (en) * | 2000-09-20 | 2004-04-13 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
US6995162B2 (en) * | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
AR036608A1 (es) * | 2001-09-24 | 2004-09-22 | Bayer Corp | Derivados de imidazol, composiciones farmaceuticas y el uso de dichos derivados para la fabricacion de un medicamento para el tratamiento de la obesidad |
EA009201B1 (ru) * | 2003-09-03 | 2007-12-28 | Пфайзер Инк. | Фенил - или пиридиламидные соединения в качестве антагонистов простагландина e2 |
JP4336678B2 (ja) | 2003-09-04 | 2009-09-30 | 株式会社日立超エル・エス・アイ・システムズ | 半導体装置 |
US7973161B2 (en) | 2003-11-13 | 2011-07-05 | Abbott Laboratories | Apoptosis promoters |
US8614318B2 (en) * | 2003-11-13 | 2013-12-24 | Abbvie Inc. | Apoptosis promoters |
WO2005049593A2 (en) * | 2003-11-13 | 2005-06-02 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
DE602004009344T2 (de) | 2004-04-19 | 2008-07-10 | Symed Labs Ltd., Hyderabad | Neues verfahren zur herstellung von linezolid und verwandten verbindungen |
ES2382383T3 (es) * | 2004-06-17 | 2012-06-07 | Infinity Discovery, Inc. | Compuestos y procedimientos para inhibir la interacción de proteínas Bcl con componentes de unión |
ATE429423T1 (de) | 2004-07-20 | 2009-05-15 | Symed Labs Ltd | Neue zwischenprodukte für linezolid und verwandte verbindungen |
ZA200702257B (en) * | 2004-08-20 | 2009-06-24 | Univ Michigan | Small molecule inhibitors of anti-apoptotic BCL-2 family members and the uses thereof |
WO2006039164A2 (en) | 2004-09-29 | 2006-04-13 | Amr Technology, Inc. | Novel cyclosporin analogues and their pharmaceutical uses |
PT1888550E (pt) * | 2005-05-12 | 2014-09-03 | Abbvie Bahamas Ltd | Promotores de apoptose |
TW200716636A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
US7514068B2 (en) | 2005-09-14 | 2009-04-07 | Concert Pharmaceuticals Inc. | Biphenyl-pyrazolecarboxamide compounds |
CN101534904B (zh) * | 2006-09-05 | 2013-11-06 | Abbvie公司 | 治疗血小板过量的bcl抑制剂 |
US8796267B2 (en) | 2006-10-23 | 2014-08-05 | Concert Pharmaceuticals, Inc. | Oxazolidinone derivatives and methods of use |
WO2008064116A2 (en) | 2006-11-16 | 2008-05-29 | Abbott Laboratories | Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection |
MX2009008465A (es) | 2007-02-15 | 2009-08-20 | Hoffmann La Roche | Nuevas 2-aminooxazolinas como ligandos de taar1. |
WO2008131259A1 (en) | 2007-04-19 | 2008-10-30 | Concert Pharmaceuticals Inc. | Deuterated morpholinyl compounds |
US7531685B2 (en) | 2007-06-01 | 2009-05-12 | Protia, Llc | Deuterium-enriched oxybutynin |
WO2009035598A1 (en) | 2007-09-10 | 2009-03-19 | Concert Pharmaceuticals, Inc. | Deuterated pirfenidone |
US20090118238A1 (en) | 2007-09-17 | 2009-05-07 | Protia, Llc | Deuterium-enriched alendronate |
US20090082471A1 (en) | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched fingolimod |
US20090088416A1 (en) | 2007-09-26 | 2009-04-02 | Protia, Llc | Deuterium-enriched lapaquistat |
JP2010540635A (ja) | 2007-10-02 | 2010-12-24 | コンサート ファーマシューティカルズ インコーポレイテッド | ピリミジンジオン誘導体 |
US20090105338A1 (en) | 2007-10-18 | 2009-04-23 | Protia, Llc | Deuterium-enriched gabexate mesylate |
US8410124B2 (en) | 2007-10-18 | 2013-04-02 | Concert Pharmaceuticals Inc. | Deuterated etravirine |
CA2703591C (en) | 2007-10-26 | 2013-05-07 | Concert Pharmaceuticals, Inc. | Deuterated darunavir |
UA108193C2 (uk) * | 2008-12-04 | 2015-04-10 | Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань | |
HUE027698T2 (en) * | 2009-05-26 | 2016-10-28 | Abbvie Bahamas Ltd | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
KR102516131B1 (ko) | 2018-09-21 | 2023-04-03 | 삼성디스플레이 주식회사 | 표시 장치 및 그의 제조 방법 |
-
2009
- 2009-12-04 HU HUE09795606A patent/HUE029289T2/en unknown
- 2009-12-04 KR KR1020117015478A patent/KR101692705B1/ko active IP Right Grant
- 2009-12-04 CN CN200980156232.3A patent/CN102307872B/zh active Active
- 2009-12-04 KR KR1020167036778A patent/KR101787993B1/ko active IP Right Grant
- 2009-12-04 CN CN201610329916.0A patent/CN106008322B/zh active Active
- 2009-12-04 ME MEP-2016-209A patent/ME02642B/me unknown
- 2009-12-04 SG SG10201500767RA patent/SG10201500767RA/en unknown
- 2009-12-04 PL PL09795606.4T patent/PL2376480T3/pl unknown
- 2009-12-04 ES ES09795606.4T patent/ES2588374T3/es active Active
- 2009-12-04 LT LTEP09795606.4T patent/LT2376480T/lt unknown
- 2009-12-04 TW TW098141654A patent/TWI600652B/zh not_active IP Right Cessation
- 2009-12-04 WO PCT/US2009/066790 patent/WO2010065865A2/en active Application Filing
- 2009-12-04 NZ NZ61430509A patent/NZ614305A/en not_active IP Right Cessation
- 2009-12-04 SI SI200931509A patent/SI2376480T1/sl unknown
- 2009-12-04 RU RU2011127402/04A patent/RU2497822C2/ru active
- 2009-12-04 MX MX2011005922A patent/MX2011005922A/es active IP Right Grant
- 2009-12-04 TW TW104108824A patent/TWI600642B/zh not_active IP Right Cessation
- 2009-12-04 DK DK09795606.4T patent/DK2376480T3/da active
- 2009-12-04 CA CA2744711A patent/CA2744711C/en not_active Expired - Fee Related
- 2009-12-04 BR BRPI0922771A patent/BRPI0922771A2/pt not_active Application Discontinuation
- 2009-12-04 JP JP2011539741A patent/JP5684720B2/ja active Active
- 2009-12-04 MX MX2013007760A patent/MX363470B/es unknown
- 2009-12-04 PE PE2011001158A patent/PE20120119A1/es active IP Right Grant
- 2009-12-04 MY MYPI2011002530A patent/MY158932A/en unknown
- 2009-12-04 NZ NZ592801A patent/NZ592801A/xx not_active IP Right Cessation
- 2009-12-04 PE PE2014001365A patent/PE20142316A1/es active IP Right Grant
- 2009-12-04 EP EP09795606.4A patent/EP2376480B1/en active Active
- 2009-12-04 RS RS20160721A patent/RS55176B1/sr unknown
- 2009-12-04 PT PT97956064T patent/PT2376480T/pt unknown
- 2009-12-04 AU AU2009322219A patent/AU2009322219B2/en not_active Ceased
- 2009-12-04 EP EP19206559.7A patent/EP3666758A1/en not_active Withdrawn
- 2009-12-04 CR CR20160269A patent/CR20160269A/es unknown
- 2009-12-04 EP EP16169764.4A patent/EP3101019A1/en not_active Withdrawn
- 2009-12-07 UY UY0001032305A patent/UY32305A/es not_active Application Discontinuation
- 2009-12-07 AR ARP090104743A patent/AR074510A1/es active IP Right Grant
-
2010
- 2010-06-02 UY UY0001032680A patent/UY32680A/es not_active Application Discontinuation
-
2011
- 2011-05-17 IL IL212960A patent/IL212960A/en active IP Right Grant
- 2011-05-24 DO DO2011000152A patent/DOP2011000152A/es unknown
- 2011-05-24 ZA ZA2011/03806A patent/ZA201103806B/en unknown
- 2011-06-02 CL CL2011001313A patent/CL2011001313A1/es unknown
- 2011-06-17 CO CO11075957A patent/CO6390038A2/es not_active Application Discontinuation
- 2011-06-22 CR CR20110351A patent/CR20110351A/es unknown
- 2011-07-04 EC EC2011011174A patent/ECSP11011174A/es unknown
-
2012
- 2012-03-12 HK HK12102482.7A patent/HK1162031A1/zh not_active IP Right Cessation
-
2013
- 2013-07-19 RU RU2013133800A patent/RU2621052C2/ru active
-
2015
- 2015-01-14 JP JP2015005014A patent/JP6034412B2/ja active Active
- 2015-11-13 PH PH12015502581A patent/PH12015502581B1/en unknown
-
2016
- 2016-05-26 IL IL245889A patent/IL245889B/en active IP Right Grant
- 2016-08-25 HR HRP20161085TT patent/HRP20161085T1/hr unknown
- 2016-08-29 CY CY20161100842T patent/CY1117929T1/el unknown
- 2016-09-09 SM SM201600313T patent/SMT201600313B/it unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2376480T3 (da) | Sulfonamidderivater som bcl-2-selektive apoptoseinducerende midler til behandling af cancer og immunsygdomme | |
US9315488B2 (en) | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases | |
US9045420B2 (en) | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases | |
US9029404B2 (en) | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | |
WO2011068560A1 (en) | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | |
WO2010065824A2 (en) | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | |
AU2013211540B2 (en) | Sulfonamide derivatives as Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |